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“Science is all about: building and communicating knowledge. 
You may have a beautiful experiment in your lab notebook, or in 
your head, but it isn’t science until you make it available to 
others so that they can build on it.”  
— Nobel Laureate Oliver Smithie
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Abstract	
Convergence of exponentially advancing technologies is driving medical research with life 
changing discoveries. On the contrary, repeated failures of high-profile drugs to battle 
Alzheimer’s disease (AD) has made it one of the least successful therapeutic area. This 
failure pattern has provoked researchers to grapple with their beliefs about Alzheimer’s 
aetiology. Thus, growing realisation that Amyloid-β and tau are not ‘the’ but rather ‘one of 
the’ factors necessitates the reassessment of pre-existing data to add new perspectives. To 
enable a holistic view of the disease, integrative modelling approaches are emerging as a 
powerful technique. Combining data at different scales and modes could considerably 
increase the predictive power of the integrative model by filling biological knowledge gaps. 
However, the reliability of the derived hypotheses largely depends on the completeness, 
quality, consistency, and context-specificity of the data. Thus, there is a need for agile 
methods and approaches that efficiently interrogate and utilise existing public data.  
This thesis presents the development of novel approaches and methods that address 
intrinsic issues of data integration and analysis in AD research. It aims to prioritise lesser-
known AD candidates using highly curated and precise knowledge derived from integrated 
data. Here much of the emphasis is put on quality, reliability, and context-specificity. This 
thesis work showcases the benefit of integrating well-curated and disease-specific 
heterogeneous data in a semantic web-based framework for mining actionable knowledge. 
Furthermore, it introduces to the challenges encountered while harvesting information from 
literature and transcriptomic resources. State-of-the-art text-mining methodology is 
developed to extract miRNAs and its regulatory role in diseases and genes from the 
biomedical literature. To enable meta-analysis of biologically related transcriptomic data, 
a highly-curated metadata database has been developed, which explicates annotations 
specific to human and animal models. Finally, to corroborate common mechanistic patterns 
— embedded with novel candidates — across large-scale AD transcriptomic data, a new 
approach to generate gene regulatory networks has been developed.  
The work presented here has demonstrated its capability in identifying testable mechanistic 
hypotheses containing previously unknown or emerging knowledge from public data in 
two major publicly funded projects for Alzheimer’s, Parkinson’s and Epilepsy diseases.  
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Zusammenfassung	
Die Konvergenz exponentiell fortschreitender Technologien treibt die medizinische 
Forschung mit lebensverändernden Entdeckungen voran. Andererseits das wiederholte 
Versagen von hochkarätigen Medikamenten gegen die Alzheimer-Krankheit hat sie zu 
einem der am wenigsten erfolgreichen Therapiegebiet gemacht. Dieses Versagensmuster 
hat Forscher dazu veranlasst, sich mit ihren Überzeugungen über die Alzheimer-Ätiologie 
auseinanderzusetzen. Die wachsende Erkenntnis, dass Aβ und tau nicht die Faktoren, 
sondern einer der Faktoren sind, macht eine Neubewertung bereits vorhandener Daten 
erforderlich, um neue Perspektiven zu eröffnen. Um eine ganzheitliche Betrachtung der 
Krankheit zu ermöglichen, entwickeln sich integrative Modellierungsansätze zu einer 
wirkungsvollen Methode. Die Kombination von Daten aus verschiedenen Ebenen und 
Modi wird die Vorhersagekraft des integrativen Modells erheblich erhöhen, indem 
biologische Wissenslücken geschlossen werden. Die Zuverlässigkeit der abgeleiteten 
Hypothesen hängt jedoch in hohem Maße von der Vollständigkeit, Qualität, Konsistenz 
und Kontextspezifität der Daten ab. Daher bedarf es agiler Methoden und Ansätze, die 
öffentlich verfügbare Datensätze effektiv und effizient abfragen und nutzen. 
Diese Arbeit stellt die Entwicklung neuer Ansätze und Methoden vor, die sich mit 
wesentlichen Fragen der Datenintegration und -analyse in der Alzheimer-Forschung 
befassen. Sie zielt auf die Priorisierung von weniger bekannten Alzheimer-Kandidaten mit 
Hilfe von hochgradig kuratiertem und präzisem Wissen, das aus integrierten Daten 
gewonnen wird. Dabei wird der Schwerpunkt auf Qualität, Zuverlässigkeit und 
Kontextspezifität gelegt. Diese Arbeit zeigt den Nutzen der Integration gut kuratierter und 
krankheitsspezifischer heterogener Daten in ein semantisches web-basiertes Framework 
für die Gewinnung von handlungsfähigem Wissen. Darüber hinaus werden die 
Herausforderungen bei der Extraktion von Informationen aus Literatur und 
transkriptomischen Ressourcen vorgestellt. Modernste Text-Mining-Methodik werden 
entwickelt, um miRNAs und ihre regulatorische Rolle bei Krankheiten und Genen aus der 
biomedizinischen Literatur zu extrahieren. Um die Metaanalyse von biologisch verwandten 
transkriptomischen Daten zu ermöglichen, wird eine hochgradig kuratierte Metadaten-
Datenbank entwickelt, die Annotationen spezifisch für menschliche und tierische Modelle 
bereitstellt. Schließlich wird ein neuer Ansatz zur Generierung von 
Genregulationsnetzwerken entwickelt, um gemeinsame mechanistische Zusammenhänge
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 nachzuweisen, die mit neuartigen Kandidaten in umfangreichen transkriptomischen 
Alzheimer-Daten eingebettet sind. 
Die hier vorgestellte Arbeit hat gezeigt, dass sie in der Lage ist, testbare mechanistische 
Hypothesen zu identifizieren, die bisher unbekannte oder neu entstehende Erkenntnisse aus 
bestehenden öffentlich verfügbare Daten enthalten. Diese Daten stammen aus zwei 
öffentlich finanziert Projekten, die sich mit Alzheimer-, Parkinson- und Epilepsie-
Erkrankung beschäftigen 
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Glossary	
This glossary provides information on the tools applied in this thesis. Further information 
on the listed tools can be found under the URLs provided. 
Cytoscape 
A software platform for visualization and analysis of complex 
biological networks along with integration of experimental of data 
http://www.cytoscape.org/  
Knowtator 
A text annotation tool integrated in the Protégé for manual 
information extractions tasks 
http://knowtator.sourceforge.net/index.shtml  
ProMiner 
A named entity and concepts recognition tool used in the field of life 
sciences 
https://www.scai.fraunhofer.de/de/geschaeftsfelder/bioinformatik/pr
odukte/prominer.html  
Protégé 
A knowledge representation framework for ontology development 
and management  
https://protege.stanford.edu/products.php  
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A semantic search engine for biomedical concepts and entities from 
scientific literature using comprehensive biomedical terminologies 
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https://www.scaiview.com/en/introduction.html  
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A SQL-based relational database management system  
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storage and data mining applications needed for translational research 
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Chapter	1 Introduction	
The irreversible and debilitating nature of neurodegenerative diseases (NDD) — with no 
cure — has made it a daunting medical and socio-economic issues of our time. A focused 
interdisciplinary effort to transform our biological understanding of the brain, driven by 
technological advancements and large-scale data, aims to treat and eradicate NDDs. Today, 
it is possible to sequence a human genome in a day with cost of approx. $1000 compared 
to the cost of $3 billion and several years of effort needed for the first human genome 
sequencing. Yet, the multifactorial nature of these diseases has made it difficult to unravel 
its molecular underpinnings; leading to repeated drug failures. Thus, innovative paradigms 
are needed to discover meaningful players and gain biological insights from high 
dimensional feature space.  
1.1 Alzheimer’s	disease:	A	looming	global	crisis	
NDDs share a common property of progressive dysfunction and loss of neurons, which is 
the major cause of motor (ataxia) and mental dysfunction (dementia). In 2016, 47 million 
people were demented with an estimated global cost of $818 billion [1]. Owing to 100% 
drug attrition rate in the last two decades1 [2], WHO has recognised dementia as the “public 
health priority” [3]. Alzheimer’s disease (AD) is the most prevalent form of NDD, 
representing approximately 60–70% of the dementia cases. This global epidemic is 
currently the 6th leading cause of death and costs $160 billion in the USA alone, which will 
spike to $1 trillion by 2050 [4]. Moreover, AD prevalence has increased from less than 1% 
to 2.5% as the first baby boomers turned 65 [4]. If unaddressed, AD’s economic burden 
will simply become unsustainable, driving millions below the poverty line.  
AD is characterised clinically by progressive cognitive decline and neuropathologically by 
the presence of intraneuronal neurofibrillary tangles (NFTs) and extracellular amyloid-beta 
(Aβ) deposits — hallmark pathological features [5,6]. It begins with slowly progressing 
memory loss and advances to deteriorate higher intellectual and cognitive abilities, namely 
language, recognition, and personality [7]. The actual AD neuropathology(-ies) is thought 
                                                
1 https://www.ohe.org/publications/dementia-rd-landscape (this and subsequent URLs have been last 
accessed on 15th March 2018) 
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to begin 20–25 years before any apparent clinical symptoms, making it difficult for early 
diagnosis and treatment [8]. Moreover, a very thin line delineates the memory loss in the 
initial phase of normal ageing and AD [9]. This awareness has recently led to the refinement 
(first revision since 1984) of current AD guidelines and diagnostic criteria [10]. Thus, based 
on the disease continuum, AD is now classified as: (i) preclinical AD (newly defined stage) 
represents asymptomatic individuals with evidence of amyloidosis, synaptic dysfunction, 
and not overtly evident cognitive changes [11] (ii) in AD-MCI stage noticeable changes in 
memory and thinking are observed, disrupting day-to-day activities [12] (iii) AD dementia 
causes severe impairments of memory, thinking, and behaviour, needing support in 
everyday life [13].  
Furthermore, two major categorisations of AD cases are: (i) Based on the inheritance 
pattern — familial and sporadic (ii) Based on the age of onset — early-onset AD (EOAD) 
and late-onset AD (LOAD). Familial AD exhibits the mendelian autosomal dominant 
pattern of inheritance attributed to several and varied highly penetrant mutations in more 
than 20 genes [14]. Accounting for 95% of the AD cases, sporadic AD is the commoner 
form whose precise aetiology is not yet known. However, it is attributed to multiple 
inheritances that include low penetrant genetic variants and non-genetic factors such as 
environmental risks [15]. Since sporadic AD mostly occurs after the age of 65 years, it is 
synonymously used with LOAD. EOAD accounts for 1-2% of all the AD cases with age of 
onset earlier than 65 years and accounts for 10% of familial AD cases [16,17].  
1.2 AD	etiopathogenesis		
Although the AD cause-consequence debate still continues, many researchers have tried to 
elucidate its insidious features since its first description by Alois Alzheimer in 1907 [18]. 
Indeed, with the advent of molecular revolution in the mid-1980s, identification of AD 
genetic risks offered a promise of more rapid development in unravelling the AD aetiology 
[15]. However, some of the elementary questions asked decades ago about Aβ and NFTs, 
although highly topical, remains unanswered.  
1.2.1 Amyloid	cascade	hypothesis		
At this point of time, the central role of “neurotoxic Aβ plaques” is very strong in AD 
pathogenesis and believed to be “too big to fail”; Joseph et al. described it as the “Church 
of the Holy Amyloid” [19,20]. It has long been hypothesised that the core of Aβ plaques 
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formation is due to disordered proteolytic actions of α-, γ- and β-secretases on APP 
processing leading to abnormal folding of Aβ peptides, aggregating as insoluble plaques. 
Hardy and Allsop [21] postulated this Aβ dyshomeostasis as the primary event in AD 
pathological chain, known as the amyloid cascade hypothesis (ACH). Nonetheless, it was 
later transpired that (a) the mutations in the familial AD genes caused overproduction of 
Aβ 42 peptide (b) e4 allele of APOE (APOE4) gene is a potent risk factor [22] (c) decreased 
Aβ clearance was observed in LOAD cases [7] (d) soluble Aβ oligomers were primary 
neurotoxic agents [23] and (e) trisomy 21 (Down syndrome) led to overexpression of APP 
gene [24]. Most researchers accept that the downstream effect of Aβ plaques initiate tau 
hyperphosphorylation, leading to NFT formation, further synapse destruction, and 
subsequently causing neuronal death. However, studies also report that Aβ accumulation is 
observed in elderly individuals who show no signs of cognitive decline [25].  
1.2.2 Tau	hypothesis	
The tau hypothesis identifies hyperphosphorylated tau protein as the possible culprit of AD 
pathogenesis and that tau tangles (also known as NFTs) occur prior to Aβ plaques formation 
[26,27]. Hyperphosphorylated tau loses its ability to bind to microtubules causing it to 
aggregate into insoluble tangles (known as paired helical filaments (PHFs)) to eventually 
form NFTs2. There is good evidence that hyperphosphorylated tau and its aggregates lead 
to the disruption of axonal transport, resulting in synaptic dysfunction [28]. Recent imaging 
studies, involving a large autopsy cohort (3618 brains), have linked tau deposits more 
closely to age at onset of cognitive impairment, disease duration and dementia than Aβ 
deposits [29]. Thus, tau is a speculated to be a better and more robust predictor of different 
stages when patients transition from healthy to severe AD [30].  
1.2.3 Alternative	hypotheses	
With the passage of time, growing evidence reject the linear structure of either Aβ or tau 
being the singular cause in the cascade of AD pathogenesis. Conversely, we should not 
ignore the entirety of these hypotheses, rather revisit them with an assumption that they are 
                                                
2 NFTs are bundles of PHFs found in the cytosol of neurons 
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the consequence of paradoxical associations. To better unify and reconcile the existing 
hypotheses, alternative perspectives are proposed [31]. 
A steadily growing body of evidence suggests that the brain may compensate for the effect 
caused by Aβ, but the combined work of Aβ and tau drive the dramatic decline of healthy 
neurons [32]. The duo effect takes place either when tau renders neuronal dendrites to Aβ 
toxicity, or Aβ and tau synergistically amplify each other’s toxic effect [28]. Some 
researchers have repositioned the causal molecular events of AD within the ageing 
spectrum as the histological boundaries between them are not absolute. Thus, AD’s onset 
could represent the failure of the ageing brain to revert back the altered cell functioning due 
to events such as injury, infection, stress, negative life event, to name a few [33,34].  
A recent study by AddNeuroMed Consortium [35], posits mitochondrial dysfunction as the 
primary pathology; reported altered mitochondrial genes in blood before any clinical 
diagnosis of AD. Furthermore, strong indications of oxidative stress and DNA damage in 
early AD pathology due to redox imbalance is reported [36,37]. Several neuroscientists 
argue that continuum of abnormalities in the cholinergic system [38], autophagy and/or 
lysosomal pathways [39,40], hormonal imbalance [41] and Ca2+ homeostasis [42] lies in 
the core of AD pathology. The vital role of neuroinflammation [43,44], highly active innate 
immune system [45,46], and disrupted insulin signalling [47,48] are strongly argued. 
Figure 1.1 depicts this conceptualization using three of the major AD contributing factors, 
refer [9,50,52,53].  
Evidence suggests that some or all the above-mentioned events may augment to Aβ plaque 
formation and tau hyperphosphorylation, forming a vicious cycle that promotes AD 
pathogenesis [49,50]. Given this, Prof. Garrett proposes to approach the AD pathology as 
‘A Complexity Theory’ where the effects of several causal variances are seemingly 
independent but rely on each other in ways, yet unknown, to bring about systematic 
malfunctions linking to the disease symptoms [51]. 
1.3 Status	quo	of	AD	therapeutics	
Since 1960, ACH hypothesis has maintained supremacy in driving AD drug development 
strategies. Additional burden has been casted by gnawing controversies and major gaps in 
the basic biology and clinical pathophysiology. Despite huge investments, AD is one of the  
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Figure 1.1: Overview of several factors that contribute to the clinical symptoms of AD. 
Three major AD contributing factors are represented in the ovals: cellular imbalances (orange), genetic risk 
factors (green), and modifiable and non-modifiable factors (blue). Genes emphasized in green indicate their 
role in EOAD. The intersection between any two ovals remain empty to depict interaction between factors 
in ways currently unknown, contributing (trigger symbol) to common AD symptoms (in red). 
least successful therapeutic areas with 0.5% success rate and with no blockbuster drug yet 
[52]. Many pharma companies are wary about investing significantly (both time and 
money) in AD after a series of high profile late stage failures, questioning investment in 
AD research [53]. To increase the probability of being successful and to speed up the hunt 
for AD’s holy grail, several public-private initiatives such as the Innovative Medicines 
Initiative (IMI)3 are providing platforms for collaborative projects to boost pharmaceutical 
innovation. Given the burning need for AD (prevention) therapy, FDA is now granting fast-
track designations to potential interventions to reach the global deadline set in G8 summit 
— to prevent or effectively treat AD by 2025 [54,55]. Several countries have joined this 
global fight by encouraging a number of key strategic initiatives [55,56]. 
                                                
3 http://www.imi.europa.eu/content/home  
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Figure 1.2: Overview of the ongoing clinical trials for AD therapeutics, reported according to their 
mechanism of action, phase of study, type of agents and targeted subjects.  
Reproduced from Cumming et al. [57] under Creative Commons Attribution-NonCommercial-No 
Derivatives License. 
Knowledge of neurotransmitter disturbances led to the development of currently approved 
AD palliative treatments [6]: (i) inhibitors of cholinesterase (tacrine, donepezil, 
galantamine, and rivastigmine) and (ii) NMDA (N-methyl-D-aspartate) antagonist 
(memantine). These drugs show no evidence of modifying the disease pathology but rather 
aim to slow the decline in quality of life — symptomatic treatment. However, increasing 
knowledge of AD’s multifactorial nature has amplified the drug discovery ecosystem and 
rationales for modification in therapeutic strategies [58,59]. Although lagging behind Aβ-
directed agents, some of these disease-modifying agents have advanced to initial human 
trials.  Figure 1.2 provides an overview of the currently investigated AD drugs along with 
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the details of their mechanism of action, broadly categorised under (visit the PhRMA 
Foundation4 for more details) [9,58,60,61]: 
• Aβ related —targeting α-, γ- and β-secretases, clearance of Aβ aggregates, 
proteases, chaperones, immunotherapy (both active and passive) 
• tau related — inhibition/clearance of tau aggregates, immunotherapy (both active 
and passive), targeting kinases and phosphatases, stabilizing microtubules  
• others — modulating abnormalities in multiple neurotransmitters pathways such as 
cholinergic, glutamatergic, and GABAergic system, microglia-mediated 
inflammatory response, modifying epigenetics and/or epidemiological factors such 
as mitochondrial dysfunction, and metabolic disorders 
Adding to the decade of bitter disappointments, two of the potential ground-breaking drugs 
have recently failed, verubecestat (MK-8931) and solanezumab, despite promising results 
in phase 2 trials [62]. Nevertheless, repeated drug failures have not yet unequivocally 
disproved the ACH belief [63]. Examining closer, failed trials provide no evidence of target 
being the problem but rather acknowledges methodological weaknesses: lack of 
drug/placebo difference, unacceptable toxicity, misdiagnosis of the enrolled patients, low 
dosage, and so on [58,59,64,65]. Many experts argue that the fundamental problem is the 
lack of awareness between cause and visible effects [66] and the lack of translation from 
mouse to human [67]. 
Increasing interest in combination drug therapies involving a “cocktail” of medications5, 
aimed at several targets — with common associated biology — could address the profound 
complexity in AD, similar to current treatments in cancer [68]. This represents an important 
future direction in AD therapeutics; genuinely considering the systems biology approach 
and ending the vigorous debate between TAUists and BAPtists [69,70]. Moreover, 
neuroscientists suggest intervening early in the disease process before irreversible neuronal 
dysfunction prevails; similar to treating hypertension years before the incidence of cerebral 
infarction [66,71]. Unravelling new pathways amenable to neuronal changes (genetics or 
epigenetics) could improve the disease understanding and provide new therapeutic 
approaches [72].   
                                                
4 http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-alzheimers.pdf  
5 http://www.alz.org/research/science/alzheimers_treatment_horizon.asp  
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1.4 Elucidating	AD	mechanisms	through	computational	
approaches	
Modern biomedical research is driven by technological advancements with growing 
prodigious amount of disparate data; drowning with information. Yet, it is the one that 
bedevils the progress as we still starve for knowledge. With millions of data points and 
myriad clinical information6, the life science industry faces an increasing challenge of 
converting the harvested (complex-)data into actionable knowledge. In addition, there 
remain incredible barriers that have significantly stigmatized AD diagnosis and 
therapeutics: the high complexity of brain, the inaccessibility to good quality brain tissue, 
the lack of direct access to brain tissue in living patients, the lack of well characterised 
animal models, inadequate molecular diagnosis for cohort selection, huge cost and the time 
for extensive drug development processes, and current graveyard of AD clinical trials [73]. 
Thus, to stay in AD treatment race, pharma companies need to remain agile by skilfully 
drawing meaningful insights in a relatively short time, from limited observations and sparse 
data [74]. To increase the prediction accuracy, maximising the yield and biological 
relevance in downstream processes and critical evaluation of planned research, they need 
to leverage on huge volume of accumulated prior knowledge [75,76].  
To derive a realistic model on modular nature of cellular architecture and functioning, 
taking stock of available knowledge on physical and functional associations between 
biomolecules have become a standard approach. In contrast, not all domain expert’s 
knowledge is explicitly stated and manual interpretation is a daunting task; often leading 
to the question “How can I realise the potential of these resources to construct a systems-
level understanding?”  
Data integration approaches capable of describing complex systems and supporting broader 
interoperability are key to efficient integrative data analysis. Through these approaches, we 
may bring together previously overlooked factors (may or may not involve indicative 
biomarkers) that can uncover essential mechanistic relationships between molecular 
changes and diseases [77]. Biological information about diseases, genetic variants, 
experimental datasets, protein-protein interaction (PPIs), among others are well-
                                                
6 https://www.nia.nih.gov/research/blog/2016/12/increasing-usability-big-data-alzheimers-research  
Connecting the dots: semantic data integration to boost identification of AD driving mechanisms 
9 
documented and well-annotated in databases. However, these databases represent only a 
small percentage of information when the bulk of scientific publications are taken into 
account. Furthermore, experimental data, not being fully exploited contain compelling 
evidence for biological understanding (or validating) a new hypothesis. Moreover, to 
harness the full potential of the integrated data, the inferred biological hypothesis must 
assume the form of biological networks such as gene regulatory networks or projected onto 
previously compiled pathways. On the other hand, one must take into account that these 
public resources are fragmented, lack harmonisation and reproducibility is by and large 
inconsistent7,8 [78–82].  
Technological and data resources required to determine links to diseases are pieces of the 
puzzle that when put together, promise to reveal novel regulators in pathomechanisms. The 
following paragraphs introduce fundamentals and applications of various bioinformatic 
approaches and resources used in this thesis: first, introduction to integrative approaches 
applied to the AD domain, focusing on semantic web (SW) technology; second, a detailed 
description of the technologies and methods applied to distil knowledge from existing 
resources before integration.  
1.5 Connecting	the	dots:	semantic	data	integration	to	boost	
identification	of	AD	driving	mechanisms	
To generate new insights into AD, several researchers have developed methods/tools to 
combine and show the extraordinary value of a wide variety of existing data through 
innovative re-analyses. Fowler et al. prioritized two genes involved in neuronal oxidative 
damage, to stratify patient subsets based on gender and APOE status: NEUROD6 for 
APOE4+ female and SNAP25 APOE4+ male patients; through the integration of publicly 
available gene expression datasets, a disease associated SNP datasets, and multiple 
databases [83]. Chen et al. developed a heuristic algorithm and scoring method to rank-
order proteins based on their functional relevance in an AD-PPI network [84]. To derive a 
highly-connected AD-PPI network, an initial seed of AD-related genes was extracted from 
the OMIM database, which was further enriched with PPIs from OPHID database using a 
                                                
7 http://www.alzforum.org/news/research-news/replication-challenge-quest-alzheimers-blood-test  
8 http://protomag.com/articles/replication-in-research-problem  
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nearest-neighbour expansion method. Similar to Chen et al., Soler-López et al. applied an 
interaction discovery strategy using initial seed gene list, and interaction network from 
public databases to prioritize novel genes, suggesting a link between plaque formation and 
inflammatory processes [85]. Krauthammer et al. presented a molecular triangulation to 
predict unknown genetic variants by computing the graph-theoretic distance between 
expert-curated seed genes and other biomolecules in the literature-derived molecular 
network [86]. Considerable studies integrated information about genetics, functional, 
dysregulated expression, and interaction from public data to unveil novel AD candidates 
and provide new hypotheses for mechanisms underlying AD [87]; for drug discovery [88–
90]. Among others, most widely used data integration strategies include data warehousing, 
data centralization, and federated databases [91].  
Problems for data integration are rooted in the data itself; resources are broadly distributed, 
across the web and encompass heterogeneity and diversity in data formats, concepts, 
semantics, syntax, to name a few. Of course, these approaches have strengths and 
limitations and there is no “one-size fits all” solution [75,92]. Furthermore, these 
integration solutions are local and fail to operate at the global level and cannot cope with 
the updates of resources such as newly added information and changes in the data structure, 
formats, and naming convention. In general, most of these approaches overlook the 
importance of data quality, and context-specificity. Semantic web technology is the first 
truly global integrative solution revolutionising the lossless exchange and formalisation of 
data, calling it “smart data” [93].  
Since the inception of World Wide Web, its inventor Tim Berners-Lee et al. envisioned 
SW as “intelligent agents” capable of universal integration and exchange of data through 
the incorporation of machine-readable meaning (or semantics) and logical relations 
between data elements 9  [94]. Thus, resulting in a network of linked data, whose 
formalization allows identification of new implicit connections by reasoning over the data. 
To realize the vision of SW, World Wide Web Consortium (W3C) focused on empowering 
SW technologies, among which RDF, OWL, SKOS, and SPARQL have become de facto 
standards10. The 7-layered Semantic Web Stack, depicted in Figure 1.3, shows, how the 
                                                
9 the definitions and descriptions of SW are taken from W3C’s web page https://www.w3.org/TR/  
10 https://www.w3.org/standards/semanticweb/  
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proposed technologies (although still evolving) realise each other’s capabilities towards 
building SW. Interested readers are referred to Glimm et al. for the overview of the SW 
developments since its inception 15 years ago [95]. 
 
Figure 1.3: Semantic Web Architecture, also informally known as “layer cake”  
This figure is taken from Wikipedia page11 under Creative Commons (CC0) License. The original 
illustration proposed by Tim Berners-Lee is available here12 Copyright © 2015 W3C® (MIT, ERCIM, 
Keio, Beihang)13.  
1.5.1 Semantic	web	technology	standards		
Resource Description Framework (RDF) is a W3C’s proposed standard for publishing and 
exchanging data on the web [96]. The core concept of RDF lies in the usage of a unique 
global identification system called as “Universal Resource Identifiers (URIs)” and more 
recently IRIs (Internationalized Resource Identifier) [97]. RDF data model uses the syntax 
of Extensible Markup Language (XML) to impose structural constraints for representing 
the data as graph structures. Due to high flexibility and cost effectiveness of graph 
databases (introduced in sub-section Biological databases), RDF-centric databases have 
                                                
11 https://en.wikipedia.org/wiki/Semantic_Web_Stack  
12 https://www.w3.org/2007/Talks/0130-sb-W3CTechSemWeb/#(24)  
13 http://www.w3.org/Consortium/Legal/2015/doc-license  
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become a choice for managing highly connected data. RDF triplestore is a semantic graph 
database which stores semantic facts as a network of links containing directed edges; 
termed as RDF statements or triples, hence the name triplestore [98]. Figure 1.4 shows the 
anatomy of a basic triple statement; subjects and objects are concepts (called resources), 
connected using verbs which represents the relationship types, called predicates and literals 
(also a resource) are the constant values mapped to the resources. 
 
Figure 1.4: Anatomy of a triple statement. 
Ovals represent subjects and objects; rectangle literals; arc predicates.   
The RDF’s simple triple format — although simpler to implement — does not allow higher 
levels of expressiveness such as the union of existing concepts, hierarchical relations 
between concepts, reasoning, among others [99]. Thus, W3C introduced two data modeling 
languages: RDF schema (RDFS) and Web Ontology Language (OWL). RDFS is objected 
oriented in nature and formally describes RDF data properties as taxonomies of object 
classes, and relationship properties using ontologies. Simply put, it defines a metamodel of 
concepts such as Resource, Literal, Class, and Datatype and relationships such as 
subClassOf, domain, and subPropertyOf. Ontologies allow explicit formal description of 
the terms — rich vocabulary with highest level of expressivity — in the data to map distinct 
terms to the same concept. Semantic Web Rule Language (SWRL) is an extension of OWL 
to provide more powerful “deductive reasoning” capabilities [99]. Although it is a daunting 
task to provide data linked to ontologies, the merit lies in higher interoperability. SPARQL, 
a self-referencing acronym for SPARQL Protocol and RDF Query Language, is a SQL-like 
query language for accessing RDF data. SPARQL queries can be federated, meaning one 
can access diverse and evolving data from various RDF resources in one query. The 
advantage of SPARQL over other query languages is the availability of a query interface 
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called SPARQL endpoint. Several programming environments have been developed to 
parse RDF data: PerlRDF for Perl, and Apache Jena for Java framework. Data exchange 
standards 14  for RDF include: RDFa, RDF/XML, N-Triples, Turtle, Javascript Object 
Notation-LD (JSON-LD), among others. Several optimized databases15 are available for 
storing RDF data, namely Virtuoso, GraphDB™, Stardog, and AllegroGraph. Among the 
variety of extraction tools, strategies, and interfaces to transform non-RDF into RDF 
resources: GRDDL transforms XML into RDF, and R2RML maps relational databases to 
RDF.  
RDF is capable of handling intuitive and powerful semantic queries (set of inference rules) 
to infer new triples (logical consequences) out of asserted facts; turning information into 
knowledge. For example, “If two diseases have common genes, then they affect each 
other’s incidence”. This gives a competitive edge for most pharma industries by creating 
more value and easily scaling up the derived knowledge into smart solutions. RIF (Rule 
Interchange Format) is a standard for exchanging rules between disparate semantic data 
models by combining ontologies. Using semantic reasoners, one can infer implicit facts out 
of explicit statements, thus uncovering hidden relationships. Since OWL provides 
Description Logic (DL)-based reasoning capabilities, a number of reasoners including 
Racer [100], Fact++ [101], Pellet [102], and KAON216 have been developed. Mishra et al. 
[103] have published an overview of semantic reasoners recently.  
1.5.2 Bridging	the	knowledge	gap	through	semantic	web:	focus	
on	neuroscience		
Despite the youth of SW technologies, active researchers and developers have been 
developing tools and infrastructures, both open source and commercial, that foster FAIR 
data (findable, accessible, interoperable and reusable) principles [104]. The OBO Foundry 
and BioPortal serve as an umbrella of ongoing collaborative efforts for standardisation, 
storage, and linking of public biomedical ontologies [105]. The Identifiers.org registry 
provides persistent official identifiers to scientific terms. Observing the immense advantage 
                                                
14 https://www.w3.org/TR/rdf11-new/  
15 https://www.w3.org/wiki/LargeTripleStores  
16 http://kaon2.semanticweb.org/  
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of linked open data, a number of existing bioinformatics resources have adopted SW as 
data exchange standards: Entrez Gene, EBI data resources, KEGG, and many more 
[106,107]. The importance of semantic data integration and mining in the life science 
domain was brought to limelight by the Bio2RDF and subsequently by Linking Open Drug 
Data (LODD) project [82,107]. These projects demonstrated the possibility of querying 
heterogeneous life science resources (public) as linked data. Steady efforts by W3C’s 
Semantic Web interest group to focus on Health Care and Life Sciences (HCLSIG) has led 
to the launch of projects such as for modeling ontologies [108], RDF-based graph system 
(LinkHub [109]), biological pathways (BioPAX [110]), and drug discovery (AlzPharm 
[111], TMKB [112][113]). A series of annually hosted DBCLS BioHackathons17 serve as 
the driving force to integrate life science databases using SW technologies, through 
improved interaction between providers of data and bioinformatics tools. Recently, "The 
Monarch Initiative18" has taken the semantic route to enable reasoning over genotype-
phenotype equivalence (similarity analysis of biochemical models) for generating new 
hypothesis and prioritising candidates/variants within and across species. 
A number of initiatives and projects are striving to advance neuroscience research by 
allowing sustained interlinking between data using SW technologies. Government-
sponsored endeavours such as the USA’s BRAIN19 initiative and Europe’s Human Brain 
Project (HBP)20 are among a few leveraging on SW technologies for data management. 
Under the premise of the US government, the Neuroscience Information framework (NIF)21 
project, an initiative of NIH Blueprint for Neuroscience, aims to advance neuroscience 
research by providing “one-stop-shop” to public neuroscience data and tools in a 
semantically enhanced networked environment. Some of the NIF – backend research 
outcome includes BIRN, NIFSTD, NeuroLex, and many more 22 . Other NIH-funded 
                                                
17 http://www.biohackathon.org/  
18 https://monarchinitiative.org/  
19 http://www.darpa.mil/program/our-research/darpa-and-the-brain-initiative  
20 https://www.humanbrainproject.eu/en/  
21 http://neuinfo.org  
22 https://neuinfo.org/Resources/search?q=%2A&l=  
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projects that use SW technologies include BD2K [114], and Commons23. The Open Science 
Framework24, the International Neuroinformatics Coordination Facility’s (INCF)25, the 
Neuroscience Database Gateway (NDG) [115], NeuroML26, DARPA’s Big Mechanism 
program [116], and others are fostering community efforts to use SW technologies as the 
core to catalyse neuroscience research. Originally as a part of HBP, the SenseLab project 
provides a suite of interrelated databases to gain insights into the neuronal basis of 
behaviour [117]. As part of SenseLab, the BrainPharm database27 stores information of 
NDD drugs/agents targeting neuronal receptors and signal transduction pathways 
(differentiates between diseased and healthy). The Linked Neuron Data (LND) [118] 
provides a platform for integration of multi-scale brain and neuroscience data and 
knowledge sources with the aim to understand the association between cognitive functions 
and brain diseases. Currently, LND integrates structured neuroscience knowledge from 
Allen Brain Atlas, NeuroLex, NeuroMorpho, Mesh terms, etc. The IMI’s Open PHACTS 
project [119] aimed to integrate diverse chemical and biological data resources for 
pharmacological research. Apart from these, BioGateway, BAMS, NeuroMorpho, 
NeuroSynth database, Entrez Neuron, DisGeNet, Cognitive Atlas, to name a few also apply 
SW technologies [120]. For more details refer to Nielsen for neuroinformatics databases 
[121] and Okano et al. for brain mapping projects [120].  
Among the several collaborative AD projects that receive European Union funding and that 
are under Framework Programme, European Medical Information Framework (EMIF)28, 
AETIONOMY30, EU Joint Programme – Neurodegenerative Disease Research (JPND)31, 
and ELIXIR32 utilise(-d) (partially-)SW technologies for data management. One notable 
community effort in AD is The Alzheimer Research Forum (Alzforum) [122], which 
                                                
23 https://datascience.nih.gov/commons  
24 https://osf.io/  
25 https://www.incf.org/  
26 https://www.neuroml.org/  
27 https://senselab.med.yale.edu/brainpharm/  
28 www.emif.eu 
30 http://www.aetionomy.eu/en/vision.html  
31 http://www.neurodegenerationresearch.eu/  
32 https://www.elixir-europe.org/about-us/how-funded/eu-projects  
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benefits from both social and technical solutions to nurture productive discussion and 
informal discourse to advance AD therapeutics. Alzforum’s SW initiative, AlzSWAN 
(SWAN — Semantic Web Applications in Neuromedicine) is a hypotheses management 
system that captures a significant amount of AD scientific discourse from hypotheses, 
claims, dialogues, publications, and digital repositories. Active participation of Alzforum 
in the HCLSIG has led AlzPharm development – integrates BrainPharm and SWAN [111]. 
The Global Alzheimer’s Association Interactive Network (GAAIN) project [80] attempts 
to build a global collaborative platform for sharing AD data such as ADNI, by overcoming 
data-sensitive sharing impediments. 
1.6 Knowledge	discovery:	Needles	in	stacks	of	needles		
An important requirement for any data integration approach is to first capture the relevant 
data from diverse resources in an efficient and effective way. However, the most common 
problem is to condense useful information from these data mountains and transform them 
into actionable knowledge. Several data mining methods have shown great promise in 
closing the gap between large disparate data and discovering hidden/new knowledge. In 
this thesis, we have focused on three major data sources: databases, literature, and 
transcriptomic data. 
A compendium of transcriptomic studies provides quantitative information on the state of 
the gene in a cell. Most certainly, modeling of interactome and regulatory relations 
represent confirmed knowledge when derived from omics data. However, they do not 
account for the domain knowledge, which is important in any scientific discovery. 
Databases provide a systematised collection of biologically important information; 
increasing in number every year according to Nucleic Acids Research journal’s annual 
compendium of peer reviewed databases [123]. However, they do not fully represent the 
current state of rapidly growing knowledge. Conversely, vast collections of literature data 
are a massive body of existing current knowledge that can fill knowledge gaps and assist 
in informed decision making. However, due the data deluge, it becomes unmanageable. 
Below we discuss how data mining approaches applied to these data models contribute to 
knowledge discovery.   
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1.6.1 Omics	data	analysis:	complex	biological	data	streams	
The advent of high-throughput technologies has fuelled the search for unique molecular 
markers that govern the information flow in “the central dogma” framework of molecular 
biology. Omics-based approaches are now broadly used for the identification of disease 
markers and understanding underlying pathomechanisms; supporting hypothesis-free 
elucidation. Particularly, it provides a holistic view of genes (genomics), gene expression 
(transcriptomics), proteins (proteomics), and metabolites (metabolomics) through a variety 
of techniques including mRNA and miRNA arrays, NGS, and mass spectrometry [124]. 
Recent research has led to the revelation that RNA is not just a simple genetic messenger 
but rather plays a central role in translating genetic code into protein, gene silencing, post-
transcriptional regulation, and as a modulator of epigenetic elements [125]. Relative to the 
fixed nature of DNA sequence variation, gene expression varies tremendously between 
tissues, cells, and response to external stimuli [126]. Thus, gene expression profiling, 
encompassing many species of RNA such as miRNA, mRNA, and snoRNA, represents a 
rich source for early diagnosis by revealing altered transcriptome signatures of the cells, 
and tissues under a given biological state [127]. 
Quantification of RNA abundance using microarray technologies [128] or, more recently, 
developed RNA-Seq [127] methods have led to the accumulation of large amounts of data 
in public repositories. As of 15th March 2018, GEO contains 2,429,236 samples from 4,348 
datasets[129] and ArrayExpress hosts 70,834 experiments [130]. Although RNA-Seq is a 
substantially advanced technology with several advantages over microarray [127,131], 
microarrays are still widely used as they are less expensive, more consistent with the 
already existing wealth of data, and there exist substantial number of robust statistical 
methods [132,133]. Extracting biological information from these data is done by 
identifying individual genes (differentially expressed (DE) genes) associated with a 
particular biological effect (such as fold change) or finding global signatures composed of 
multiple gene expression changes. A more consistent and robust approach is looking for 
genes that share a particular biological characteristic [134]. However, low reproducibility 
and low overlap with similar studies performed by other study groups, render gene 
expression levels incomparable, mainly arising due to several technical and biological 
variabilities like applied analytical methods, different platforms, and dependency on library 
preparation [131,135,136]. Due to difficulties in acquiring human brain tissue and the 
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associated cost, NDD research experiments are composed of small sample sizes, resulting 
in less robust gene signatures and missing out on less apparent signals [137]. Thus, there is 
a need to fully exploit the existing data for more compelling evidence that could pave way 
for next ground-breaking discoveries. 
Combining multiple transcriptomic studies (termed as “cross-platform normalisation 
(CPN)”) or their results (termed as “horizontal meta-analysis”) has been advocated to 
increase the power of derived conclusion by overcoming the biases of individual studies 
[137–140]. These approaches have been used to uncover disease subtypes, predict survival, 
discover new biomarker and therapeutic targets [141–144]. Although it is argued that CPN 
is more powerful, it is less frequently used as: (i) it fails to eliminate batch effects across 
experiments (ii) very few well-established algorithms are available and (iii) increased 
complexity of data integration [145]. Refer to Rudy and Valafar for detailed comparative 
analysis of different CPN methods [146]. Most current meta-analysis methods are gene-
centric, combining DE genes based on majority voting, gene rank aggregation, and 
combining univariate summary statistics, such as p-values and effect sizes [147–149]. A 
more consistent and robust approach is through functional enrichment of the identified 
genes using established pathway knowledge such as KEGG [150], MSigDB [151], or, more 
recently, NeuroMMSig [152]. For the majority of the meta-analysis approaches, functional 
enrichment has become a standard follow-up. However, these approaches often have a 
tendency to converge towards genes that express in large magnitudes and generated 
hypotheses are restricted by current understanding of pathways. Moreover, these 
approaches do not shed light on the coordinated genes that collectively orchestrates the 
underlying (patho-)mechanism, unravelling dysregulated events heralding known and 
unknown patterns. Network-based approaches that rely on the coherence of functionally 
dependent genes could ameliorate DE gene’s dependency and increase confidence in 
biological validation by collapsing the number of testable hypotheses with regulatory clues. 
1.6.2 Biological	network	inference		
Cellular and molecular components work in concert with a large number of dynamic 
partners — directly or indirectly — to execute or govern cell/tissue phenotypes [153]. The 
power of biological networks resides precisely in simplifying the complex systems merely 
as nodes (biomolecules) and edges (intramolecular interactions) in the form of pathways, 
protein-protein interactions (PPIs), miRNA-target interactions (MTIs), among others. In an 
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attempt to dissect higher level organisation of molecular and cellular communications, 
information on modules of genes, proteins, or miRNAs that are physically associated, or 
functionally co-ordinated are translated into physical and functional networks. Physical 
interaction networks represent how biomolecules of interest interact with each other. 
Functional networks aim to connect not only interacting but also non-interacting 
biomolecules that depict functional or regulatory dependencies; examples include 
pathways, co-expression networks (CENs), and gene regulatory networks (GRNs). 
Analysis of these networks relies on characteristic topological properties, which serve as 
scaffold information for global and local graph theory [154–156]. Through these networks, 
useful discoveries for identification of putative biomarkers, understanding the disease-
driving mechanisms, and insights into the research findings can be made.  
Network inference (NI) methods have recently emerged as highly effective “reverse 
engineering framework” to reconstruct biological networks based on educated inference 
from data profiles, reducing the cost and time associated with the experimental 
investigation by prioritising putative candidates [157–161]. In the last few years, we have 
seen a swarm of NI approaches that majorly fall under: (i) deconvolution methods applied 
to the literature [162,163], databases [150], and multi-omics data and (ii) prediction 
algorithms based on thermodynamic stability, and sequence similarity [164,165].  
Networks inferred from literature and databases represent “what is already known” and are 
usually used as reference or gold standard to put the inferred results from other NI 
approaches in a specific biological context. Although, these networks as quite large, most 
of the interactions cannot be easily filtered for a specific biological context and data formats 
are not easily interchangeable. Recent endeavours have led to the development of 
standardised languages that use rich semantics for modelling networks: OpenBEL, and 
PySB [166]. On the other hand, use of genomic profiling technologies is more reliable for 
uncovering previously unknown and underappreciated mechanistic links along with 
involved putative candidates. Genomic data-based NI approaches have transformed 
biological research by enabling comprehensive monitoring of co-expressed and co-
regulated components. I refer the reader to Lee et al. [167] for conceptually different GRN 
methods, Markowetz et al. [168] for other NI approaches, and a book chapter by Vert [169] 
for machine-learning based NI approaches. Series of The Dialogue for Reverse Engineering 
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Assessment and Methods (DREAM) challenges allow comparison of strengths and 
weaknesses of different network inference methods33. 
Gene regulatory networks and co-expression networks 
Most researchers mistakenly use GRNs and CENs synonymously, however, the latter may 
contain co-regulated genes that represent the former [170–173]. CENs comprise of gene 
clusters where the edge (non-directed) represent similarity or dependency in expression 
patterns between two genes across tissues/cells. Similarities are usually quantified by 
Pearson correlation, Spearman correlation, mutual information, or linear modelling [174–
176]. On the other hand, GRNs (directed graphs) capture regulatory relationships (such as 
causal influence, and transcription regulation) assuming that changes in expression level of 
regulatory elements should be mirrored in expression levels of its regulated elements [170]. 
Allen et al. proposes four co-expression measures to define gene similarity metric for 
inferring GRNs [177]: (i) probabilistic-based, e.g. Bayesian networks [178] (ii) correlation-
based, e.g. Weighted Correlation Network Analysis (WGCNA) [179] (iii) partial 
correlation [180], and (iv) mutual information-based (MI), e.g. ARACNE [181], MRNET 
[182], and CLR [183]. For details of these measures, I refer the reader to Song et al. [184] 
and Kiani et al. [185].  
Failure to identify more complex dependencies between the genes by correlation-based 
methods is overcome by MI methods. Moreover, MI-based methods apply refinement 
approaches to eliminate indirect interactions for a given threshold using empirical 
distribution (CLR), Data Processing Inequality (ARACNE), maximum 
relevance/minimum redundancy criterion (MRNET), and predictions based on estimates of 
MI values with a maximisation step (C3NET [186]). Although Bayesian inferred networks 
are capable of modelling higher order dependencies, they lack feedback loops and some 
are limited to time series data [187,188]. A recent trend, ensemble-based methods are 
reported to improve stability and accuracy by formulating feature selection using random 
forests [189], gradient boosting [190], least angle regression [191], and partial least squares 
[192]. Briefly explained, these methods apply NI approach(-es) on bootstrapped data, 
aggregating the results in a final network; examples include BC3Net [193], and GENIE3. 
                                                
33 http://dreamchallenges.org/publications/  
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Clearly, these methods have an advantage of being straightforward and efficient on large 
computer clusters. A recently patented approach by Leiserson et al., called the heat 
diffusion based genetic network analysis [194], identifies known and unknown pathways 
by determining local neighbourhood influence of each mutated gene via physics of heat 
diffusion in the network [195,196] has brought a lot of attention to GRNs.  
Choice of the method to infer GRNs depends on the studied conditions such as type of data 
(real or simulated), network size, number of samples, noise level, experimental design 
(intervention, observational), underlying interaction structure (scale-free, random), error 
measure (local, global), among others [197]. However, recently, de Matos Simoes et al. 
demonstrated for C3Net, BC3Net, and ARACNE that the differences are not large if one 
focuses on the biological consistency rather than technical [198]. 
Application of GRNs and CENs in AD 
Using public transcriptomic data, Rhinn et al. identified key regulatory molecules (APBA2, 
FYN, RNF219 and SV2A) and pathways (endocytosis, intracellular trafficking) involved 
in APOE-based risk for LOAD [199,200]. Their work focuses on differences between 
diseased and healthy co-expression patterns. Zhang et al. [201] identified eight immunity- 
and microglia-specific genes, including TYROBP, strongly dominating the LOAD 
pathology; inferred from GRNs generated using 1,647 post-mortem brain tissue of LOAD 
and non-demented subjects. From these results, the authors concluded that the causal 
network framework was a useful predictor of response to gene perturbations and could be 
used to test models of disease mechanisms underlying LOAD. Forabosco et al. [202] 
reported TREM2 to be a hub gene in 5 out of 10 brain regions in neuropathologically 
normal individuals using the co-expression network analysis. Additionally, they found 
highly enriched genes in TREM2-containg module that are genetically implicated in AD, 
sharing common pathways centred on microglia functioning. Miller et al. [203] identified 
convergent and divergent co-expression modules between 18 human and 20 mouse public 
microarray datasets. Significantly, they determined three hub genes (for human only) with 
zinc-finger motifs, whose exact functioning in dementia was previously unknown. In a 
similar approach, Ray et al. [204] revealed transcriptional commonalities that might 
explain the co-occurrence of cardiovascular diseases and AD. Additionally, several efforts 
have been made to unfold the links and common mechanisms between AD and ageing 
[134].  
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The current multi-omics-based GRN approaches have an intrinsic limitation of dependency 
on (i) known interactions catalogued in databases and literature for follow-up analysis (ii) 
well-known gene candidates to refine networks within its proximity and (iii) restricting 
inference on genes that exhibit a clear shift in expression behaviour. This means that the 
derived results have a tendency to converge to “what is already known”, missing out on 
lesser-known candidates. Additionally, none of the above approaches elaborates on 
context-specificity and completeness of the generated networks, undermining the modules 
that approximate the biological truth.  
1.6.3 Biological	databases	
Databases provide convenient, searchable, visualisable, and computable access to 
organised prior knowledge. They are indispensable research tools for translating “big data 
to big discovery”, hosting enriched and pertinent information, [205]. Biological databases 
are developed for diverse purposes and encompass heterogeneous data types, and formats, 
refer Kumari et al. [206]. These databases can be classified based on: 
• type: primary, secondary (curated or/and value-added) 
• nature of stored information: RNA, drugs, pathway, miRNAs, among others 
• curation: expert-curated, community curated (crowd-sourced) 
• storage type: MySQL, NoSQL, flat files 
Primary databases host experimentally derived raw sequence read data (for proteins, 
nucleotide, so on) or macromolecular structure, which is directly submitted by the 
researchers; examples include ArrayExpress [207], miRBase [208], and GEO [129]. 
Secondary databases, mostly curated, build upon the information derived from primary 
databases. For example, ExpressionAtlas derives knowledge about gene expression 
patterns from ArrayExpress archive [209]. Zou et al. provides a comprehensive overview 
of human databases, categorised based on the data type and nature of information stored 
[205]. Highly knowledgeable and experienced biocurators critically assimilate and review 
the information before being stored in expert-curated databases, namely UniProt [210,211]. 
Crowd-sourced databases have proven to be an efficient, economical, and faster way to 
harness knowledge from the scientific community with broad coverage; RiceWiki is a good 
example [212]. Relational databases (e.g. MySQL and PostgreSQL) are an efficient way to 
access structured information using declarative query language (e.g. SQL) for a pre-
specified set of operations and schema. NoSQL databases are whiteboard friendly that 
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reflect our natural thinking and support agile development for dynamic schemas and are 
quickly scalable for additional data integration [213]. NoSQL databases include key-value 
stores (e.g. Berkeley DB), document stores (e.g. MongoDB), wide column stores (e.g. 
Cassandra), and graph databases (e.g. Neo4j) [214].  
Community efforts keep researchers abreast with the growth of bioinformatics tools and 
databases in the form of trusted directories/databanks, such as Biological Links Directory 
[215], and OmicTools [216]. Several core bioinformatics organisations provide an 
amalgamation of multiple primary and secondary databases covering different data types 
and species; examples include NCBI [217], EMBL-EBI 34 , and Swiss Institute of 
Bioinformatics [218]. In addition, several commercial ventures such as Ingenuity 
Pathway35, NextBio36, and MetaCore™37 provide a wealth of curated information in a 
structured form. However, most of the databases vary in data quality and become obsolete 
over time [219].  
Primary transcriptomic repositories, namely GEO and ArrayExpress, provide a wealth of 
molecular data to conduct integrative meta-analysis and inferring GRNs. This allows 
researchers to reproduce and/or reanalyse existing data for new discoveries, especially 
when the data availability is limited (see section Omics data analysis: complex biological 
data streams). To consistently integrate heterogeneous data, accurate details of the 
associated metadata information including patient’s age, gender, pathological diagnosis, 
and comorbidity are crucial in clinical practice. In addition, mapping of this information to 
standard ontologies could increase the compatibility and usability across studies. The 
Ioannidis study [220] highlighted the importance of metadata information in reproducible 
science. Pioneering attempts to adopt guidelines for submission of minimum metadata 
information required for data reproducibility such as MIAME38 and MINISEQE39, still lack 
compliance. Often, the data submitter and data generator are different persons, increasing 
                                                
34 https://www.ebi.ac.uk/services/all  
35 https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/  
36 http://www.nextbio.com/b/nextbio.nb  
37 https://lsresearch.thomsonreuters.com/pages/solutions/1/metacore  
38 https://www.ncbi.nlm.nih.gov/geo/info/MIAME.html  
39 http://fged.org/projects/minseqe/  
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the risk of errors and missing information [221]; sometimes leading to the metadata 
information being scattered in the associated publication(s). There is no easy way to tackle 
this problem and extensive manual effort is needed. Several (non-)commercial value-added 
databases and tools such as NextBio, and ArrayExpress have invested considerably to 
manually extract and correct the missing and erroneous metadata information. Indeed, to 
our knowledge none of the value-added databases capture NDD specific metadata 
information. In addition, they fail to explicate annotations that distinguish diseased human 
from NDD-induced immortalised cell lines, and mouse/rat strains, which are critical for 
translating preclinical studies to drug trials. Thus, there is a need for a dedicated approach 
to extract and refine metadata annotations catered to NDD research. 
1.6.4 Text	mining:	discovering	hidden	connections	
Biomedical literature is the key communication channel for scientific findings and 
hypotheses in the form of research articles, conference proceedings, reviews, books, and 
monographs [222]. Advancing with impressive speed, automated technologies — text 
mining — have complemented the manual reading for extracting and reconstructing mosaic 
of non-trivial and implicit knowledge from unstructured (or semi-structured) text, along 
with provenance [223]. Although not trivial, text mined information has the capability to 
shed perspective on modeling complex biological systems by summarising the entirety of 
prior research [224]. Text mining techniques can be simply abstracted to four phases: 
information retrieval (IR), information extraction (IE), knowledge discovery (KD), and 
hypothesis generation [225,226]. 
IR deals in identifying and triaging relevant textual sources to seek background 
information, addressing a research question at hand. For the overview of current IR 
tools/services refer to Lu et al. [227]. In the biomedical domain, IE involves identification 
of predefined classes of biomedical entities (genes/proteins, miRNAs, drugs, etc.) and 
relations between these entities (drug-gene, gene-miRNAs) from the text. Tagging key 
biological entity mentions in the text is the first step in IE, called as named entity 
recognition (NER), performed using predefined vocabulary (dictionary-based), applying 
rules (rule-based), or classifying (machine-learning-based) on the basis of training data 
[228,229]. Relation extraction (RE) adds context to the identified entities by extracting 
relationship(s) between them through association-based (co-occurrence and tri-occurrence) 
or natural language processing (NLP)-based methods [222,230,231]. More narrowed 
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application of RE is event extraction (EE) [232], which focuses on identifying specific 
events such as phosphorylation, and inhibition. To benchmark the developed methodology, 
several expert-annotated reference corpora are available, but they do not cover all the 
entities and relations [230,231,233]. In contrast to IE, which extracts nuggets of 
information, KD aims to extract new knowledge for answering biomedical queries [234]. 
Furthermore, hypothesis generation infers novel and testable insights from hidden clues in 
the text that are not easily derivable through expert reading [235]. However, text-mined 
information is error prone and must be crucially assessed by human experts as they are 
inherently limited by variable quality, lack of systematisation, and absence of reporting 
negative data [236–238]. Several annotation tools are in place to speed up manual curation 
process [239–241]. Specialised databases are established to provide standardised and 
structured accessibility of the harvested literature knowledge [242–245]. 
Many cellular functions — biological and pathological — are a result of cross-talk between 
different bio-entities, namely genes, proteins, transcription factors, and miRNAs. 
Therefore, to fully uncover the modular organization of the cellular networks it is crucial 
to elucidate these players. Although extensively researched, protein-coding genes represent 
only 2% of the human genome suggesting that PPIs are just half of the story in AD biology. 
With the beginning of miRNA era in 2001, non-coding RNAs have become attractive 
targets and research topic for novel diagnostic and therapeutic approaches [246]. 
Information about miRNA’s regulatory roles has been widely discussed in the literature. 
Thus, utilising biomedical text-mining approaches to extract new evidence from existing 
literature has become very crucial to drive AD research.  
MicroRNAs (miRNAs) are highly conserved small non-coding RNAs (21-25nt), post-
transcriptionally regulating 30% of protein-coding genes through mRNA degradation and 
translational inhibition. Previous studies have reported on the essential roles of miRNAs in 
neuronal functioning, and survival and its potential implications in modulating AD genes 
[247–249]. The cross-talks between AD-related miRNAs and genes/proteins are far more 
intricate and dynamic than anticipated but poorly understood. Significant research efforts 
in dissecting miRNA-related associations (e.g. miRNA-target, miRNA-disease) have 
resulted in high-quality databases, curated networks, and prediction algorithms. In reality, 
relative to PPIs, automated text-mining methods dedicated to the identification of miRNA-
related relationships are limited and not widely adopted [250]. Indeed, resulting in a lack 
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of expert-annotated corpus needed for benchmarking the developed tools [251]. Thus, there 
is a clear need for automated text-mining approaches/tools/resources to support and drive 
the miRNA research for a new perspective on diseases at post-transcriptional level. 
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Chapter	2 Goals	and	Objectives		
Enabling scientists to reuse and extend the work of other researchers is frequently perceived 
to have “an upper hand” in generating time and cost efficient testable hypotheses, assisting 
biomarker and mechanism discovery. Repurposing public data using data collation and 
integrative approaches could act as an evidence store for deriving new knowledge where 
traditional approaches fail to deliver [252]. Several studies and projects have employed 
data mining approaches on public data to identify novel mutations, genes, pathways, among 
others that were previously undetected in AD [253–255]. These reports are a proof that 
retrospective analysis of public data can provide important insights for clinical utility. 
However, they have also inherently raised several questions illuminating fundamental 
aspects of data reusability and retrospective analysis: (i) lack of high-quality and 
informative data (ii) lack of sufficient metadata information for more focused reanalysis 
(iii) overfitting the developed models to prior knowledge (iv) data bias, and (iv) a need of 
a high-quality pre-competitive infrastructure for data integration.  
2.1 Issues	addressed	and	goal	of	this	thesis	
Motivated by the need of novel approaches for integrative analysis and considering the 
scepticism around public data, the primary goal of my PhD thesis is to provide improved 
and novel solutions for accessibility, reusability, and unbiased retrospective analysis of 
high-quality public data with a potential impact on uncovering previously unattended AD 
insights towards real world drug development. In this thesis, I offer a perspective on the 
looming central issues of data reusability and limitation of current approaches that hinder 
the progress in research on AD therapeutics. 
Taking into account my previously made statement: “Technological and data resources 
required to determine links to diseases are pieces of the puzzle that when put together, 
promise to reveal novel regulators in pathomechanisms. — refer page 9”, the objectives 
of my thesis work are summarised in Figure 2.1. The specific objectives of this thesis 
addressing the issues stated above and in Chapter 1 are:   
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Figure 2.1: Objectives of my thesis work 
1. Problem Statement: Problems for data integration are rooted in the data itself; 
resources are broadly distributed, across the web and encompass heterogeneity and 
diversity in data formats, concepts, semantics, syntax, to name a few. Of course, 
these approaches have strengths and limitations and there is no “one-size fits all” 
solution [75,92]. Furthermore, these integration solutions are local and fail to 
operate at the global level and cannot cope with the updates of resources such as 
newly added information and changes in the data structure, formats, and naming 
convention. In general, most of these approaches overlook the importance of data 
quality, and context-specificity. — page 10  
Objective: To build a high-quality and domain-specific pre-competitive 
infrastructure for intellectual integration of existing resources to facilitate 
interrogation of the distributed data legacy; enabling a systematic and objective 
prioritisation of molecular protagonists and mechanisms in AD 
2. Problem Statement: Many cellular functions — biological and pathological — are 
a result of cross-talk between different bio-entities, namely genes, proteins, 
transcription factors, and miRNAs. Therefore, to fully uncover the modular 
organization of the cellular networks it is crucial to elucidate these players. 
Although extensively researched, protein-coding genes represent only 2% of the 
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human genome suggesting that PPIs are just half of the story in AD biology. With 
the beginning of miRNA era in 2001, non-coding RNAs have become attractive 
targets and research topic for novel diagnostic and therapeutic approaches [247]. 
Information about miRNA’s regulatory roles has been widely discussed in the 
literature. Thus, utilising biomedical text-mining approaches to extract new 
evidence from existing literature has become very crucial to drive AD research. — 
page 25 
Objective: To develop an automated text-mining method for extracting new 
interaction evidence from existing scientific literature using miRNA research 
domain as an example.  
3. Problem Statement: Indeed, to our knowledge none of the value-added databases 
capture NDD specific metadata information. In addition, they fail to explicate 
annotations that distinguish diseased human from NDD-induced immortalised cell 
lines, and mouse/rat strains, which are critical for translating preclinical studies to 
drug trials. Thus, there is a need for a dedicated approach to extract and refine 
metadata annotations catered to NDD research. — page 24 
Objective: To develop a comprehensive and highly curated metadata database for 
public NDD gene-expression studies that allow precise selection of data subsets for 
meta-analysis and translational research 
4. Problem Statement: The current multi-omics-based GRN approaches have an 
intrinsic limitation of dependency on (i) known interactions catalogued in 
databases and literature for follow-up analysis (ii) well-known gene candidates to 
refine networks within its proximity and (iii) restricting inference on genes that 
exhibit a clear shift in expression behaviour. This means that the derived results 
have a tendency to converge to “what is already known”, missing out on lesser-
known candidates. Additionally, none of the above approaches elaborates on 
context-specificity and completeness of the generated networks, undermining the 
modules that approximate the biological truth. — page 22 
Objective: To establish an approach for constructing a more reliable and complete 
large-scale AD GRNs that is not biased towards prior knowledge, but rather extends 
the scope to not so obvious players 
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2.2 Thesis	organisation	
The dissertation consists of four publications, fulfilling the above listed objectives, 
organised as individual chapters40: 
RDF Framework for data integration In Chapter 3, an integrative approach based on 
RDF technology for modelling curated knowledge to prioritise potential AD candidates 
and mechanisms is introduced. This study utilises the data resources reported in Chapter 4, 
and Chapter 5. 
Extracting new interaction evidence from literature — applied to miRNA domain In 
Chapter 4, the state-of-the-art text-mining methodology for extracting miRNA mentions 
and its relations from biomedical literature is reported. In addition, the generated 
benchmark corpus to evaluate this and previously reported similar studies is described.  
Capturing metadata information from public transcriptomic studies In Chapter 5, 
systematic harvesting and curation of NDD-specific metadata from publically available 
transcriptomics studies is reported, which lead to the development of NeuroTransDB 
database. 
Knowledge-instructed gene regulatory network construction The high-quality and 
NDD-specific data harvested in Chapter 5 can contribute to more comprehensive meta-
analysis to derive new-novel insights in AD. Therefore, a new computational approach to 
construct more reliable GRNs across large-scale omics studies has been developed in 
Chapter 6. This approach is capable of identifying lesser-known players and mechanisms 
in AD. 
Conclusion and outlook The key aspects and utilisation of the work presented in this 
dissertation are concluded in Chapter 7. 
	
                                                
40 Supplementary files, other than supplementary figures and tables, from the publications are not included 
in this thesis. Please refer to the publication’s webpage for downloading these files.  
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Chapter	3 Semantic-based	Integrative	
Strategy	for	Candidate	Prioritization	
and	their	Mechanistic	Analysis	
 
3.1 Introduction	
Combining data and knowledge in a robust, scalable, shareable, and extensible framework 
is the fundamental need to understand the dynamics of neurodegenerative mechanisms. It 
increases the confidence of the derived hypotheses if the consensus is shown by different 
data resources. Indeed, such a framework should provide the capability to refine the search 
paths for dynamic exploration of the data without losing the underlying biological meaning. 
Disparate data types coming from literature, databases, imaging, omics experiments, 
GWAS studies, among others are an integral part of such a framework. However, 
assembling ever-growing information from several disciplines that represent complex and 
heterogeneous data is far from trivial. This is due to high variability in distribution, quality, 
representation, and applied statistical methods. If not addressed, these issues have a huge 
impact on the derived hypotheses and decisions made.  
This publication presents an approach using RDF framework to facilitate representation 
and integration of heterogeneous AD data. It shows that well-curated and precise data 
enables novel biomarker and mechanism discovery. It additionally points out the need and 
effort of manual curation for precise modelling. 
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Background
Alzheimer's disease (AD), the most prominent neurode-
generative disease (NDD), has become a global threat to
the aging society, affecting nearly 115 million people by
2050 [1]. The imperfect understanding of the AD
etiology has created a large gap in translating the pre-
clinical findings into clinical trials dominantly observed
in high drug attrition rates [2]. Early diagnosis and pre-
ventive interventions could facilitate substantial reduc-
tion in the number of affected cases to 9 million by 2050
[3, 4]. Particularly, reliable biological markers of disease
and disease progression could assist in early diagnosis
and treatments catered to the patient [5]. In this direc-
tion, considerable global research efforts have been dedi-
cated to investigate molecular players underlying AD
pathogenic events, contributing to an ever-growing
wealth of disparate data. Refinement of this information
into actionable knowledge representations requires a
good interoperable and formalized framework, capable
of inferring potential biomarkers across different facets
of the molecular physiology. Additionally, in silico
disease models that integrate complementary data from
various resources are capable of recapitulating key
mechanisms for a given condition [6–8].
Among others, most widely used data integration
strategies include data warehousing (e. g., Pathway Com-
mons [9]), data centralization (e. g., UniProt [10], IntAct
[11]), and federated databases (e. g., BioMart [12]). An
example of a data integration framework is tranSMART
[13], which consists of a data warehouse covering vari-
ous types of data and related data mining applications
required for translational research and biomarker
discovery workflows. Such a harmonized aggregation of
heterogeneous data sources facilitates interpretation over
a large knowledge space [14].
However, one fundamental challenge with most of
these integration approaches is to cope with the variabil-
ity and heterogeneity in content, language, and formats
of incoming data from different source repositories.
Moreover, regular updates of these data resources are
necessary to keep up with newly added information and
to avoid incompleteness. The inaccessibility to the inte-
grated data resources, due to altered database structure
or change in the naming conventions is unavoidable
[15]. Semantic web technologies have overcome the
above described challenges up to an extent by revolu-
tionizing the lossless exchange of data and formalizing
the data format into a computable knowledge [16],
calling it “smart data" [17]. The capability of using rich
formal descriptions for data and its standardized map-
ping allows complex querying in a more efficient way
without information loss.
Resource Description Framework (RDF) is the World
Wide Web Consortium (W3C) proposed standard for
semantic integration and modeling of data. RDF uses the
syntax of Extensible Markup Language (XML) and im-
poses structural constraints to represent the meta-data
as a set of triples containing directed edges. One big ad-
vantage lies in the usage of common namespaces across
the different data domains encoded as Unified Resource
Identifiers (URIs). Initiatives such as Identifiers.org [18]
provide persistent official identifiers in the biomedical
domain, allowing sustained interlinking between distinct
data resources. This allows high levels of seamless inter-
operability between data sources and the capability to
access and map against additional related data unam-
biguously, called data federation. On the contrary, large
efforts are still needed during an initial definition of the
ontologies to build the schema for data representation.
Semantics in life sciences
The idea of semantic web prevails in various domains,
including life sciences. Recently, "The Monarch Initia-
tive" [19] has taken the semantic route to enable reason-
ing over genotype-phenotype equivalence within and
across species. They leverage on ontologies to link exter-
nal curated data resources for generating new hypothesis
and prioritizing candidates/variants based on the pheno-
typic similarity. Stevens et al. [20] launched TAMBIS,
multi-data application tool, which allows biologists to for-
mulate complex molecular biology questions to databases
such as Swiss-Prot [21], Enzyme [22], CATH [23], BLAST
[24], and Prosite [25] through well-defined semantics.
Among the early users of RDF, Lindemann et al. [26]
applied it to centralize and flexibly access the heteroge-
neous and varying quality of medical data obtained from
several clinical partners. The importance of semantic
mining in the life science domain was brought to lime-
light by the Bio2RDF project [27], which demonstrated
the possibility of querying life science knowledgebases
by linking public bioinformatics databases and providing
public SPARQL endpoints. Subsequently, Linking Open
Drug Data (LODD) [16] demonstrated linking drug data
information from DrugBank [28] and clinical trials
resources. Chem2Bio2RDF [29] demonstrates the poten-
tial usage of the above two mentioned RDF repositories
in the field of chemoinformatics.
Observing the immense advantage of linked open data,
several major publicly available life science databases
such as UniProt, DisGeNet [30], Protein Data Bank
Japan (PDBj) [17], and EBI resources such as Gene Ex-
pression Atlas [31], ChEMBL [32], BioModels [33],
Reactome [34], and BioSamples [35], have made their
data available in the form of RDF. Thus, the RDF plat-
form has been increasingly adopted as a standard for
data exchange. Amidst prime users of RDF in elucidating
disease pathophysiology, Shin et al. [36] demonstrated
systematic querying of linked experimental data to
Iyappan et al. Journal of Biomedical Semantics  (2016) 7:45 Page 2 of 15
Semantic-based Integrative Strategy for Candidate Prioritization and their Mechanistic Analysis 
38 
 
explore the effect of genes that are regulated by volatile
organic compounds in human blood. Qu et al. [6]
showed semantic framework capability in drug re-
purposing by proposing Tamoxifen, an FDA approved
drug for Breast Cancer, as a candidate drug for Systemic
Lupus Erythematosus. The above reported association
has already been tested in mice by Sthoeger et al. [37],
showing a leverage of semantic web in a real world sce-
nario. Furthermore, Willighagen et al. [38] presented the
linkage of several RDF technologies in molecular che-
moinformatics and proteochemometrics.
To our knowledge, there has been very limited applica-
tion of semantic web approaches to the research of neuro-
degenerative diseases. Linked Brain Data (LBD) [39] is an
upcoming initiative which focusses on understanding the
brain functionality by integrating resources such as gen-
omic, proteomic, anatomical and biochemical resources
with respect to neuroscience. Using such a multi-level
knowledgebase, they aim to understand the association
between cognitive functions and brain diseases. Lam et al.
[40] made the first attempt to develop an e-Neuroscience
data integration framework, AlzPharm [41]. They ex-
tracted AD-related drug information from BrainPharm
[42] to be further integrated with manually inferred
hypotheses from the scientific literature and published ar-
ticles (SWAN [43]). They demonstrated the usage of such
a model by clustering AD drugs based on their molecular
targets and to filter publications (claims and hypotheses)
specific to Donepezil effect on treatment of AD. Although
AlzPharm made use of manually inferred hypothesis, they
lack the validation of their findings with experimental data
such as gene expression and pathways.
Motivation
Despite the current advancements in semantic web tech-
nology, we still do not have cure for complex diseases like
AD. One of the key reasons accountable for this could be
the increasing gap between generated data and the derived
knowledge. In order to increase the probability of the
derived knowledge to be novel, data quality and data
reliability is highly desirable. Moreover, the contextual
specificity of the data is of paramount importance.
Compared to relational database management system
(RDBMS) technologies, in RDF the relations have expli-
cit meaning (expressiveness) in a given context and are
directly accessible; allowing the user to extract meaning-
ful knowledge from the data as opposed to an unstated
structured data. In addition, RDF structures are more
adaptive and flexible, allowing fluidity in the data rela-
tionships. This overcomes the fragility of RDBMS; where
if the underlying representation of the keys and flat table
changes, the tentacled connections are lost. Moreover,
triples from RDF can be transformed into RDBMS struc-
ture and vice-versa. One another advantage of RDF is its
graph representation that enables us to better explore
relations through network topological characteristics
such as relatedness, network perturbation, centrality, in-
fluence, etc. The usage of automated reasoners have
largely been beneficial to understand the semantics and
to expand the associated relations [44].
In this paper we propose NeuroRDF, an approach harnes-
sing the potential of RDF as a framework for modeling neu-
rodegenerative diseases to enable a close, biologically
sensitive integration of well curated, complementary, and
multi-faceted data. The fundamental principle of this strat-
egy is to take advantage of semantics to develop a context
specific, multi-layered in silico disease model, represented
as a formalized, and computationally processable domain
knowledge. A fine-grained analysis of the metadata from
various data resources empowers the user to ask more fo-
cused questions around a hypothesized pathomechanism
involving previously neglected or hidden candidates, further
leveraged for experimental investigations. Considerable ef-
forts have been invested to process and manually curate
huge amounts of data that is required to build such a
knowledge base around a specific indication. This includes
for example the in-depth assessment of the respective
phenotype, the type of tissue used in an experiment, and in-
formation around the donor of the tissue like gender, age,
and possible comorbidities. Querying such a highly curated
and focused knowledgebase increases the chances of unrav-
eling novel hypothesis, which could have been lost over
time or pave way to newly emerging knowledge.
We used SPARQL to traverse each of these knowledge
graphs (derived from distinct resources) in an integrative
manner, allowing highly disease specific analysis of the
underlying data. Using this approach, we demonstrate an
example on how to prioritize novel candidates in AD
mechanism.
Methods
The developed generic semantic web-based workflow in-
tegrating heterogeneous data resources is outlined in
Fig. 1. This multi-layered model integrates data from
various public resources such as databases, literature,
and gene expression information. The harmonization of
heterogeneous data to build RDF models was achieved
by using several data/file parsers. The workflow also
includes a pre-processing step to monitor the quality of
each incoming data type for specificity.
Data collection and resources
This subsection depicts briefly the different data re-
sources integrated into the NeuroRDF.
Database-derived interactions for healthy brain
A closer look into the healthy human brain interac-
tions could improve identification of the dysregulated
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mechanisms which further surges the plausibility of
identifying AD drugs in clinical trails [45, 46]. How-
ever, the mainstream AD research is biased towards
the well known disrupted events such as APP, and tau
rather than recognizing their role in normal brain
functions [47].
Several publicly available databases provide protein-
protein interactions (PPIs) and microRNA-target inter-
actions (MTIs), which can be derived using multiple
sources and methodologies. For instance, Human Pro-
tein Reference Database [48], Molecular INTeraction
database [49], and miRTarBase [50] focus on experimentally
verified interactions that are manually mined from litera-
ture by expert biologists. In addition to literature-derived
information, Biomolecular Interaction Network Database
[51] centralizes interactions from high-throughput tech-
nologies. Few other databases such as STRING [52], and
miRWalk [53] also provide predicted interactions.
However, none of these databases mine interactions
specific to a given context (for example AD pathology
or normal physiology).
A lot of published healthy state PPIs are not directly
measured in human cells but in artificial conditions such
as human cell lines, human genes transfected into yeast
cells, etc., missing out on the biological plausibility in
humans and context specificity [54]. Hence, considerable
effort by Bossi and Lehner [55] was invested to verify
the tissue specificity of PPI interactions from 21 data-
bases (including a few above mentioned) using human
gene expression data. Furthermore, this additional action
to ensure validity of the interactions in normal state aids
improved prediction of genes in disease state [56]. In
that direction, our group has extracted a subset of these
experimentally confirmed PPIs belonging to healthy
brain physiology [57]. Currently, the healthy brain PPI
network contains 7,192 genes and 45,001 PPIs.
Extracting AD-specific interactions from literature
The bridging factor between researchers and scientific
accomplishments are published as texts, warehoused in
large repositories like PubMed [58]. These biomedical
articles are the major information source of functional
factors such as proteins, genes, microRNAs (miRNAs),
etc. However, their functional descriptions are scattered
as unstructured text in literature [59]. Text-mining
methods could help us mine these articles and retrieve
the associated relations/evidence for a given context.
Since proteins are the chief players in almost all bio-
logical processes and miRNAs have been established in
the last decade as important regulators of gene expres-
sion, we focus our current research on MTIs and PPIs.
In order to harvest AD-specific knowledge from the
literature, we used our in-house state-of-the-art named
entity recognition (NER) system ProMiner [60] and the
semantic search engine SCAIView [61]. Identification of
genes/proteins and disease mentions was accomplished
using dictionaries. The disease dictionary was built using
MeSH [62], MedDRA [63], and Allie [64] databases.
Currently, it contains 4,729 concepts and 64,776 syno-
nyms [65], which are normalized to MeSH names.
Human Genes/Proteins dictionary [60] was compiled
from three different resources: SwissProt, EntrezGene
[66], and HGNC [67]. Currently, this dictionary consists
of 36,312 entries and 515,191 synonyms. All the identi-
fied gene/protein names were normalized to HUGO
gene symbols for maintaining homogeneity across all
Fig. 1 Overall workflow of NeuroRDF. The workflow illustrates the collection of data from various resources such as databases, and literature,
followed by steps taken to pre-process and prune the collected data. These high-quality data are represented semantically as RDF models and
stored in a triplestore. The stored knowledge can later be queried for biologically interesting questions
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data resources and also for future comparisons and
visualizations.
To identify MTIs from MEDLINE abstracts, we applied
our previously developed approach [65]. Here we ex-
tracted novel miRNA mentions using a regular expression.
These mentions were normalized to miRBase database
identifiers [68]. In addition, relation dictionary containing
the major classes of relationship terms between miRNAs
and their target genes/proteins was also developed. A tri-
occurrence based approach was used to extract the MTIs
(co-occurring with a relation term) at the sentence level.
Using the above-mentioned dictionaries, our group
previously harvested AD specific PPIs from MEDLINE
abstracts and full text articles [69]. Here we used the
interaction terms compiled by Thomas et al. [70]. A
state-of-the-art machine learning based approach [71]
was applied to retain true pairs of PPIs in a given sen-
tence. Both approaches have been optimized for recall.
Hence, the obtained relations have been manually fil-
tered for false positives. After manual inspection, 339
PPIs for 301 proteins and 99 MTIs for 36 microRNAs
that are specific to AD were obtained. Articles published
in languages other than English could lead to increased
information content, however a dedicated approach to
harvest them is needed. Moreover, separate parsers are
needed. Thus, for this work we extracted interactions
from the biomedical literature in English.
AD gene expression data
A standard approach to test any generated hypothesis is
to assess the gene expression of the involved candidates
between affected and healthy patients or in the absence of
human data we fall back to animal models or derived cell
cultures [72–75]. High-throughput technologies such as
microarray, RNA-seq provide potential to measure gene
expression simultaneously for different experimental/bio-
logical conditions. These studies are assembled in widely
adopted public archives: The NCBI Gene Expression
Omnibus (GEO) [76] and ArrayExpress [77].
For querying AD-specific gene expression data, we used
previously developed database, NeuroTransDB [78], which
contains highly curated meta-data information for eligible
AD studies. It assembles studies from public resources
namely, GEO and ArrayExpress, using a keyword based
search approach. Among the 45 prioritized AD human
studies, we filtered for microarray studies that measure
gene expression in brain tissue extracted from both AD
and healthy patients. In addition, availability of raw data
was a mandate for applying uniform pre-processing. In
total, we obtained eight microarray studies to be integrated
in NeuroRDF: GSE12685, GSE1297, GSE28146, GSE5281,
E-MEXP-2280, GSE44768, GSE44770, and GSE44771.
To assess the quality of the arrays we applied ArrayQuali-
tyMetrics [79] package. The selected studies (independent
of the platform type) were pre-processed using Bioconduc-
tor (Version 3.0) packages in R [80], by applying similar
methods for maintaining consistency by reducing variance.
All studies conducted on Affymetrix chips were normalized
by robust multi-array average method (rma) [81]. Similarly,
package limma [82] was applied on Rosetta/Merck Human
44 k 1.1 microarray chip. All the chips were normalized for
background correction and quantile normalization. The
normalized intensity values were log2-transformed
and duplicate probes were averaged. To identify the
differentially expressed genes between healthy and
Alzheimer’s patients we used limma package by ap-
plying Benjamini and Hochberg's method to control
for false discovery rate (adjusted p-value ≤ 0.05).
Data curation
Although the current text-mining methods have started
to leverage expert curators to extract PPIs, MTIs, etc.
from text, the extracted information are still prone to
false positives [83]. Moreover, it is not straightforward to
use these systems for retrieval of context-specific triples
due to technological limitations [84]. Hence, the meticu-
lousness of the identified triples to occur in a certain cell
type, disease state, or events captured in AD-specific
documents is not guaranteed. Thus, the need for manual
verification is unavoidable, especially when considering
the full text articles. The previously published test cor-
pus used for evaluating the constructed AD PPI network
contained AD-specific PPIs extracted by the machine
learning approach from 200 full text articles [69]. Man-
ual inspection by the authors resulted in retaining PPIs
from 38 articles that are truly specific to AD, thus dis-
carding 81 % of the originally retrieved articles. Similarly,
we retained only 68 abstracts from 250 articles (27 %)
that were retrieved using our tri-occurrence based ap-
proach for AD MTIs [65]. Thus, we can conclude that
only about 20–30 % of the (relation extraction based)
extracted PPIs and MTIs are truly relevant to AD, point-
ing out the need of manual curation.
Similarly, in our recent publication [78], we have
highlighted the key issues related to retrieval and reusabil-
ity of the datasets from public transcriptomics archives,
such as GEO and ArrayExpress. We showed that a simple
keyword based search not necessarily asserts the specifi-
city of the retrieved datasets to the queried disease or
organism. When manually inspected, we reported nearly
20 % of these retrieved studies to be irrelevant for AD
query. In addition, basic metadata annotations such as
age, gender, etc., which strongly contributes to the differ-
ential estimates, were observed to be incomplete. Brazma
et al. [85] had earlier reported that not all the data submit-
ted to GEO or ArrayExpress are MIAME compliant [86].
We additionally noticed these missing annotations being
scattered as unstructured prose in database webpages,
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publications, supplementary material, figures, etc., leading
to a steep increase in the needed curation effort. Al-
though the published research articles are rich in anno-
tations, a large number of experiments have missing
citations [87], which have to be added manually. More-
over, inconsistencies between the information stored in
the archives and in the associated publications were
also noted. On an average, about 30 min to 2 h of cur-
ation effort was needed to retrieve pertinent informa-
tion for a single dataset. The outcome of this work
resulted in a highly curated metadata database, Neuro-
TransDB, which is used in this work for extracting rele-
vant AD gene expression studies.
Generation of RDF models
RDF data model
RDF allows the generation of models for processed data
that exchanges information on the Web [82]. The RDF
data model stores all the relationships between different
entities as triples (subject-predicate-object). In RDF
terminology, the subject, the predicate and the object
are known as resources and are represented by a
unique “Uniform Resource Identifiers (URIs)" in order
to support global data exchange. Literals are constant
values such as numbers and strings mapped to the re-
sources. Literals can only be used as objects but never
as subjects or predicates.
RDF schemas
We constructed the RDF schemata by abiding the stand-
ard RDF graph notation where an ellipse represents
Resource, an arrow for Property, and rectangle for Literal.
In all the RDF schemas, we have maintained a common
resource representation for the “Gene" namespace adapted
from Bio2RDF that maps to the NCBI gene database. For
the namespaces with no available ontologies, we created
an internal namespace, called “SCAI". Some of the proper-
ties were described using URIs from Dubin Core Metadata
Element [88].
Four separate schemas (for each data resource) have
been generated that are centered on genes for interoper-
ability, associating each gene product to its official gene
symbol. In the AD PPI schema (see Fig. 2), proteins and
their interactions were represented using the Uniprot
Core Ontology [89]. Supporting literature evidence were
adapted to URIs from Bio2RDF namespaces. The article
resource was linked to its PubMed ID, sentence in which
the interaction has been mentioned, and the associated
journal. Experimental evidence that validates the given
interaction (if any) were mapped to BioPax [90], MGED
[91], ONTOAD [92], and SCAI namespaces. In the MTI
models (see Fig. 3), literature, genes, and proteins name-
spaces were adapted similarly to the PPIs. To represent
the miRNAs, we applied the Bio2RDF namespace that
links it to miRBase database [93].
For the PPI schema encoding the healthy state, as seen
in Fig. 4, we used the same ontologies as in case of AD
PPI. Additional interaction evidence such as brain
region, reference database, experimental evidence, and
literature information were described using Core, BioPax,
and Bio2RDF namespaces.
The microarray schema has two branches that are
linked to the experiment: sample details and differential
expression analysis. The majority of the resources and
properties are linked to URIs from EBI's Atlas (atlas) [94]
and MGED [91] namespaces, cf. Fig. 5. Gene expression
experiments could contain several samples that are
measured in different conditions. A detailed description of
Fig. 2 Schematic representation of the Diseased PPIs in RDF. The figure describes AD specific PPI interactions along with supporting evidence
mined from literature
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each sample is needed for accurate analysis. Thus, we
associated each sample to its meta-data annotations,
namely age, gender, organism, organism part, platform,
and phenotype. Organism under investigation is mapped
to NCBI Taxonomy URIs [95]. The factor value of each
sample, i.e., the phenotype information, is described using
the EFO ontology [96]. Each platform array is made up of
multiple probes that may represent a gene. To be able to
retain the expression values for individual probes, we
linked the probe ID resource to platform. However, for
better reasoning, quantitative values retrieved from
statistical analysis are linked to genes and not to probes.
The meta-analysis results, derived from limma [82], such
as differential expression value of a gene and its associated
p-value are all linked to the gene symbols.
Construction, validation and storage of RDF models
We modeled all the triples (represented in the schemas)
using the Apache Jena API [97]. Resources, and Proper-
ties as Java classes were created from the ontologies
using the corresponding in-built methods in the API
and with the help of Schemagen [98].
In order to check for the correctness of our generated
RDF models, we made use of the online service RDF
validator [99]. By using such a service, we verified the
models using their graph and triples representation.
Fig. 4 Schematic representation of Healthy PPIs in RDF. The figure represents PPIs of healthy subjects extracted from
literature and PPI specific databases. The schema also contains meta-information about these PPIs
Fig. 3 Schematic representation of MiRNA-target interactions in RDF. The figure encapsulates miRNA mentions along with their corresponding
gene identifier from literature
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Triple stores, such as Virtuoso [100], provides an op-
portunity to store individual or integrated RDF models
in one endpoint. Taking advantage of this, we stored all
the generated RDF models as individual graphs in a sin-
gle Virtuoso instance. Using common URIs (e.g., “Gene"
identifier) as the connecting link between these models,
it is possible to traverse through them integratively.
Data mining and analysis
In RDF, all the stored triples are accessible using a com-
mon query language, SPARQL Protocol and RDF Query
Language (SPARQL) [101]. We generated a Java library
with embedded SPARQL queries to ask our endpoint
and the underlying networks biologically relevant ques-
tions. Queries were generated from individual models,
which were further integrated as nested queries to
traverse different graphs. Each query uses the common
Gene URI namespace (which is common across all
models) to pass on the results used to the next nested
query. One possibility to visualize the query results is
the SemScape Cytoscape [102], to represent the return
values as (sub-) graphs again.
Results and discussions
NeuroRDF covers a wide range of curated AD related
data resources, stored as four separate RDF models in a
single Virtuoso endpoint. It tries to address the main
concepts (complementary) that contributes significantly
to unraveling AD pathology.
Differentially expressed genes
For the eight selected microarray datasets, gene expres-
sion analysis was performed between healthy and
diseased patients. Among these, GSE1297, GSE28146,
and E-MEXP-2280 resulted in no differential genes for
adjusted p-value cutoff 0.05. From the remaining studies,
only genes that exhibited a log2 fold change of > 1.5
were selected for analysis. In total, GSE5281 resulted in
4,278 genes under p-value cutoff and 2 up-, and 48 down-
regulated genes for the defined fold change cutoff. Simi-
larly, GSE44770 provided 254 differentially expressed
genes, among which 16 up- and 11 down-regulated were
selected further. In case of GSE44771, we obtained 335
differential genes that contain 11 up and 11 down-
regulated genes that show > 1.5 log2 fold change. For both,
GSE12685 and GSE44768, we obtained 1 and 51 genes
under the p-value cut-off. However, there were no genes
that had log2 fold change of >1.5. The list of all the
differentially expressed genes that were selected for fur-
ther analysis is provided in Additional file 1.
RDF models
Table 1 summarizes the content of the generated triple
store by providing some statistics of all integrated
networks. In total, there are 8353 unique triples in AD
PPI, 1,204,194, 667 unique triples in Healthy PPI, and
20,454 unique triples in gene expression RDF models
(Additional file 2). The number of unique predicates
(relations) for AD and healthy PPIs are 11, whereas
for MTI there are 5 and the gene expression model
Fig. 5 Schematic representation of Gene Expression Data in RDF. This figure represents gene expression data obtained from public resources
such as GEO and ArrayExpress
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consists of 16. The number of entities present in
these models range from 300 to 78,852 (cf. Table 1).
In case of the gene expression data, to avoid large
triples we excluded the gene expression values of in-
dividual probes and included information only related
to differential expression. Uploading and querying these
models was not computationally expensive due to lower
set of predicates and relatively small file size.
Prioritization of AD candidates
To illustrate the potential of NeuroRDF approach and to
determine novel AD candidates from the high quality
integrated data, we exploit the underlying biological
association between the different data resources and
identify the previously unknown information.
Our prioritization criteria was based on the notion
that every data resource brings with it a piece of missing
biological information which is needed to understand
the mechanism of a certain candidate. We tried to
associate this distributed information by systematically
addressing the following questions:
(1)Whether candidates in the diseased network tend to
be associated with normal physiology. If yes, what
are the common players that could help us in the
differential estimates (called as causal candidates);
(2)Which microRNAs regulate the selected causal
candidates that could give insights into their post-
transcriptional dysregulation;
(3)Have any of the selected causal candidates assessed
for their level of differential expression in an
unbiased data source (e. g., gene expression data);
(4)How strong is the influence of the neighboring
genes on the casual candidates. This is based on the
assumption that strong candidates tend be
surrounded by dysregulated genes and have an
influence on the candidate itself;
(5)Is there any functional relatedness between the
causal candidates and their neighbors;
To answer these questions, we generated a set of
SPARQL queries. Figure 6 is an example SPARQL query
syntax used to obtain miRNAs that regulate the genes in
the AD networks. Similar querying has been applied to
build a system of faceted searches for the above de-
scribed questions. Firstly, we identified common genes
between the healthy and AD PPI networks. This query
resulted in 230 intersecting genes. Looking into the
MTIs, we found 13 of these genes to be regulated by at
least one microRNA (cf. Table 2). Among these 13
genes, 9 were observed to be differentially expressed:
APP, BACE1, ADAM10, IL1B, MAPK3, DLG4, LRP1
PTGS2, and TGFB1. Except for APLP2, and IL6, all the
other genes contained differentially expressed neighbors
either in AD or in healthy PPIs. There were no miRNAs
that were common to these 13 genes.
Sub-networks from the AD and healthy PPIs were ex-
tracted to investigate the prioritized candidates (see
Figs. 7 and 8). As observed from Fig. 8, for healthy PPIs
there was one larger sub-network (containing APP,
ADAM10, BACE1, MIF, MAPT, and LRP1) and a
smaller one containing two genes (PTGS2, and IL1B).
On the other hand, for diseased PPIs in Fig. 7, there
were two large sub-networks containing four (STAT4,
JUN, MAPK3, and STMN2) and five genes (APP, LRP1,
BACE1, DLG4, and TGFB1). The third sub-network was
made up of two genes (MAPT, and TUBA4A). Among
the prioritized candidates, APLP2 and IL6 had no com-
mon links to other prioritized candidates. Thus, they
were discarded for further analysis.
Relevance of prioritized AD candidates
The remarkability of complementing wet lab research
using the predictability and reproducibility of measured
outcomes is one of the core reasons why researchers are
Table 1 Statistics of generated RDF models stored in Virtuoso
endpoint
Models No. of triples No. of entries No. of
properties
Size (mb)
Alzheimer’s disease
PPI
8353 19900 11 0.894
Healthy State PPI 1204194 78852 11 99.102
MTI 667 300 5 0.095
Microarray 20454 9477 16 303.5
Fig. 6 Example SPARQL query for information retrieval from NeuroRDF. SPARQL query as seen in the figure retrieves the miRNAs for a given gene
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more inclined to the field of bioinformatics. Therefore,
in silico validation of predicted candidates for its rele-
vancy is of utmost importance. In this direction, we pin-
point the relevance of our prioritized candidates through
a literature survey.
AD established candidates
Although there are no FDA approved biomarkers for AD,
researchers focus on some of the key candidates that are
hypothesized to be involved in AD. In the current NDD
research practice, APP has been established as the widely
used biomarker candidate. The classical pathological hall-
mark of AD is formation of amyloid-beta aggregates (lead-
ing to plaques) in brain. This is reported to be caused by
faulty proteolytic processing of APP that releases amyloid-
beta [103]. Another hallmark of AD is tau pathology
(MAPT gene), regulated by amyloid-beta. Hyperphosphor-
ylation of tau causes accumulation of neurofibrillary tan-
gles due to the disrupted functioning of axonal transport
[5]. However, it is also interesting to note the paradigm
shift in AD research due to recently failed drug trails that
focused mostly around these hypotheses [2]. Never-
theless, several neuroscientists still believe in the po-
tential of APP and the tau hypothesis for elucidation
of the underlying pathomechanism. As observed from
our generated sub-networks, our largest sub-network
was established around the APP gene.
When compared to APP, BACE1 has not been so fre-
quently studied. However these genes often fall into the
"most interesting gene zone" as far as AD is concerned
since it is involved in the formation of amyloid-beta.
BACE1 is the major enzyme (beta secretase) involved in
the cleaving of APP at beta site and generating soluble
amyloid-beta [104]. However, increased BACE1 activity
has been reported to be associated with amyloid-beta ag-
gregation in AD patients [105]. Bu et al. have detailed out
the evidence that LRP1 is a receptor for APOE, a contrib-
uting factor to AD [106]. Furthermore, in 1993, Strittmat-
ter, Roses and colleagues [107] have identified APOE4 as
the major risk for late-onset AD. TGFB1 polymorphism
has been widely associated with an increased risk of late-
onset AD. Deficiency in TGFB1 signaling leads to neuro-
fibrillary tangle formation increasing the advancement of
mild cognitive impairment patients to AD, by increasing
the depressive symptoms [108]. DLG4 is a post-synaptic
scaffolding protein that interacts with postsynaptic recep-
tors such as NMDA receptors for efficient postsynaptic
response [109]. However, its impairment has largely con-
tributed to the synaptic degeneration in AD. Mutations in
ADAM10 gene have been associated to late-onset AD.
ADAM10 enzyme has alpha-secretase activity to cleave
amyloid-beta, however BACE1 competes with ADAM10
for cleavage. Thus, its decreased expression has been
implicated in AD pathogenesis [110].
Table 2 Prioritized AD candidate genes
Intersected genes
between healthy
and AD PPI
MiRNAs Differentially expressed
neighbors
Number of
literature articles
for intersected
genes
Healthy PPI AD PPI
APP MIR101-1, ADAM10, TGFB1,
MIR106A, MAPT, BACE1,
MIR106B, MIF, LRP1
MIR124-1, BACE1, 24550
MIR137, LRP1
MIR153-1,
MIR181-C,
MIR29A,
MIR520C,
MIR19-1
BACE1 MIR107,
MIR124-1, APP,
MIR145, APP LRP1 1883
MIR298,
MIR29A,
MIR29B1,
MIR328,
MIR9-1
ADAM10 MIR451,
MIR144,
MIR1306, APP - 231
MIR107,
MIR103
IL1B MIR146A,
MIR155 PTGS2 - 1099
MAPK3 MIR15A, - STMN2, 276
MIR155 JUN
MAPT MIR16-1, APP TUBA4A 3367
MIR132
APLP2 MIR153-1 - - 134
DLG4 MIR485 - LRP1 151
IL6 MIR27B - - 748
JUN MIR144 - STAT4, 142
MAPK3
LRP1 MIR205 APP DLG4, 305
APP,
BACE1
PTGS2 MIR146A IL1B - 474
TGFB1 MIR155 - APP 276
This table summarizes the literature based evidences of intersected genes
between healthy and AD PPI and their corresponding miRNAs and
differentially expressed genes
Iyappan et al. Journal of Biomedical Semantics  (2016) 7:45 Page 10 of 15
Semantic-based Integrative Strategy for Candidate Prioritization and their Mechanistic Analysis 
46 
 
AD emerging candidates
To identify emerging knowledge in the context of AD, we
performed an individual gene analysis using SCAIView for
publications in PubMed. Here, we measured the co-
occurrence of the causal genes (including its differential
neighbors) and AD over a period of last 10 years, see Fig. 9.
Since the number of articles for the APP gene was rela-
tively too high each year, we normalized the number of lit-
erature evidence of other candidates using the APP gene's
article count for that year. Hence, the normalized range
for the literature distribution is between 0 and 1, where 1
is the highest number of articles for that year (the APP
gene). Please refer to Additional file 3 for details of the lit-
erature counts. Inspecting literature evidence, we found
that all the prioritized causal candidates have been studied
in the context of AD. Moreover, among their differentially
expressed neighbors, STMN2 (8 articles), MAPK4 (1 art-
icle), TUBA4A (2 articles), and MIF (15 articles) contained
fewer articles related to AD. Among these genes, STMN2
and MIF have been recently studied in the context of AD,
whereas, MAPK4, STMN2, and TUBA4A were implicated
in AD nearly two decades before but failed to establish as
robust biomarker candidates.
MIF's role in AD
Macrophage Migration Inhibitory Factor (MIF) has for
long been known to participate in tumor proliferation
due to its pro-inflammatory cytokine functionality [111].
In general, MIF acts as a key regulator of inflammatory
activities such as innate and adaptive immunity [112].
Apart from that, it is also known to play a significant
role as an anti-apoptotic factor of neutrophils as well as
macrophages [113].
The MIF gene has been well studied in cancer and
inflammation. However, recent studies are emerging
around a plausible role of MIF in neurodegenerative dis-
eases, in particular AD. Moreover, Flex et al. [114] have
earlier reported that MIF polymorphisms are not linked
Fig. 7 Extracted sub-networks from AD PPIs network. This figure symbolizes the diseased sub-graphs that were generated using prioritized
candidates and their differentially expressed neighbors
Fig. 8 Extracted sub-networks from healthy PPIs network. This figure
symbolizes the healthy sub-graphs that were generated using
prioritized candidates and their differentially expressed neighbors
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to AD, but confirmed its complex immune and inflam-
matory activities. Although, APP and tau have been as-
sociated to play a key role in the pathophysiology of AD,
many researchers strongly believe in the role of inflam-
matory processes subsidizing to the pathology of AD.
This stems from the fact that activated microglial cells
discharge immunoregulatory cytokines which result in
various side-effects such as neuronal dysfunction and in-
hibition of hippocampal neurogenesis [115]. MIF is one
such pro-inflammatory cytokine which is known to bind
with amyloid-beta protein and enhance the plaque re-
moval and neuronal debris from the brain during normal
conditions [116]. Also, MIF has been identified to play a
role in neuronal survival by inhibiting the activation of
ERK-1/MAP kinases [117] (regulatory role in cell prolif-
eration and glucocorticoid action) as well as its ability to
surpass the p53 mediated apoptosis [118]. Although, the
precise molecular function of MIF in the context of AD
is unknown, it is known to play a role in inflammatory
processes around the plaque formation. MIF is also
highly expressed in the neurons of rat hippocampus, one
of the primary regions to be affected by AD [117]. Bryan
et al. [119] also report on the abnormal expression of
MIF in both microglia and in the hippocampal neurons
in human. This all makes MIF a plausible biomarker for
inflammatory responses in AD.
Conclusion
NeuroRDF approach has been designed to identify new
knowledge through semantic mining. The proposed inte-
grative approach takes advantage of the RDF technology
to integrate well-curated data from various sources
within a specific indication area. From our perspective,
it is necessary to focus on one indication or at least a
group of indications to build such a knowledge base for
precise modeling and analysis due to the high curation
effort one has to spend in order to reach the necessary
details. We showed how to harmonize three major het-
erogeneous resources (databases, gene expression data,
and literature) used in the research area to generate
hypotheses for underlying disease mechanisms. This ap-
proach supports identification of novel insights without
compromising over quality. Furthermore, new data re-
sources can be included without altering the overall
framework. The usage of well-accepted ontologies pro-
vides the advantage for further integration of external re-
sources and databases (e.g., federated queries). Using
such an approach, we were able to prioritize MIF gene
as an emerging candidate due to its role in inflammatory
processes implicated in AD pathogenesis.
The advantage of using an RDF schema is that it is
highly supportive for data interoperability. Although this
work represents the usage of the RDF schema specific
for AD, we have also extended the same to other disease
models such as Parkinson's and Epilepsy. However, the
curated data and the generated hypothesis for these two
diseases will be released in future under the terms of a
Neuroallianz agreement [120]. Also, these resources are
constantly kept up-to-date as they are transferred to
various upcoming projects such as AETIONOMY [121].
Additional files
Additional file 1: List of differentially expressed genes. This file contains
the list of differentially expressed genes (for each dataset used) that fall
under the adjusted p-value cutoff of 0.05. The differential expression
analysis was performed using limma package in R statistical environment.
The file is provided in an Excel format. (XLSX 68 kb)
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Fig. 9 Statistics of the literature evidence for emerging candidate genes in the speculated sub-networks
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Additional file 2: The developed RDF models and the SPARQL queries
used are made available at: http://www.scai.fraunhofer.de/en/business-
research-areas/bioinformatics/downloads/neurordf.html. (ZIP 178 kb)
Additional file 3: Detailed count of literature evidences for prioritized
candidates. This file contains the detailed count of number of evidences
available for each prioritized candidate for each year since 2005 in
context of Alzheimer's disease. These statistics were retrieved using
SCAIView knowledge discovery tool (as of 18 May, 2016). (XLSX 35 kb)
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3.3 Summary	
This work leverages on semantic-web technologies to develop a context-specific 
integrative and interoperable disease model. The proposed approach, NeuroRDF, 
harmonises and integrates data from three public resources: PPI databases, text-mined 
MTIs and PPIs from literature, and gene dysregulation information derived from 
transcriptomic studies. It outlines the pre-processing steps applied to each data resource to 
monitor quality and context-specificity. In addition, it reports on the need of huge manual 
effort for inspecting missing and incorrect metadata information. The main benefits of this 
work lie in enabling semantic interoperability across heterogeneous data to foster 
innovation in NDD research. 
Querying such a framework empowers the user to ask more fine-grained questions across 
the knowledge graphs. Exemplary questions, as SPARQL queries, that account for patho-
mechanisms and network topology illustrated the power of NeuroRDF in identifying 
previously unattended candidates in AD. The prioritised candidate, MIF, has a pro-
inflammatory cytokine functionality that is crucial in inflammatory responses implicated 
in AD plaque formation. Thus, such an approach has the capability to assist in identification 
of reliable biomarkers for early diagnosis and treatment. The overall work presented here 
can be easily extended to other domains. The manual effort needed may vary depending on 
the formalization and interoperability of the selected data. 
Integration of other data resources such as GWAS, NGS, imaging, so on can increase the 
biological confidence of the derived hypothesis in NeuroRDF. Additionally, drug-target 
information can aid in drug repurposing. The methodologies and approaches to harvest and 
integrate multiple resources are not well established in AD research. Particularly, 
knowledge representing miRNA’s regulatory roles in AD and regulatory relationships 
between expression levels of genes. Work addressing these two topics are presented in 
Chapter 4, Chapter 5, and Chapter 6. 
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Chapter	4 	Hypothesis-driven	
Knowledge	Discovery	
 
4.1 Introduction	
A wealth of untapped information is available in the ever-growing biomedical literature, 
Delivering crucial background knowledge, it can maximise insights into AD research. 
Automated approaches are required to provide rapid access to this information by gleaning 
over large textual documents. Most of these methods unearth relationships between 
biological entities and additionally enrich it with a multitude of contextual information. 
When integrated with other data, the harvested knowledge allows generation and 
exploration of novel hypotheses. Text-mining approaches are well-established in some 
fields to identify biological entities and their relationships — like PPIs, drug-drug 
interaction. However, its development in other domains — like miRNAs and its 
interactions — is limited.  
MiRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. 
Due to its involvement in several normal and pathophysiological processes, miRNAs are 
considered as potential biomarkers for diagnosis, prognosis, and therapeutics. This chapter 
describes the automated text-mining methods developed to extract miRNA’s regulatory 
roles in diseases and gene expression from Pubmed abstracts. It provides step-by-step 
guidelines for annotating entities and their relationships for generating the benchmark 
corpus. The work here evaluates different relations extraction approaches for identification 
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of miRNA-disease and miRNA-target associations. This work demonstrates how domain- 
specific highly relevant information — for miRNAs — can be extracted from existing 
scientific literature.  
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Abstract
 MicroRNAs (miRNAs) have demonstrated their potential asIntroduction:
post-transcriptional gene expression regulators, participating in a wide
spectrum of regulatory events such as apoptosis, differentiation, and stress
response. Apart from the role of miRNAs in normal physiology, their
dysregulation is implicated in a vast array of diseases. Dissection of
miRNA-related associations are valuable for contemplating their mechanism in
diseases, leading to the discovery of novel miRNAs for disease prognosis,
diagnosis, and therapy.
 Apart from databases and prediction tools, miRNA-relatedMotivation:
information is largely available as unstructured text. Manual retrieval of these
associations can be labor-intensive due to steadily growing number of
publications. Additionally, most of the published miRNA entity recognition
methods are keyword based, further subjected to manual inspection for
retrieval of relations. Despite the fact that several databases host
miRNA-associations derived from text, lower sensitivity and lack of published
details for miRNA entity recognition and associated relations identification has
motivated the need for developing comprehensive methods that are freely
available for the scientific community. Additionally, the lack of a standard
corpus for miRNA-relations has caused difficulty in evaluating the available
systems.
We propose methods to automatically extract mentions of miRNAs, species,
genes/proteins, disease, and relations from scientific literature. Our generated
corpora, along with dictionaries, and miRNA regular expression are freely
available for academic purposes. To our knowledge, these resources are the
most comprehensive developed so far.
 The identification of specific miRNA mentions reaches a recall of 0.94Results:
and precision of 0.93.  Extraction of miRNA-disease and miRNA-gene relations
lead to an  score of up to 0.76. A comparison of the information extracted byF
our approach to the databases  and  for the extraction ofmiR2Disease miRSel
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lead to an  score of up to 0.76. A comparison of the information extracted byF
our approach to the databases  and  for the extraction ofmiR2Disease miRSel
Alzheimer's disease related relations shows the capability of our proposed
methods in identifying correct relations with improved sensitivity. The published
resources and described methods can help the researchers for maximal
retrieval of miRNA-relations and generation of miRNA-regulatory networks.
 The training and test corpora, annotation guidelines, developedAvailability:
dictionaries, and supplementary files are available at 
http://www.scai.fraunhofer.de/mirna-corpora.html
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Introduction
Functionally important non-coding RNAs (ncRNAs) are now better 
understood with the progress of high-throughput technologies. Dis-
covery of the major class of ncRNAs, microRNAs (miRNAs1) has 
further facilitated the molecular aspects of biomedical research.
MicroRNAs are a large group of small endogenous single-stranded 
non-coding RNAs (17–22nt long) found in eukaryotic cells. They 
post-transcriptionally regulate gene expression of specific mRNAs 
by degradation, translational inhibition, or destabilization of the 
targets (transcripts of protein-coding genes)2. Esquela-Kerscher 
et al. have reported on miRNAs involvement in almost every 
regulation aspect of biological processes such as apoptosis, and 
stress response3. Wubin et al. demonstrated that miR-29a regula-
tory circuitry plays an important role in epididymal development 
and its functions4. Additionally, tissue-specificity of miRNAs has 
been shown to provide a better clue of their fundamental roles in 
normal physiology5.
Dysregulation of miRNAs and their ability to regulate repertoires of 
genes (as well as co-ordinate multiple biological pathways) has been 
linked to several diseases6,7. One example is chronic lymphocytic 
leukemia where (in about 68% of the cases) miRNA genes (miR15  
and miR16 ) are missing or down-regulated8. Thus, uncovering the 
relations between miRNAs and diseases as well as genes/proteins is 
crucial for our understanding of miRNA regulatory mechanisms for 
diagnosis and therapy9,10.
Several databases, prediction algorithms and tools are available, 
providing insight into miRNA-disease and miRNA-mRNA associa-
tions. Although the detailed target recognition mechanism is still 
elusive, several algorithms attempt to predict miRNA targets. How-
ever, a limited precision of 0.50 and recall of 0.12 has been reported 
when evaluated against proteomics supported miRNA targets11. 
Despite the fact that these resources provide insight into miRNA-
associated relationships, the majority of relations are scattered as 
unstructured text in scientific publications12. Figure 1 shows the 
growth of publications in MEDLINE and in addition depicts the 
normalized growth of publications that reference the keyword 
“microRNA”.
Some databases such as miR2Disease and PhenomiR store manu-
ally extracted relations from literature. The miR2Disease database13 
contains information about miRNA-disease relationships with 3273 
entries (as of the last update on March 14, 2011). PhenomiR14 is a 
database on miRNA-related phenotypes extracted from published 
experiments. It consists of 675 unique miRNAs, 145 diseases, and 
98 bioprocesses from 365 articles (Version 2.0, last updated on 
February 2011). TarBase11 hosts more than 6500 experimentally 
validated miRNA targets extracted from literature.
However, manual retrieval of relevant articles and extraction of 
relation mentions from them is labor-intensive. A solution is to 
use text-mining techniques. Moreover, the vast majority of the 
research in this direction is mainly focused around extraction of 
      Amendments from Version 2
The final revised version of the manuscript includes changes as 
per the reviewers’ recommendation. We have mainly modified text 
in the “Corpus selection, annotation and properties” section to 
simplify the ambiguous texts, as pointed out by Robert Leaman. 
Additionally, grammatical errors pointed out by the reviewers 
have also been corrected. Please read the response provided to 
reviewers’ comments for detailed information of the changes. 
See referee reports
REVISED
Figure 1. Growth of miRNA-related publications in comparison with the growth of MEDLINE. The dotted line points out the relative 
increase of miRNA-related publications per year in comparison to the growth of MEDLINE (as of 31 December, 2013).
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protein-protein interactions15. On the contrary, miRNA relation 
extraction is still naive. The shift of focus towards identification 
of miRNA-relations is slowly establishing with the rise in systems 
approaches to investigate complex diseases. The manually curated 
database miRTarbase16 incorporates such text-mining techniques 
to retrieve miRNA-related articles. Recently, the miRCancer data-
base has been constructed using a rule-based approach to extract 
miRNA-cancer associations from text17. As of June 14, 2014, this 
database contains 2271 associations between 38562 miRNAs and 
161 human cancers from 1478 articles.
Related work
Text-mining technologies are established for a variety of applica-
tions. For instance, the BioCreative competition18,19 and BioNLP 
Shared Task20–22 series have been conducted to benchmark text min-
ing techniques for gene mention identification, protein-protein rela-
tion extraction and event extraction, among others.
To our knowledge, only limited work has been carried out in 
the area of miRNA-related text-mining. Murray et al. consid-
ered miRNA-gene associations from PubMed database using 
semantic search techniques23. For their analysis, experimentally 
derived datasets were examined, combined with network analy-
sis and ontological enrichment. Regular expressions were used to 
detect miRNA mentions. The authors claim to have optimized the 
approach to reach 100% accuracy and recall for detecting miRNAs 
mentions as in miRBase. Relations were identified based on a 
manually curated rule set. The authors extracted 1165 associations 
between 270 miRNAs and 581 genes from the whole MEDLINE.
The freely available miRSel12 database integrates automatically 
extracted miRNA-target relationships from PubMed Abstracts. 
A set of regular expressions is used for miRNA recognition that 
matches all miRBase synonyms and generic occurrences. The 
authors reach a recall of 0.96 and precision of 1.0 on 50 manu-
ally annotated abstracts for miRNA mention identification. Further, 
the relations between miRNA and genes were extracted at sentence 
level employing a rule-based approach. They evaluated on 89 sen-
tences from 50 abstracts resulting in a recall of 0.90 and precision 
of 0.65. Currently, it hosts 3690 miRNA-gene interactions11.
Since the miRNA naming convention has been formalized very 
early in comparison to other biological entities such as genes and 
proteins, applying text-mining approaches is relatively simple17. 
Thus, most of the previously applied text mining approaches for 
miRNA detection has been based on keywords. miRCancer uses 
keywords to obtain abstracts from PubMed, further miRNA entities 
have been identified using regular expressions based on prefix and 
suffix variations. Similarly, miRWalk database uses keyword search 
approach to download abstracts and applies a curated dictionary 
(compiled from six databases) for miRNA identification of human, 
rat, and mouse species24. TarBase, miR2Disease, miRTarBase, and 
several others have followed related search strategies. However, 
several authors still tend to use naming variations for acronyms, 
abbreviations, nested representations, etc. for listing miRNAs. 
Additionally, in contrast to the previous text-mining approaches 
focusing purely on miRNA gene relations, we extend the informa-
tion extraction approach additionally to retrieve miRNA-disease 
relations. Furthermore, we evaluate our approach using a larger 
corpus to achieve robustness. We differentiate between actual 
miRNA mentions (refered to as SPECIFIC MIRNAs) and co-refer-
encing miRNAs (NON-SPECIFIC MIRNAs), which could in addition 
enhance keyword search. We evaluated three different relation 
extraction approaches, namely co-occurrence, tri-occurrence and 
machine learning based methods.
To support further research, our corpora are made publicly available 
in an established XML format as proposed by Pyysalo et al.25, as 
well as the regular expressions used for miRNAs named entity rec-
ognition. In addition, our dictionary for trigger term detection and 
general miRNA mention identification are made available. To our 
knowledge, the annotated corpora as well as the information extrac-
tion resources are the most comprehensive developed so far.
Methods
Data curation and corpus selection
Named entities annotation. Mentions of miRNAs consisting 
of keywords (case-insensitive and not containing any suffixed 
numerical identifier) such as “Micro-RNAs” or “miRs” are anno-
tated as NON-SPECIFIC MIRNA. Names of particular miRNAs such 
as miRNA-101, suffixed with numerical identifiers are labeled as 
SPECIFIC MIRNA. Numerical identifiers (separated by delimiters such 
as “,”, “/”, and “and”) occurring as part of specific miRNA mentions 
are annotated as a single entity. Box 1 depicts the annotation of spe-
cific miRNA mentions (including an example for part mentions). In 
addition, DISEASE, GENE/PROTEIN, SPECIES, and RELATION TRIGGER are 
annotated. The detailed annotation guideline for annotating specific 
miRNA mentions is available as a supplementary file.
Box 1. Example of miRNAs annotations. Here “-181b”, and 
“-181c” are the part mentions annotated as a single entity along 
with “miR-181a” in box. A non-specific miRNA mention is shown 
in italics.
Interesting results were obtained from  miR-181a, -181b, and -181c . 
These set of brain-enriched miRNAs are down-regulated in 
glioblastoma. However,  miR-222 , and  miR-128  are strongly 
up-regulated.
Mentions of disease names, disease abbreviations, signs, defi-
ciencies, physiological dysfunction, disease symptoms, disorders, 
abnormalities, or organ damages are annotated as DISEASE. Only 
disease nouns were considered, adjective terms such as “Diabetic 
patients” are not marked; however, specific adjectives that can be 
treated as nouns were marked, e.g. “Parkinson’s disease patients”. 
Mentions referring to proteins/genes which are either single word 
(e.g. “trypsin”), multi-word, gene symbols (e.g. “SMN”), or com-
plex names (including of hyphens, slashes, Greek letters, Roman or 
Arabic numerals) are annotated as GENE/PROTEIN. Only those organ-
isms that are having published miRNA sequences and annotations 
represented in miRBase database are labeled as SPECIES. Any verb, 
noun, verb phrase, or noun phrase associating miRNA mention to 
either labeled disease or gene/protein term is annotated as RELATION 
TRIGGER.
Relations annotation. We restrict the relationship extraction to sen-
tence level and four different interacting entity pairs: SPECIFIC MIRNA-
DISEASE (SpMiR-D), SPECIFIC MIRNA-GENE/PROTEIN (SpMiR-GP), 
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NON-SPECIFIC MIRNA-DISEASE (NonSpMiR-D), and NON-SPECIFIC 
MIRNA-GENE/PROTEIN (NonSpMiR-GP). Relevant triples, an inter-
acting pair (from one of the above-mentioned) co-occurring with 
a RELATION TRIGGER in a sentence are defined to form a relation and 
can belong to one of the four above-mentioned Relation classes. 
On the contrary, if an interacting pair does not co-occur with any 
RELATION TRIGGER then we do not tag such pair as a relation.
The annotation has been performed using Knowtator26 integrated 
within the Protégé framework27.
Corpus selection, annotation and properties. We develop a new 
corpus based on MEDLINE, annotated with miRNA mentions and 
relations. Shah et al.28 showed that abstracts provide a comprehensive 
description of key results obtained from a study, whereas full text is 
a better source for biological relevant data. Thus, we choose to build 
the corpus for abstracts only. Out of 27001 abstracts retrieved using 
the keyword “miRNA”, 201 were randomly selected as training and 
100 as test corpus. Two annotators performed the annotation. The 
first annotator annotated the training corpus iteratively to develop 
guidelines and built the consensus annotation. The second annotator 
followed these guidelines and annotated the same corpus. Disagree-
ing instances were harmonized by both the annotators through man-
ual inspection for correctness and its adherence to the guidelines. 
Any changes to the guidelines were made if needed. During the 
harmonization process only the non-overlapping instances between 
the two annotators were investigated. Decisions were based on the 
rule that only noun forms were to be marked (specific adjectives 
that can be treated as nouns were also considered). In case of partial 
matches, where conflicting parts could be interpreted as an adjec-
tive were not resolved. For example, in “chronic inflammation”, 
marking either “chronic inflammation” or just “inflammation” were 
considered correct. Table 1 provides the inter-annotator agreement 
(measured as F1, for both exact and boundary match, and Cohen’s 
g) for the test corpus. Exact string match occurs only when both the 
annotators annotate identical strings, whereas in partial match frac-
tion of the string has been annotated by either of the annotators. It is 
evident (cf. Table 1) that in almost all cases partial match performs 
better than exact string match, indicating variations in span of men-
tioned entities. An example annotation is shown in Box 1.
Table 2 shows the number of annotated concepts in the training 
and test corpora for each entity class and the count for manually 
extracted relations (triplets), categorized for different interacting 
entity pairs. Table 3 provides the overall statistics of the published 
corpora (additional information about the corpus is given in the 
README supplementary file).
Table 1. Inter-annotator agreement scores for the test corpus.
Annotation Class F1 (Exact Match)
F1 (Partial Match) g
Non-specific MiRNAs 0.9985 0.9985 0.996
Specific MiRNAs 0.9545 0.9779 0.916
Genes/Proteins 0.8343 0.8705 0.752
Diseases 0.8270 0.9575 0.853
Species 0.9329 0.9437 0.875
Relation Triggers 0.8441 0.9543 0.798
Table 2. Manually annotated entities 
statistics. Counts of manually annotated 
entities in the training and the test corpora as well 
as annotated sentences describing relations.
Annotation Class
Corpus
Training Test
Non-specific MiRNAs 1170 336
Specific MiRNAs 529 376
Genes/Proteins 734 324
Diseases 1522 640
Species 546 182
Relation Triggers 1335 625
SpMiR-D 171 127
SpMiR-GP 195 123
NonSpMiR-D 124 54
NonSpMiR-GP 77 16
Table 3. Statistics of the published miRNA corpora.
Occurrences in the corpus Training Test
Sentences 1864 780
Entities 5836 2483
Entity pairs 2001 868
Positive entity pairs 567 320
Negative entity pairs 1434 548
Automated named entity recognition
For identification of specific miRNA mentions in text (cf. Table 4), 
we developed regular expression patterns using manual annotations 
of miRNA mentions as the basis. Similarly, a dictionary has been 
generated for general miRNA recognition. The regular expression 
patterns are represented in the format as defined by Oualline et al.29. 
For simplicity and reusability, several aliases are defined (cf. Table 5) 
to be used in the final regular expression patterns for specific miRNA 
identification, given in Table 4. Detected entities are resolved to a 
unique miRNA name and disambiguated to adhere to standard nam-
ing conventions as authors use several morphological variants to 
report the same miRNA term. For example, miR-107 can be repre-
sented as miRNA-107, Micro RNA-107, MicroRNA 107, has-mir-
107, mir-107/108, micro RNA 107 and 108, micro RNA (miR) 107 
and so on. Thus, the identified miRNA entity has been resolved to 
its base form (e. g. hsa-microRNA-21 to hsa-mir-21 and microRNA 
101 to mir-101) following the miRBase naming convention. Man-
ual inspection of the test corpus for species distribution revealed 
that 71% of the documents belonged to human, followed by mouse 
(15%), rat (8%). Pig has 2 abstracts, zebrafish, HIV-1, HSV-1, 
and Caenorhabditis elegans 1 each (cf. Supplementary Figure A 
for the distribution). Thus, we assumed that most of the abstracts 
belonged to human and resolved the identified miRNA entities to 
human identifier in miRBase. Unique miRNA terms are mapped to 
human miRBase database identifiers through the mirMaid Restful 
web service. For those names where we do not retrieve any database 
identifiers, we fall back to another organism mention found in the 
abstract (if any), using the NCBI taxonomy dictionary (see below) 
Page 5 of 33
F1000Research 2015, 3:205 Last updated: 01 OCT 2015
Hypothesis-driven Knowledge Discovery 
60 
 
Table 5. MiRNAs regex aliases. Aliases used in regular expression patterns for miRNAs identification 
(highlighted in bold).
Description Alias Regular Expression Pattern
Digit sequences D (\d?\d*)
Admissible hypens with a trailing space Z ([\-]?[\-]*)
Admissible hypens with a leading space S ([\-]?[\-]*)
3-letter prefix for human followed by a 
hyphen Pref ([hH][sS][aA][\-])
Non-specific miRNA mentions miRNA ([mM][iI]([cC][rR][oO])+[rR]([nN][aA]s+)+)
Let-7 miRNA mention Let ([lL][eE][tT]S*[7]?\l+)
Lin-4 miRNA mention Lin ([lL][iI][nN]S*[4]?\l+)
Oncomir miRNA mention Onco ([oO][nN][cC][oO][mM][iI][rR])
Admissible tilde and word boundaries Cluster (^[\b]-[\b]-*)
Admissible hyphen and separator and and 
comma Sep (S*((and?,S,\/,)? S*)+)
Admissible combination of upper and lower 
case alphabets UL (?\l?\l+,?\u?\u+)
Admissible alpha-numerical identifiers in 
specific miRNA mentions AN (UL((/, *and*,D+)? UL)+)
Admissible alpha-numerical identifiers in 
oncomir mentions Tail (D(AN Cluster+,\-D AN+)+)
(cf. Supplementary Figure B), otherwise we retain the unique nor-
malized name (cf. Box 2).
Box 2. Un-normalized and normalized entities that are 
mapped to miRBase identifiers. Here MIR0000007, MIR0000008, 
and MIR0000005 are internal identifiers used by ProMiner.
We detect SPECIES with a dictionary-based approach. The built dic-
tionary consists of all the concepts from the NCBI taxonomy cor-
responding to only those organisms mentioned in miRBase.
Similarly, for identification of DISEASE and GENE/PROTEIN men-
tions in text we adapted a dictionary-based approach. To detect 
DISEASE, we apply three dictionaries: MeSH, MedDRA30  and Allie. 
For GENE/PROTEIN, a dictionary31 based on SwissProt, EntrezGene, 
and HGNC is included. Gene synonyms which could be poten-
tially tagged as miRNAs are removed to overcome redundancy. 
For example, genes encoding microRNA, hsa-mir-21 are named 
as miR-21, miRNA21 and hsa-mir-21, the gene symbol of MIR16 
membrane interacting protein of RGS16 is MIR16, which can repre-
sent a miRNA mention.
The RELATION TRIGGER dictionary comprises of all interaction terms 
from the training corpus. After reviewing the training corpus for 
relation trigger terms, we retrieved not one but many variants of 
the same RELATION TRIGGER occurring in alternative verb-phrase 
groups. For example, “change in expression” can be represented as 
one of the following verb-phrases: Change MicroRNA-21 Expres-
sion, Expression of caveolin-1 was changed, Change in high levels 
of high-mobility group A2 expression, change of the let-7e and 
miR-23a/b expression, expression of miR-199b-5p in the non-met-
astatic cases was significantly changed, etc. To allow flexibility for 
capturing RELATION TRIGGER along with its variants spanning over 
different phrase length, we first manually represented all the rela-
tions in its root form, such as “regulate expression” to “regulate” 
(cf. Relation_Dictionary.txt file in Dataset 1). The base form has 
been extended manually to different spelling variants, e.g. regulate 
to regulatory, regulation, etc., the detailed listing of variants is pro-
vided in Word_variations.txt in Dataset 1. Not all combinations of 
Table 4. Regular expression patterns used for miRNAs identification. Aliases used to form the final regular 
expression, see Table 5, are highlighted in bold.
Regular expression patterns Description Example of identified text
(Pref+(Lin,Let)) Detection of Lin and Let variations of miRNAs lin-4; hsa-let-7a-1
(Pref+(miRNA, Onco)(S*Tail)(Sep Tail)*) MiRNAs mentions for different separators hsa-mir-21/22; Oncomir-17^92
(Pref+(miRNA, Onco) S*(D(Z([/]Z)*)+) ([\,] 
S*? (Pref+(miRNA, Onco) S*(D(Z([/]Z)*)+)*)))
Multiple miRNA mentions 
occurring progressively
miR-17b, -1a; hsa-miR-21,22, 
and hsa-miR-17
MIR0000007:MIMAT0015092@MIRBASE|MI0000002@MIRBASE|cel-lin-4|lin-4
MIR0000008: miR-171|microRNA 171
MIR0000005:MIMAT0000416@MIRBASE|has-miR-1|miRNA-1 
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the root forms are logical; target and up-regulation terms cannot be 
combined to form a relation trigger. Thus, we additionally defined 
a set of relation combinations that are allowed (see Permutation_
terms.txt in Dataset 1 for all combinations).
For all named entity recognition performed, the dictionary-based 
system ProMiner31 is used. Supplementary Table A (Dataset 1) pro-
vides a quantitative estimate of the entities available in the diction-
aries used in this work.
Relation extraction
We consider three approaches for addressing automatic extrac-
tion of interacting entity pairs from free text, described in the 
following.
The co-occurrence approach serves as a baseline. Assuming all 
interactions to be present in isolated sentences, this approach is 
complete but may be limited in precision. Reducing the number 
of false positives can be achieved by filtering with the dictionary 
of relation triggers occurring in the same sentence. The rationale 
behind this filter is that the interaction is more likely to be described 
if such a term is present (we refer to this as tri-occurrence).
To increase the precision, we use a machine learning-based approach 
formulating the relation detection as a binary classification prob-
lem: each instance (consisting of a pair of entities) is classified 
either as not-containing a relation or belonging to one of the four-
relation classes. Our system uses lexical and dependency parsing 
features. We evaluate linear support vector machines (SVM)32 as 
implemented in the LibSVM library, as well as LibLINEAR, a spe-
cialized implementation for processing large data sets33, and naive 
Bayes classifiers34. For more details, we refer to Bobić et al.35.
Lexical features capture characteristics of tokens around the 
inspected pair of entities. The sentence text can roughly be divided 
into three parts: text between the entities, text before the entities, 
and text after the entities. Stemming36 and entity blinding is per-
formed to improve generalization. Features are bag-of-words and 
bi, tri, and quadri-gram based. This feature setting follows Yu et al. 
and Yang et al.37,38. The presence of relation triggers is also taken 
into account, using the previously described manually generated 
list. Next to lexical features, dependency parsing (created using 
Stanford parser) provides an insight into the entire grammatical 
structure of the sentence39 and was performed using the Stanford 
CoreNLP library (http://nlp.stanford.edu/software/corenlp.shtml). 
Deep parsing follows the shortest dependency path hypothesis40. 
We analyzed the vertices v (tokens from the sentence) in the 
dependency tree from a lexical (text of the token) and syntacti-
cal (POS tag) perspective. Edges e in the tree correspond to the 
information about the grammatical relations between the vertices. 
Extracting relevant information from the dependency parse tree is 
usually done following the shortest dependency path hypothesis40. 
Lexical and syntactical e-walks and v-walks on the shortest path 
are created by alternating sequence of vertices and edges, with the 
length of 3. We capture the information about the common ancestor 
vertex, in addition to checking whether the ancestor node represents 
a verb form (e.g. POS tag could be VB, VBZ, VBD, etc.). Finally, 
the length of the shortest path (number of edges) between the enti-
ties is considered as a numerical feature.
Results and discussion
Dataset 1. Version 2. Manually  annotated miRNA-disease and 
miRNA-gene interaction corpora
http://dx.doi.org/10.5256/f1000research.4591.d40643
Please see README.txt in the zip file for precise details about the 
corpus and supplementary files. The updated zip file contains new 
files (Permutation_terms.txt, Non-Specific_miRNAs_Dictionary.txt 
and Word_variations.txt) and Table A has been updated.
In the following, we present results for named entity recognition 
and relation extraction. This section concludes with two use-case 
analyses.
Performance evaluation of named entity recognition
Among the 201 abstracts present in the training corpus, 82% con-
tained general miRNA mentions, in comparison to specific miRNAs 
with 45%. In Table 6, results for miRNA entity recognition are 
reported. Non-specific miRNA recognition is close to perfect. Spe-
cific miRNA mention recognition has an F1 measure of 0.94.
For disease mention recognition, combined dictionaries, based on 
three established resources, resulted in 0.79 and 0.69 F1 score for 
the training and test corpus respectively. The low score for disease 
identification could be due to the variation in disease mentions, such 
as multi-word, synonym combination, nested names, etc. However, 
the partial matches result for diseases reported 0.88 of F1, providing 
the possibility for detection of similar text strings for better recall 
(cf. Supplementary Table B in Dataset 1). Genes/proteins dictionary 
showed a performance of 0.84 and 0.85 of F1 in training and test 
corpus respectively.
The evaluation of the relation trigger dictionary (cf. Table 6) sug-
gests that it covers a substantial part of the vocabulary with recall of 
0.86 for the training and 0.79 for the test corpus.
Relation extraction
We queried MEDLINE for “miRNA and Epilepsy” documents, 
among which 16 documents containing miRNA-related relations 
were manually selected (cf. Supplementary Figure C for the detailed 
distribution statistics). To avoid any biased approach we choose Epi-
lepsy disease domain. Manual inspection of these articles revealed 
Table 6. Evaluation results for miRNA entity  classes. Here only 
complete match results are presented. The performance of named 
entity recognition is evaluated using recall (R), precision (P) and F1 
score.
Entity  Class
R P F1 R P F1
Training Corpus Test Corpus
Non-specific 
MiRNAs 1.000 0.995 0.997 1.000 0.997 0.999
Specific MiRNAs 0.921 0.928 0.924 0.936 0.934 0.935
Relation Triggers 0.864 0.885 0.874 0.790 0.842 0.815
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11.5% of miRNA-related associations occur outside the sentence 
level. Thus, our work focused on relations at sentence level. Sen-
tences in which co-occurring entity pairs do not participate in any 
relation are tagged as false. A comparison of the different relation 
extraction approaches is shown in Figure 2. Supplementary Table D 
in Dataset 1 provides statistical details of the applied approaches 
given in Figure 2. If all the entities are correctly identified then 
co-occurrence based approach leads to 100% recall for relation 
extraction. The recall is not diminished using the tri-occurrence 
approach, as the true entity pairs remain constant, while the preci-
sion increases between 4pp (percentage points) and 17pp when com-
pared to the co-occurrence based approach, reducing false positives 
(cf. Figure 2). However, overall the precision reaches less than 60%. 
In our work, we assume that all the entities have been identified 
giving a recall of 100% for both co-occurrence and tri-occurrence 
based approaches. Using the machine-learning based classification, 
precision is increased up to 76% for specific miRNA-gene relations 
for both LibLINEAR and LibSVM methods, although Naïve Bayes 
is not far behind. Similarly, these two methods performed nearly the 
same for specific miRNAs-disease relations, the F1 measure is not 
substantially different but a trade-off between precision and recall 
can be observed. An increase in F1 measure is observed for non-
specific miRNA relations when Naïve Bayes method is applied, out 
performing other strategies. Nevertheless, preference of the method 
highly depends on the compromise one chooses, whether better 
recall or precision. Overall, better recall and acceptable precision 
can be achieved with tri-occurrence method.
Most relation extraction approaches are dependent on the perform-
ance of named entity recognition. The impact of error propaga-
tion coming from automated entity recognizers is evaluated by 
applying the tri-occurrence method on the automatically annotated 
training and test corpus, here termed as “NERTri”. Compared to 
the results on the gold standard entity annotation a drop of 13 pp 
for NonSpMiR-D, 7pp for NonSpMiR-GP, 22pp for SpMiR-D, and 
30pp for SpMiR-GP in F1 is observed for the test corpus. Overall 
performance of the NERTri approach on training and test corpus is 
detailed in Supplementary Table C in Dataset 1.
Use case analysis
For the impact analysis of the proposed approach, we compare the 
extracted information with two databases, namely miR2Disease and 
miRSel. We focus on relations and articles concerning Alzheimer’s 
disease.
Alzheimer’s disease (AD) is ranked sixth for causing deaths in 
major developed countries41. It affects not only individuals but also 
incurs a high cost to the society. Recently, miRNAs have shown 
close associations with AD pathophysiology42,43. Increasing the 
need to identify new therapeutic targets for AD, after major set 
backs due to failed drugs, motivates the need to look in this direc-
tion. In silico methods, such as the one proposed in this work, can 
aid in building miRNA-regulatory networks specific to AD, for 
further analysis such as identifying the mechanisms, sub-networks, 
and key targets.
Extracting miRNA-Alzheimer’s disease relations from full 
MEDLINE
The database miR2Disease is queried to return all miRNA-dis-
ease relations occurring in Alzheimer’s disease. For comparison, 
we retrieved miRNA-disease relations from MEDLINE using 
NERTri approach, resulting in 41 abstracts containing 159 rela-
tions. Obtained triplets have been manually curated to remove 51 
false positives. False negatives have not been accounted, which 
may result in loss of information (cf. Relation extraction section). 
Comparison between the relations obtained from miR2Disease and 
NERTri are summarized in Table 7. The miR2Disease database 
returns 28 evidential statements from 9 articles. Among these, only 
14 evidences are present in abstracts. Moreover, 16 evidences are 
extracted from one full text document44. Only two evidences are 
identified at abstract level among these 16 evidences. Overall, 26 
miRNAs identified by miR2Disease refer to Alzheimer’s disease. 
Figure 2. Comparison of different relation extraction approaches. On the x-axis, different entity pair relations are represented as SpMiR-D 
for SPECIFIC MIRNA-DISEASE, SpMiR-GP for SPECIFIC MIRNA-GENE/PROTEIN, NonSpMiR-D for NON-SPECIFIC MIRNA-DISEASE, and NonSpMiR-GP for 
NON-SPECIFIC MIRNA-GENE/PROTEIN.
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Table 7. miR2Disease database comparison. MiRNA-Alzheimer’s disease relation 
retrieved from MEDLINE and in miR2Disease database.
miR2Disease NERTri True Positives in NERTri
NERTri and 
miR2Disease 
Overlap
Publications 9 41 36 8
Relations 28 159 108 11
Evidences (abstracts) 14 159 108 10
Unique miRNAs 26 46 40 16
Therefore, our text-based extraction proposes approximately three 
times more relations than the database provides.
The analysis of 17 false negative relations which are in the data-
base but not found by our approach shows that most of the rela-
tions could be found only in full text and that the automatic system 
misses four miRNA-Alzheimer’s disease relations from abstracts. 
Manual inspection reveals that in three out of these missing four 
evidences the disease name is not mentioned in the sentence (rela-
tion occurred at co-reference level).
Extraction of miRNA-gene relations for Alzheimer’s diseases 
from full MEDLINE
Here we compare the performance of our relation detection NER-
Tri with another text-mining database, miRSel. For comparison, 100 
abstracts from PubMed were retrieved using the query “alzheimer 
disease”[MeSHTerms] OR (“alzheimer disease”[All Fields] 
OR “alzheimer”[All Fields]) AND (“micrornas”[MeSH Terms] 
OR “micrornas”[All Fields] OR “microrna”[All Fields]) AND 
(“2001/01/01”[PDAT]:“2013/7/4”[PDAT]). Manual inspection of 
these articles leads to 184 miRNA-gene relations, at sentence level, 
(Table 8) in 37 abstracts.
NERTri approach was able to identify 140 of these found relations 
in 28 abstracts. Among the 37 abstracts from the PubMed query, 
miRSel contained only 12 abstracts with 56 miRNA-gene relations 
(cf. Table 8). False negatives in our approach when compared with 
miRSel could not be directly identified as the database is not down-
loadable and searchable for disease specific relations. However, low 
intersection between miRSel and NERTri can be observed.
In summary, our approach provides AD related gene-microRNA 
relations from PubMed which have not been available in the data-
base before.
Overall, the results are promising when compared with the miR2D-
isease and miRSel databases and indicate that we can extend the 
databases to a large extent with new relations. Such an approach 
makes it much easier to keep databases up to date. Nevertheless full 
text processing would most certainly increase the recall of auto-
matic processing.
Conclusion and future work
In this work, we proposed approaches for identification of relations 
between miRNAs and other named entities such as diseases, and 
genes/proteins from biomedical literature. In addition, details of 
named entity recognition for all the above entity classes have been 
described. We distinguished two types of miRNA mentions, namely 
Specific (with numerical identifiers) and Non-Specific (without 
numerical identifiers). Non-specific miRNAs entity recognition 
has enabled us to achieve better recall and precision in document 
retrieval. Three different relation extraction approaches are com-
pared, showing that the tri-occurrence based approach should be 
the first reliable choice among all others. The tri-occurrence based 
approach is comparable to a machine learning-based method but 
considerably faster. In comparison to two well-established data-
bases, we have shown that additional useful information can be 
extracted from MEDLINE using our proposed methods.
To best of our knowledge, this is the first work where manually 
annotated corpora containing information about miRNAs and 
miRNA-relations are published. Moreover, the corpora and meth-
ods provided represent useful basis and tools for extracting the 
information about miRNAs-associations from literature. This work 
serves as an important benchmark for current and future approaches 
in automatic identification of miRNA relations. It provides the basis 
for building a knowledge-based approach to model regulatory net-
works for identification of deregulated miRNAs and genes/proteins.
The proposed methods encourage the extension of this work to 
full-text articles, to elucidate many more relations from Biomedical 
literature. Non-specific miRNA mention identification could prove 
highly beneficial for co-reference resolution in full-text articles, in 
addition to abstracts. Proposed machine-learning approaches could 
be applied to only tri-occurrence based instances for reducing the 
false positive rates. Extending the current approach to other model 
organisms such as mouse, and rat could be helpful in revealing 
Table 8. miRSel database comparison. Comparison of 
miRNA-gene relations retrieval for Alzheimer’s disease in 
MEDLINE.
Approach Articles Relations
PubMed Query (“Alzheimer AND 
miRNA”) 100 NA
PubMed Query with relations at 
sentence level 37 184
PubMed Query  NERTri 28 140
PubMed Query  miRSel 12 56
NERTri  miRSel 14 22
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important relations for translational research. Inclusion of addi-
tional named entities such as drugs, pathways, etc. could lead to an 
interesting approach for detection of putative therapeutic or diag-
nostic drug targets through a gene-regulatory network generated 
from identified relations.
Data availability
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Supplementary Figure C. Coverage of relations occurring in Epilepsy Documents.
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4.2.1 Supplementary	Tables	
 
 
 
 
4.3 Summary	
This publication details the development of the text-mining methods to automatically 
extract miRNAs and its associations from the text. To build these automated methods, 
firstly a training corpus was developed. A detailed description of the literature curation 
workflow and the annotated entities are provided. Here two types of miRNAs were 
distinguished for annotation: specific and non-specific. Specific miRNAs represent the 
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Table A. Count of entries available in the dictionaries.
Genes/Proteins Relation Trigger
Dictionaries MeSHAbbr MedDRA Original Processed Species Dictionary Spelling variants
Entries 4,683 15,436 39,386 34,392 158 207 386
Synonyms 60,554 54,885 721,455 677,943 1,330 - -
Table B. Aliases used in regular expression patterns for miRNAs identification.
Description Alias Regular Expression Pattern
Digit sequences D ([0-9]:d?d*)
Upper and lower case letters L ([a-zA-Z]:l?l*)
Lower case letters only Low ([a-z]:low?low*)
Upper case letters only Up ([A-Z]:up?up*)
Admissible hypens Z ([[\-]:z?z*)
3-letter prefix for human Pref ([hH][sS][aA])
Non-specific miRNA mentions miRNA ([mM][iI]([cC][rR][oO])+[rR]([nN][aA]s+)+)
Let-7 miRNA mention Let ([lL][eE][tT][-]*[7]?l+)
Lin-4 miRNA mention Lin ([lL][iI][nN][-]*[4]?l+)
Oncomir miRNA mention Onco ([oO][nN][cC][oO][mM][iI][rR])
Admissible tilde and hyphens Cluster (⇠[\b]-[\b]-*)
Admissible hyphens and separator term and Sep ([-]:s*((and?s,\,)?s*)+)
Admissible alpha-numerical identifiers in specific miRNA mentions Two ((?low?low+,?up?up+):two((/, *and *?D+)?two)+)
Admissible alpha-numerical identifiers in oncomir mentions Tail (?D(?Two?Cluster+,-?D?Two+)+)
Table C. Regular expression patterns used for miRNAs identification (aliases from cf. Table 2 are highlighted in bold).
Regular expression patterns Example of identified text
(?Pref+(?Lin,?Let))=m([a-zA-Z0-9]-,\n)=><nn mirna>,?m; lin-4, hsa-let-7a-1
(?Pref+(?miRNA,?Onco)(?s?s*?Tail)(?Sep?Tail)*)=m([a-zA-Z0-9]-,\n)=><nn mirna>,?m; hsa-mir-21, microRNA 101
(?Pref+(?miRNA,?Onco)[-]*(?D(?Z([/]?Z)*)+):Expr([,][-]*?Expr)*)=m=> <nn mirna>,?m; miR-17⇠92, Oncomir-1
the sentence level, where a sentence with n entities contains at most
 n
2
 
interacting pairs. We consider three approaches, described in the following.
The co-occurrence approach is often considered as a baseline, since it
involves minimal effort. Assuming all interactions to be present in isolated
sentences, this approach is complete, but may be limited in precision.
Reducing the number of false positives can be achieved by filtering with
the dictionary of relation triggers. The rationale behind this filter is that an
interaction is more likely to be described if such a term is present (we refer to
that as tri-occurrence).
To increase the precision, we use a machine learning-based approach,
formulating the relation detection as a binary classification problem: each
instance (consisting of a pair of entities) is to be classified either as not-
containing a relation or belonging to one of the four relation classes. Our
system uses lexical and dependency parsing features. Several classifiers
are tested, out of which results obtained by Support Vector Machines
(SVM), Naive Bayes and LibLINEAR are reported. For more details of
the configuration, we refer to Bobic et al. (2012).
Lexical features capture the information coming from the tokens around
the inspected pair of entities. The sentence text can be roughly divided into
three parts: text between the entities, text before the entities and text after
the entities. To improve generalization, stemming (using the Porter stemmer
(Porter, 1980)) and entity blinding is performed. Features are bag-of-words
and bi, tri, and quadri-gram based. This feature setting follows GuoDong
et al. (2005), Yu et al. (2009) and Yang et al. (2010). The presence of relation
triggers is taken into account as well, using the previously described manually
generated list. Next to lexical features, deep parsing, which provides an
insight into the entire grammatical structure of the sentence, is applied by
using the Stanford parser (Marneffe and Manning, 2010). Vertices v (tokens
from the sentence) in the dependency tree are analyzed from a lexical (text
of the token) and a syntactical (POS tag) perspective. Edges e in the tree
correspond to the information about the grammatical relations between the
vertices. Extracting relevant information from the dependency parse tree is
usually done following the shortest dependency path hypothesis (Bunescu and
Mooney, 2005). Lexical and syntactical e-walks and v-walks on the shortest
path are created by alternating sequence of vertices and edges, with the
length of 3. The information about the common ancestor vertex is captured,
as proposed by Van Landeghem et al. (2008). Furthermore, it is checked
whether the common ancestor represents a verb form (e. g. POS tag could
be VB, VBZ, VBD etc). Finally, the length of the shortest path (number of
edges) between the entities is considered as well.
The system is developed in Java, using Weka 3.7.421 (Hall et al., 2009).
21 http://www.cs.waikato.ac.nz/ml/weka/
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system uses lexical and dependency parsing features. Several classifiers
are tested, out of which results obtained by Support Vector Machines
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Lexical features capture the information coming from the tokens around
the inspected pair of entities. The sentence text can be roughly divided into
three parts: text between the entities, text before the entities and text after
the entities. To improve generalization, stemming (using the Porter stemmer
(Porter, 1980)) and entity blinding is performed. Features are bag-of-words
and bi, tri, and quadri-gram based. This feature setting follows GuoDong
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insight into the entire grammatical structure of the sentence, is applied by
using the Stanford parser (Marneffe and Manning, 2010). Vertices v (tokens
from the sentence) in the dependency tree are analyzed from a lexical (text
of the token) and a syntactical (POS tag) perspective. Edges e in the tree
correspond to the information about the grammatical relations between the
vertices. Extracting relevant information from the dependency parse tree is
usually done following the shortest dependency path hypothesis (Bunescu and
Mooney, 2005). Lexical and syntactical e-walks and v-walks on the shortest
path are created by alternating sequence of vertices and edges, with the
length of 3. The information about the common ancestor vertex is captured,
as proposed by Van Landeghem et al. (2008). Furthermore, it is checked
whether the common ancestor represents a verb form (e. g. POS tag could
be VB, VBZ, VBD etc). Finally, the length of the shortest path (number of
edges) between the entities is considered as well.
The system is developed in Java, using Weka 3.7.421 (Hall et al., 2009).
3 RESULTS AND DISCUSSIONS
3.1 Corpus Analysis
Identification of relations between entities of interest may appear
over a span of several sentences, across document, or may occur in
a single sentence. 16 abstracts from PubMed,ret ieved using the
keyword “miRNA AND Epilepsy” were inespected to determine
the scope of of miRNA-related associations being expressed on
21 http://www.cs.waikato.ac.nz/ml/weka/
Table B. Performance evaluation of the disease dictionaries on
training corpus (CM=Complete match and PM=Partial match).
R P F1
CM PM CM PM CM PM
MeSH 0.62 0.74 0.70 0.70 0.66 0.72
MedDRA 0.50 0.59 0.73 0.86 0.60 0.70
MeSHAbbr 0.72 0.85 0.77 0.91 0.74 0.88
sentence level or by coreference. The corpus analysis revealed
two ways in which the authors write miRNA mentions in text,
with and without numerical ide tifiers. In spite of the fact that
miRNA mentions with numerical identifiers provide m re sp cific
information, authors use general miRNA mentions to coreference
specific miRNAs occurring in previous sentence, paragraph or in full
text. Incorporation both specific and non-specific miRNA into our
relation extraction approach merely 11.5% of all sentences participate
in additional coreference relations at abstract level, thus our work
focussed on relations at sentence level.
Out of 201 training abstracts, 165 abstracts constitute relations
with general miRNA mentions and specific miRNA mentions were
used in 90 abstracts. Similarly, in 100 test corpus, 76 abstracts
contain relations wherein general miRNAs are involved and 49
abstracts involving specific miRNA mentions. Thus, to avoid loss
of information, two miRNA classes were defined for annotation:
SPECIFIC MIRNAS and NON-SPECIFIC MIRNAS.
Table ?? shows the number of annotated concepts in training and
test corpus for each entity class and the count for manually relations
(triplets), categorized for different interacting entity pairs.
3.2 Performance Evaluation of NER
The recognition of miRNAs based on regular expressions performs
very well in terms of recall and precision. Non-specific miRNAs
ention ide tification performs b tter than specific-miRNAs,
indicating usage of standard terms representing non-specific miRNAs.
In specific miRNA mentions, authors tend to use uncommon
representations, including nested terms such as miRNA (miR)-223,
not covered in the regular expressions, leading to slightly lower
performance of the specific miRNAs identification. Table ?? reports
results for miRNA recognition and all other entity classes in training
a d test corpus.
For disease mention, firstly two standard dictionary performance
are c nsidered: MeSH and MedDRA, reported in Table B. For
both dictionaries we observed high differences in performance
considering complete match (CM) in comparison to partial match
4
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Table C. Results of tri-occurrence based approach for relation extraction
using entities identified by ProMi er.
Interacting Entity Classes Training Corpus Test Corpus
R P F1 R P F1
NonSpMiR-D 0.60 0.21 0.31 0.49 0.3 0.38
NonSpMiR-GP 0.53 0.35 0.42 0.87 0.36 0.51
SpMiR-D 0.62 0.31 0.41 0.52 0.38 0.44
SpMiR-GP 0.43 0.41 0.42 0.45 0.41 0.43
(PM). Especially for MeSH the recall increase of 12 % evaluating
partial match. Reasons are correct matches but more granular
descriptions of diseases in the text than the ones contained in the
MeSH dictionary. Inspection of missing hits revealed that both
dictionaries have a lack of disease name abbreviations.
The MeSHAbbr dictionary is developed to overcome this
(cf. Table B), resulting in gain of ⇠11% recall and ⇠21%
precision. Furthermore, merging results obtained from MeSHAbbr
and MedDRA dictionary led to an additional increase of 8% in recall
(cf. Table ??). Overall, it is noticeable that by considering these two
pro essing s e s, 20% recall was gai ed in comp ison to th MeSH
dictionary.
By far, most abstracts in test corpus are talking about human
(71), followed by mouse (16), and rats (8). Pig has 2 abstract ,
zebrafish, HIV-1, HSV-1, and C.elegans 1 each. Note that the
species distribut on is stro gly biased to human, facilitating better
performance of sp ci s dictiona y indicated in cf. Table ??.
Evalu tion results of dictionary containing relation t igger
(cf. Table ??) shows that covers subs antial part of the terms that
represe t relations involving miRNAs, providing sufficien coverage.
3.3 Relation Extraction
A comparison of th different relation extraction appr aches is shown
in Table D and Figure 3. For the evaluation of the relation extraction
the named entity recognition is given and result naturally in a 100
% recall for the co occurrence. This recall is not diminished using
the trio-ccurrence approach while the precision increases between 4
and 17 % when compared to the co-occurrence based approach, due
to the fact that it detects lesser false positives. For both training and
test corpus the precision is higher when entities belonging to Specific
miRNAs class are involved in interaction. However, the precision in
both classes reaches less than 60%. Using machine learning based
classification the precision could be increased up to 76 % for specific
miRNA -gene relations. The F1 measure is not substantially different
but recall is decreased and precision increased. This is true for all
three methods (LIBLINEAR, SVM, Naive Bayes) used.
Class imbalance is an evident issue for the classifier, resulting in a
lower recall and a decreased performance for the relation classes with
high ratio of negative instances. Depending on the use-case (high
recall or precision) either tri-occurrence or machine learning-based
relation extraction can be selected.
Most relation extraction approaches are dependent on the
performance of the named entity recognition. The error propagation
coming from an automated NER system is a behavior that is well
known and investigated in the community Giuliano et al. (2007).
The impact of the entity recognition on miRNA relation extraction is
evaluated by applying the tri-occurrence method on the automatically
annotated training and test corpus. Compared to the results on the
gold standard entity annotation a drop of 21 percentage points (pp)
for NSM-D, 5pp for NSM-G/P, 24pp for SM-D, and 32pp in F1 can
be observed for the test corpus.
4 EXTRACTING MIRNA -NEURODEGENRATIVE
DISEASE RELATIONS FROM FULL MEDLINE
For the neurodegenerative diseases Alzheimer, Parkinson and
Epilepsy we extract the miRNA - disease relations from full
MEDLINE applying our tri- occurrence approach. For Alzheimer’s
disease 41 abstracts with 159 relations, for Epilepsy ? publications
with ? relations and for Parkinson ? abstracts with ? disease - miRNA
relations could be retrieved. For Alzheimer’s Disease we compared
the results obtained from tri-occurrence based approach for Specific
MiRNAs with the re ults obtained by querying a manually curated
database, miR2Disease (Jia g et al., 2009) E. The mir2Disease
database contains about 28 evidences from 9 articles containing
information on miRNAs-Alzheimer disease relations. Among these
only 14 evidences were obtained from the abstracts, 50% of all
the evidences. Out of the 28 evidences, 16 were extracted from a
one full text document (PMID: 18434550). Only 2 evidences were
identified at abstract level among these 16 evidences. Overall, about
26 miRNAs were identified by miR2Disease database which are in
relation with Alzhe mer disease.
From the 159 evidences f nd by our automatic apporach 108 were
true positives revealing a precision of ... . Compared to the content
of the miR2Disease database for Alzheimer’s Disease our approach
has 3-fold increase in miRNAs-disease relation information. This
approach was able to identify about 40% more number of miRNAs
that participate in Alzheimer disease (at abstract level).
The analysis of 17 false negative relations which are in the database
but not found by our apporach shows that most of the relations could
only be found in full text and that the automatic system misses
four miRNA-Alzheimer’s disease relations from abstracts. Manual
inspection reveales that in three out of the missing four evidences the
disease name was not mentioned in the sentence (relation occurred
at coreference level).
Overall, our approach give promising results when compared
with the miR2Disease databse and indicate that we can extend the
databases to a large extend with new relations. Such an approach
makes it much easier to keep databases up to date. Nevertheless full
text processing would most certainly increase the recall of automatic
processing.
To analyse the gene - miRNA relations for those diseases we
extracted those relations for the three neurodegenerative diseases.
For the neurodegenerative diseases Alzheimer, Parkinson and
Epilepsy we extracted the miRNA - disease relations from full
MEDLINE. For We compared the results obtained from tri-
occurrence based approach with the results obtained by querying a
manually curated database, miR2Disease (Jiang et al., 2009). This
comparison was performed for only one disease, Alzheimer’s Disease.
To generate the results for comparison we followed the below steps:
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Table D. Comparison of different relation extraction approaches on test corpus.
NonSpMiR-D NonSpMiR-GP SpMiR-D SpMiR-GP
RE approaches R P F1 R P F1 R P F1 R P F1
Co-occurr ce 1.00 0.20 0.34 1.00 0.28 0.44 1.00 0.41 0.58 1.00 0.53 0.69
Tri-occurrenc 1.00 0.35 0.51 1.00 0.41 . 8 1.00 0.50 0.66 1.00 0.58 0.73
ProMiner NER 0.49 0.3 0.38 0.87 0.36 0.51 0.52 0.38 0.44 0.45 0.41 0.43
Machine Learning Approaches
LIBLINEAR 0.51 0.56 0.53 0.64 0.57 0.60 0.73 0.62 0.67 0.87 0.68 0.76
SVM 0.49 0.55 0.52 0.63 0.56 0.59 0.73 0.61 0.66 0.86 0.68 0.76
Naive Bayes 0.60 0.52 0.56 0.75 0.57 0.65 0.65 0.62 0.63 0.90 0.64 0.75
Fig. 3. Comparison of different relation extraction approaches.
• Tri-occurrence based approach was applied for Specific MiRNAs-
disease (Alzheimer Disease only) interacting entity classes over
whole MEDLINE.
The result file (tab separated) contained information of the
PMID, interacting Specific miRNAs and disease mentions, the
relation term, and the sentence.
• Entries in this file were manually curated to remove false
positives.
Comparison of our results with the miR2Disease results are shown
in Table E. An entry in our result file was considered as a true positive,
if the interacting entities identified in a particular abstract exists in
the miR2Disease entries. From the result table we observe that with
our approach, content of miR2Disease database can be increased by
nearly 3 times. This approach reduces the effort involved in
the identification of abstracts (and sentences) depicting miRNAs-
disease relationship and reduces the time required to read articles.
Discussion For ....describe what you have found .... We compared
the found relations with the contend of another automatic generated
database miRSel containing gene miRNA relations. Since we focused
on disease related gene - miRSel we can not directly compare to
the contend of miRSel because there is no possibility to search the
database using the disease and miRNA pair or even just disease
name. Thus we compared for a set of ab tracts retrieved with the
query (Alzheimer, parkinson or epilepsy) and miRNA and t st if the
PMIDs are contained in miRSel.
we hae to discuss this again
Thus, I compared for individual disease files I generated
(Alzheimer, parkinson and epilepsy). I took each individual PMID
and searched in miRSel. Compared the triplets(miRNA-relation
trigger-gene/proteins) from my file if they re occurring in MiRSEL.
If miRSel identified more relations which my approach could not, I
have added it them to the sum of relations identified by miRSel in
the table.
mir2Disease database contains about 28 evidences from 9 articles
containing information on miRNAs-Alzheimer disease relations.
Among these only 14 evidences were obtained from the abstracts,
50% of all the evidences. Out of the 28 evidences, 16 were extracted
from a one full text document (PMID: 18434550). Only 2 evidences
were identified at abstract level among these 16 evidences. Overall,
about 26 miRNAs were identified by miR2Disease database which
are in relation with Alzheimer disease.
Our approach was applied only at the sentence level. From the
comparison results, it is observed that our approach has 3-fold
increase in miRNAs-disease relation information when compared
6
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mentions that can directly be mapped to miRBase database identifiers, whereas non-
specific mentions aid in co-reference resolution. Annotated relations include miRNA-
disease and miRNA-gene associations. To our knowledge, this is the first work which has 
published a comprehensive corpus for miRNA research. Currently, this corpus serves as 
the gold standard for developing text-mining-based methods for miRNA research.  
The automated text-mining workflow was implemented in the ProMiner tool. Specific 
miRNA mentions were identified using a set of regular expressions. Dictionaries were 
developed to extract non-specific miRNAs and relation trigger terms. Existing dictionaries 
were adapted for extracting genes/proteins and disease mentions. Three relation extraction 
approaches were evaluated: co-occurrence, tri-occurrence and machine learning-based. 
Among these, tri-occurrence-based and machine-learning approaches were comparable, the 
latter with a slightly better precision than the former.  
To showcase the potential of the developed approach, an AD use-case was presented. The 
developed approach outperformed well-known databases: miR2Disease and miRSel. To 
conclude, this work serves as an important benchmark for current and upcoming attempts 
at aggregating highly specific and relevant miRNAs information. 
 69 
Chapter	5 	Discovery-based	Data	
Harvesting		
 
5.1 Introduction	
With rapid advancements in high-throughput technologies, a number of omics studies have 
grown over the years. Indeed, the cumulative effort of several NDD researchers to decipher 
the underlying aetiology has added to these mountains of public data. More and more of 
these datasets are made available to the community to accelerate the much needed 
discoveries and innovations to aid NDD patients. Hence, there is an urgent need to organize 
the existing digital data objects for sharing and reusability. If reused and reanalyzed from 
a different perspective, such a large collection of data has huge potential to uncover hidden 
knowledge. However, only a small subset of these data holdings support efficient 
reusability. A potential reason is that most of the repositories allow data search based on 
the metadata provided by the researchers, which is often far from complete and are not 
adapted to standard ontologies. Moreover, it still requires significant effort to retrieve a 
relevant study or obtain experiment-related metadata information. In addition, these 
databases lack context-specific metadata information that is vital for comprehending 
disease-specific studies. For example, in NDD it is important to understand symptoms or 
comorbidities of the patients, treatment methods applied to induce neurodegeneration in 
animal models, etc. To retrieve pertinent studies and thus obtain the most context-specific 
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datasets for analysis, there is a need to harvest more granular, formalised, searchable, and 
context-specific metadata information. 
In the following publication, a NDD-specific metadata database has been developed, 
named NeuroTransDB. Our study outlines the challenges faced during precise retrieval of 
omics data from GEO and ArrayExpress. Several examples have been provided that show 
the lack of compliance by data submitters. In addition, it describes the need for additional 
metadata fields needed for NDD research with good data coverage in humans and animal 
models. This publication emphasises on the approach and effort required to achieve 
FAIRness (Findable, Accessible, Interoperable, Reusable) of exisitng data in NDD. 
 
  Publication 
71 
5.2 Publication	
 
Original Article
NeuroTransDB: highly curated and structured
transcriptomic metadata for neurodegenerative
diseases
Shweta Bagewadi1,2,*, Subash Adhikari3, Anjani Dhrangadhariya1,2,†,
Afroza Khanam Irin1,2,†, Christian Ebeling1,
Aishwarya Alex Namasivayam4, Matthew Page5,
Martin Hofmann-Apitius1,2 and Philipp Senger1
1Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI),
Schloss Birlinghoven, 53754 Sankt Augustin, Germany, 2Rheinische Friedrich-Wilhelms-Universitaet
Bonn, Bonn-Aachen International Center for Information Technology, 53113, Bonn, Germany,
3Department of Chemistry, South University of Science and Technology of China, No 1088, Xueyuan
Road, Xili, Shenzhen, China, 4Luxembourg Centre for Systems Biomedicine, University of Luxembourg,
7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg and 5Translational
Bioinformatics, UCB Pharma, 216 Bath Rd, Slough SL1 3WE, United Kingdom
*Corresponding author: Tel: þ49-2241-14-2360, Fax: þ49-2241-14-2656, Email: shweta.bagewadi@scai.fraunhofer.de
Correspondence may also be addressed to Philipp Senger. Tel: þ49-2241-14-2280, Fax: þ49-2241-14-2656, Email:
philipp.senger@scai.fraunhofer.de
†These authors contributed equally to this work.
Citation details: Bagewadi,S., Adhikari,S., Dhrangadhariya,A. et al. NeuroTransDB: highly curated and structured transcrip-
tomic metadata for neurodegenerative diseases. Database (2015) Vol. 2015: article ID bav099; doi:10.1093/database/bav099
Received 2 April 2015; Revised 7 September 2015; Accepted 10 September 2015
Abstract
Neurodegenerative diseases are chronic debilitating conditions, characterized by
progressive loss of neurons that represent a significant health care burden as the global eld-
erly population continues to grow. Over the past decade, high-throughput technologies
such as the Affymetrix GeneChip microarrays have provided new perspectives into the path-
omechanisms underlying neurodegeneration. Public transcriptomic data repositories,
namely Gene Expression Omnibus and curated ArrayExpress, enable researchers to con-
duct integrative meta-analysis; increasing the power to detect differentially regulated genes
in disease and explore patterns of gene dysregulation across biologically related studies.
The reliability of retrospective, large-scale integrative analyses depends on an appropriate
combination of related datasets, in turn requiring detailed meta-annotations capturing the
experimental setup. In most cases, we observe huge variation in compliance to defined
standards for submitted metadata in public databases. Much of the information to complete,
or refinemeta-annotations are distributed in the associated publications. For example, tissue
preparation or comorbidity information is frequently described in an article’s supplementary
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tables. Several value-added databases have employed additional manual efforts to over-
come this limitation. However, none of these databases explicate annotations that distin-
guish human and animal models in neurodegeneration context. Therefore, adopting a more
specific disease focus, in combination with dedicated disease ontologies, will better em-
power the selection of comparable studies with refined annotations to address the research
question at hand. In this article, we describe the detailed development of NeuroTransDB, a
manually curated database containing metadata annotations for neurodegenerative studies.
The database contains more than 20 dimensions of metadata annotations within 31 mouse,
5 rat and 45 human studies, defined in collaboration with domain disease experts. We eluci-
date the step-by-step guidelines used to critically prioritize studies from public archives and
their metadata curation and discuss the key challenges encountered. Curated metadata for
Alzheimer’s disease gene expression studies are available for download.
Database URL:www.scai.fraunhofer.de/NeuroTransDB.html
Background
Considerable effort by the global research community has
been dedicated to addressing a limited understanding of the
pathogenic events underlying neurodegenerative disease
(NDD) (1, 2). The cumulative output of these efforts has es-
tablished an increased amount of deposited molecular data
and published knowledge. As life expectancy continues to
rise and treatment options for NDD remain limited, there is
an increasing urgency to translate this amassed molecular
data into biomarker tools for early diagnosis; to open the
possibility of disease altering and preventative therapy (3,
4). Furthermore, biomarkers aiding the decision-making
process for therapies targeting specific pathophysiological
mechanisms will help to address the high drug attrition rate
in the NDD pharmaceutical industry. Informatic efforts to
facilitate the integration and interrogation of the distributed
molecular data legacy for NDD can enable a systematic and
objective prioritization of molecular protagonists and there-
fore potential biomarkers in NDD (5–8).
In this direction, we have previously developed a seman-
tic framework, called NeuroRDF (9), for integration of
heterogeneous molecular data types, extracted from bio-
medical literature, transcriptomic repositories and bespoke
databases. NeuroRDF enables researchers to formulate
biological questions that relate to the interplay of different
facets of molecular biology as a formalized query. Even
today, the most abundant source of quantitative molecular
data remains transcriptomic data, which can support hy-
pothesis-free, elucidation of biological function (10). When
the same biological function is replicated in additional ex-
pression data sets, it increases the plausibility of the
derived hypothesis (11).
The inaccessibility of the brain is a significant barrier
to molecular analysis of NDD and this frequently limits
the availability of samples from post-mortem tissue (12,
13). This is evident when simply comparing the availabil-
ity of NDD studies to other disease domains, like cancer
(14), in public archives such as Gene Expression
Omnibus (GEO) (15) and ArrayExpress (16) (see
Supplementary Figure S1). For instance, GEO contains
157 NDD studies in contrast to 16,910 cancer studies.
Therefore, animal models are an important complement
to human-derived samples but are at best an incomplete re-
flection of the human conditions. Assessing the biological
complementarity of studies is important when considering
a meta-analysis. Such an assessment can be a cumbersome
process as searching in these public repositories is princi-
pally based on free text. Additionally, limited adoption of
controlled vocabularies, such as the Experimental Factor
Ontology (EFO) (17), to describe the metadata fields and
lack of compliance to defined standards (18) has contrib-
uted to the dilemma. This has resulted in metadata being
scattered as unstructured prose in public databases and as
additional annotations, widely distributed in originating
publications. Moreover, applying automated methods to
retrieve information from these databases could comprom-
ise on the accuracy. On the other hand, capturing missing
annotations through the manual curation can incur huge
costs of trained labour.
Capturing the associated metadata in a standardized
and precise fashion will empower integrative analysis by
helping to control sources of variability that do not relate
to the hypothesis under investigation (11, 19–21). Ober
et al. (22) have reported on differing gene-expression pat-
terns related to gender and suggest gender-specific gene
architectures that underlay pathological phenotypes. Li
et al. (23) observed distinct expression patterns, strongly
correlated with tissue pH of the studied subjects; these pat-
terns are not random but dependent on the cause of death:
brief or prolonged agonal states. Thus, studies enriched
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with metadata annotations provide the power to obtain
more precise differential estimates.
Related work
Numerous approaches have been proposed to tackle the
problem of identifying relevant gene-expression studies
and annotating metadata information resulting in several
databases, web servers and data exploration tools. These
(value added) databases differ from one another based on
their objectives, information content and mode of query.
AnnotCompute (24) is an information discovery plat-
form that allows effective querying and grouping of similar
experiments from ArrayExpress, based on conceptual dis-
similarity. The dissimilarity measure used, Jaccard dis-
tance, which is derived from the MAGE-TAB fields
submitted by the data owners. Another tool, Microarray
Retriever (MaRe) (25) enables simultaneous querying and
batch retrieval from both GEO and ArrayExpress for a
range of common attributes (e.g. authors, species)
(MAGE-TAB is a submission template, tab-delimited, for
loading functional genomics data into ArrayExpress.
https://www.ebi.ac.uk/fgpt/magetab/help/). GEOmetadb
(26) is a downloadable database of structured GEO meta-
data with programmatic querying libraries in both R and
MATLAB. However, all the above-mentioned resources
suffer from a common limitation: they rely completely on
the submitted data and do not provide solutions for miss-
ing metadata information.
Several value-added databases invest manual curation
effort to enrich metadata information for gene-expression
studies. Many Microbe Microarrays Database (M3D) (27)
contains manually curated metadata, retrieved from the
originating publications, for three microbial species, con-
ducted on Affymetrix platforms. Similarly, the Oncomine
database (28) contains extensive, standardized and curated
human cancer microarray data. A-MADMAN (19); an
open source web application, mediates batch retrieval and
reannotation of Affymetrix experiments contained in GEO
for integrative analyses. Microarray meta-analysis data-
base (M2DB) (11) contains curated single-channel human
Affymetrix experiments (from GEO, ArrayExpress and lit-
erature); categorized into five clinical characteristics, repre-
senting disease state and sample origin. However,
experiments with missing link to the published paper in
GEO and ArrayExpress were excluded. A substantial pau-
city of sample associated gender information in GEO and
ArrayExpress motivated Buckberry et al. (29) to develop a
R package, massiR (MicroArray Sample Sex Identifier) to
label the missing and mislabelled samples retrospectively
with gender information, based on data from Y chromo-
some probes. Apart from publicly available resources,
there are various commercial products that contain manu-
ally curated transcriptomic metadata: NextBio, Genevesti-
gator and InSilicoDB (30) (http://www.nextbio.com/b/
nextbioCorp.nb and https://genevestigator.com/gv/).
However, none of the above databases are optimized to
capture detailed metadata specific to neurodegenerative
disease. In addition, these databases fail to handle species-
specific annotations; especially treatments applied on ani-
mal models to partially explicate or treat human-related
NDD mechanisms, which may strongly contribute to in-
crease the predictive power of translating preclinical results
in NDD drug trials.
Here, we describe the detailed development of
NeuroTransDB, a manually curated database containing
metadata annotations for neurodegenerative studies and
an enabling resource for supporting integrative studies
across human, mouse and rat species. The participation of
our group, at Fraunhofer Institute SCAI, in projects funded
by the Neuroallianz Consortium (a part of the BioPharma
initiative of the German Ministry of Education and
Research) and the evident lack of a comprehensive NDD
specific metadata archive has motivated us to develop
Neurodegenerative Transcriptomic DataBase
(NeuroTransDB) (http://www.neuroallianz.de/en/mission.
html). This database now contains more than 20 dimen-
sions of metadata annotations for human studies, as well
as mouse and rat models, defined in agreement with dis-
ease experts. To demonstrate our approach, we chose to
highlight Alzheimer’s disease for this publication because it
depicts a wide spectrum of the possible annotations across
different types of metadata in neurodegeneration.
Additionally, we have applied the same approach to all
publicly available Parkinson’s and Epilepsy studies, which
shows that the overall approach is unspecific to the disease.
However, the curated data for these two diseases will be
released in the future under the terms of a Neuroallianz
agreement. The database is updated every six months using
highly trained curators. An interactive graphical user inter-
face to access this data is currently being developed as part
of the AETIONOMY IMI project (http://www.aetionomy.
eu).
Curation of gene-expression studies:
prerequisites, key issues and solutions
This section discusses the workflow we followed to re-
trieve relevant gene-expression datasets and to generate
detailed metadata annotations for each study (Figure 1).
First, we retrieved all functional genomics studies from
GEO and ArrayExpress that reference Alzheimer’s dis-
ease (AD) or a set of AD synonyms, along with the pro-
vided metadata (cf. Data Retrieval section). Each study
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was then prioritised (cf. Experiment Prioritization sec-
tion) based on the disease relevancy, experimental type
and sample source. Only studies in the top prioritization
category were subjected to rigorous, semiautomated
metadata curation (cf. Metadata Curation section).
Annotations are standardized by reference to controlled
vocabularies for each extracted metadata dimension (cf.
Normalization of Metadata Annotations section). The
curated Alzheimer’s data is stored in NeuroTransDB, but
in principle the proposed workflow can be applied with
little adaptation to any disease indication, especially
NDD.
Primary data resources
Together the GEO and ArrayExpress databases constitute
a wealth of gene expression studies and are commonly
reused for validating new hypotheses and identifying novel
signatures through meta-analysis by multi-data integration
(11). GEO is the largest public repository of functional
genomic data; maintained by the National Center for
Biotechnology Information (NCBI) in the USA.
ArrayExpress is the European counterpart of GEO and
consists of manually curated experimental information im-
ported from GEO, in addition to the data that are directly
submitted by the researchers. To support reuse of the de-
posited studies, each repository adheres to annotation
standards for submission of transcriptomic data:
‘Minimum Information about a Microarray Experiment’
(MIAME) and ‘Minimum Information about a high-
throughput nucleotide SEQuencing Experiment’
(MINSEQE) (http://fged.org/projects/miame/ and http://
www.fged.org/projects/minseqe/). GEO allows data sub-
mission in Excel, SOFT or MINiML format and
ArrayExpress as MAGE-TAB through Annotare webform
tool (http://www.ncbi.nlm.nih.gov/geo/info/submission.
html and http://www.ebi.ac.uk/arrayexpress/submit/over-
view.html).
Curation team
An obvious prerequisite for any curation process is to have
access to specially trained personnel, who understand the
key attributes required to adequately describe an expres-
sion experiment and are able to complete these attributes
by reference to appropriate resources (31). Such individ-
uals are known as biocurators. We assembled a team of
candidate biocurators who have adequate biological ex-
perience. Each biocurator underwent extensive training in
the fundamentals of curation, including the basics of gene
expression study design, outlined by experts, scientists and
disease experts. Clear curation guidelines (see Experiment
Prioritization and Metadata Curation section) and a
weekly meeting of the biocurators with one of the experts
ensured good quality, consistency, and uniformity in cur-
ation procedure. In addition, this provided an opportunity
to get feedback from the biocurators for improving and
updating the defined guidelines. To keep abreast and elim-
inate any bias, the curated data was regularly exchanged
between them for good interannotator agreement. The ex-
perts resolve any disagreement that may arise between the
curators.
Data retrieval
Putative AD studies were programmatically retrieved from
GEO and ArrayExpress by applying a recall-optimized
keyword search approach, cf. Figure 2. The keywords in-
clude a set of AD synonyms such as ‘Alzheimer’,
‘Alzheimer’s’ or ‘AD’ in combination with a species filter.
Since ArrayExpress imports and curates the majority of
GEO experiments, we firstly queried the former through
its REST service (http://www.ebi.ac.uk/arrayexpress/help/
programmatic_access.html). Conjointly, we further
queried GEO using the eSearch Entrez Programming
Utilities (E-utils) service to fetch additional identifiers
(IDs), which were not picked up by the previous query
(http://www.ncbi.nlm.nih.gov/geo/info/geo_paccess.html).
The final list of unified experiment IDs was downloaded
Data Retrieval
Experiment Priori!za!on
Manual meta-data cura!on
Normaliza!on
Priority 1
Priority 2
Storage in NeuroTransDB
Figure 1. Overall workflow for curation of gene expression studies
related to neurodegeneration from public archives. The first step in-
volves automated retrieval of gene expression studies (along with
metadata) from public archives such as GEO, and ArrayExpress. The
related studies were further assigned to one of the two prioritization
classes (priority 1 or priority 2), based on the specific experimental vari-
ables. Next, manual curation was applied to capture missing metadata
information on priority 1 studies. All the harvested metadata was nor-
malized using standard vocabularies. Both raw and normalized data are
stored in NeuroTransDB.
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(along with their metadata) and stored in
NeuroTransDB. Metadata information was captured
from Sample and Data Relationship Format (SDRF) file
of ArrayExpress and SOFT file of GEO (https://www.ebi.
ac.uk/fgpt/magetab/help/creating_a_sdrf.html and http://
www.ncbi.nlm.nih.gov/geo/info/soft.html). The above-
described steps are fully automated; enabling an auto-
matic update procedure we run every 6 months to obtain
new published studies.
Experiment prioritization
For integrative meta-analysis, combining studies that ad-
dress the same objectives could minimize biases from co-
hort selection (inclusion and exclusion criteria) and other
design effects. Anatomical and functional heterogeneity
arising from experimental sample source, imposes yet an-
other challenge for integrative analysis. Moreover, key-
word-based, recall optimized retrieval of experiments does
not guarantee its clinical relevancy to the queried indica-
tion or organism. Thus, we propose a straightforward bin-
ning approach to select potentially eligible studies for AD
as illustrated in Figure 3.
Firstly, we identified experiments relevant to AD indica-
tion, if not relevant we mark them as unrelated (referred as
AD3 in the database). Relevancy is defined on the basis of
the experiment’s characteristics: investigation on AD
mechanism, AD associated mechanism, AD genes or con-
tains samples that belong to direct or implicated effects of
or on AD. For example, GSE4757 is relevant to AD since it
investigates the role of neurofibrillary tangle formation in
Alzheimer patients between normal and affected neurons.
The retained AD-related experiment IDs were manually
classified by biocurators into one of the two-prioritization
categories (cf. Figure 3). To support this process, a set of
classification rules were devised that capture two import-
ant considerations: organism specificity and source of the
samples used in the study. Although curation with regards
to these considerations is of obvious importance, no previ-
ously published guidelines were available for reference. To
our knowledge, this is the first work where such a guide-
line has been explicitly detailed. A simplified description of
the classification rules adopted for AD disease prioritiza-
tion is provided below:
Priority 1
• Experiments that study AD pathophysiology in in vivo
systems
• Studies containing samples from:
– Human AD patients such as blood, brain tissue,
serum, etc.
– Animal model samples such as mouse brain tissue or
rat brain, e.g. C57BL/6 mice, Sprague–Dawley rat, etc.
– Animal models modified to study the role of an AD
gene (knock-out models), or AD mechanism (trans-
fected models), or diet/drug treatments (treated mod-
els), such as TgAPP23, APLP2-KO mice, etc.
• Experiments containing only healthy/normal samples
from human/mouse/rat that are a part of a bigger study
investigating AD
Priority 2
• Experiments that study AD pathophysiology in in vitro
systems
Keyword search for human, mouse, and rat:
“Alzheimer”,  “Alzheimer’s”, or “AD”
eSearch E-u!ls service
Parse XML file for experiment IDs
Storage in NeuroTransDB
REST Service
Parse XML file for experiment IDs
Fetch the SOFT file using experiment 
IDs and parse meta-data annota!ons
Fetch the SDRF file using experiment 
IDs and parse meta-data annota!ons
Figure 2. Automated data retrieval of Alzheimer’s Disease specific gene expression studies from ArrayExpress and GEO. Here, the dotted line
represents the sequence of query performed. Alzheimer’s disease specific experiment IDs were automatically retrieved from GEO and ArrayExpress,
using keywords, through eSearch and REST service respectively. Metadata information was extracted by automatically parsing sample information
files (SDRF and SOFT) of these experiment IDs.
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• Studies containing samples from derived or cultures
sources:
– Cell lines
– Pluripotent cells
– Stem cells
Incorrect organism or disease specificity
Although the experiment retrieval step was restricted to a
specific organism and disease conditions, we observed dif-
fering levels of specificity. For example, some mouse stud-
ies were retrieved when querying for human studies.
Similarly, we obtained experiments for related diseases
such as Parkinson’s disease, or diabetes, when querying for
AD. Therefore, during study prioritization it was import-
ant to confirm the species of origin and relevancy of the
study to AD. It’s also possible that keyword-based retrieval
may miss AD studies due to incorrect disease or organism
tagging. However, we did not perform an exhaustive
search for such falsely ignored studies, since it would re-
quire immense human effort.
Ambiguous species designation
In some studies, human cells such as embryonic stem cells
are injected into animal models and post-mortem samples
from these animal models are extracted for transcriptomic
analysis (e.g. GSE32658 experiment in GEO). Such a study
could arguably be classified as either human priority 2 or
mouse priority 1. After several discussions, we concluded
to prioritize such experiments based on the organism from
which the final sample was extracted. In this case,
although the mouse was grafted with human tissue, we pri-
oritized it to mouse priority 1.
Superseries redundancy
During prioritization, we retrieved several superseries ex-
periments from GEO. Manual inspection revealed that not
all the subseries IDs of these superseries experiments were
retrieved (see Data Retrieval section) (A SuperSeries is sim-
ply a wrapper to group of related Series (typically
described in a single publication). It facilitates access to the
entire dataset, and establishes a convenient reference
entry that can be quoted in the publication (definition
provided by the GEO team, as of 27 October 2014) and a
subseries is an experiment that is a part of superseries.).
With careful manual inspection, we included missing
subseries, further subjected to priorization. Conversely,
if the inclusion of superseries resulted in the duplication
of experiments, we removed the duplicates. Having assigned
priority categories to all retrieved AD studies, further meta-
data curation was focused on the priority 1 studies.
Metadata curation steps are described below.
Metadata curation
Precisely and comprehensively capturing the accessory in-
formation for a transcriptomic study as meta-annotations,
is an important precursor to identification of comparable
experiments that address the biological question at hand.
Unfortunately, the current, general, submission standards
do not cater to the needs of metadata annotations, specific
to a disease domain, during submission. In subsequent
Query downloaded experiment IDs 
from NeuroTransDB
Sample source
Alzheimer’s 
Disease 
relevancy?
Mark as unrelated
In vivo studies In vitro studies
Priority 1
Human pa!ents 
Animal models
Knock out/transfected/treated 
Animal models for AD patho-
physiology
Priority 2
Cell lines
Stem cells 
Pluripotent cells
Yes
No
Figure 3. Experiment prioritization for metadata curation in NeuroTransDB. All the downloaded Alzheimer’s Disease experiments were first checked
for their disease relevancy. Those experiments which were falsely retrieved, are marked as unrelated. The remaining experiments were classified
into one of two priority classes based on the experiment type: In vivo or In vitro studies. For priority 1, we considered direct/primary samples from
human or animal models such as brain tissue, blood, etc. Experiments that were conducted on derived sample sources such as cell lines, were put
into priority 2 class.
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sections, we discuss the metadata curation for NDD and
key issues faced during the process.
Metadata annotation fields
We assembled a list of metadata annotations determined to
be important for evaluating NDD studies in a process
involving consultation by NDD domain experts. All the
metadata fields were categorized as organism attributes
and sample annotations, based on their relevancy to organ-
ism or sample source. Table 1 provides detailed descrip-
tions of curated metadata fields including examples for
human, mouse and rat.
Several animal models and in vitro systems have been
defined that partially mimic the human diseased condi-
tions. Animal models provide experimentally tractable sys-
tems for interrogating NDD, however, not all animal
models faithfully mimic human pathophysiology. A dedi-
cated set of meta-annotation was defined for NDD animal
models to support assessments of inter-study comparability
and translatability to human disease, cf. Table 2 These
fields were defined with assistance from biologists and dis-
ease experts from industry.
Metadata curation workflow
To capture all the relevant meta-annotations, we designed
a semiautomated curation workflow, illustrated in
Figure 4. Firstly, we automatically retrieved all the avail-
able meta-annotations from GEO and ArrayExpress (cf.
Figure 2). Annotations were captured in an Excel template
as shown in Supplementary Figure S2 (A) and confirmed
by our trained curators to rectify any inaccuracies.
To capture incomplete and newly defined meta-annota-
tions, we followed a two-step approach. First, we check if
the required meta-annotation entries are directly available
in GEO, GEO2R or ArrayExpress (http://www.ncbi.nlm.
nih.gov/geo/geo2r/). Where the required information is
complete, we directly update NeuroTransDB, otherwise
we move to a second step to manually harvest information
for missing annotations. Missing information is retrieved
from the originating publications and associated
Supplementary files. When necessary, corresponding au-
thors were contacted to request missing entries. The list of
experiment IDs where we contacted the authors for further
information, along with reason of contact (priority 1 ex-
periments only) are provided in Supplementary Table S1.
In most cases, the corresponding author or one of the coau-
thors responded to our queries; whereas, in few other cases
the email addresses no longer remained valid. In the event
that the authors do not respond or we were unable to con-
tact them, information in primarily deposited database is
used as the final authorative source. Once all the relevant
data was captured, we updated the annotations in
NeuroTransDB. If needed, we updated our automated re-
trieval iteratively.
To demonstrate the metadata curation process, here we
relate our experience with study GSE36980 that includes a
total of 79 samples. Common MIAME annotations such as
gender, age and sample tissue were automatically captured
from ArrayExpress and GEO. The associated publication
contained further useful information on the enrolled
patients, namely: disease stage, post mortem interval be-
fore sample extraction and preservation, pathological
diagnosis and whether the patient suffered from
comorbidities such as diabetes. This information was
located in Supplementary File S2 of the associated publica-
tion (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128
707/bin/supp_bht101_bht101supp_table2.xls). However,
lack of a common ID to enable mapping between the sam-
ple entries in GEO and the associated Supplementary File
S2 impeded curation. For example, sample GSM907797 in
GEO is annotated as being derived from a 95-year-old fe-
male patient. However, in their Supplementary file, there
are two entries that contain information for patients with
same age and gender. The ‘No.’ column, assumed to be pa-
tient ID, in the Supplementary file was not helpful for
mapping, since it was not mentioned in GEO. Thus, we
contacted the authors for the missing link. They provided
us an additional Excel sheet where the GEO sample ID
was mapped to the ‘No.’ column in the Supplementary file
(cf. Supplementary Figure S2 (B) and (C)). As a conse-
quence, we achieved a 28.5% increase in the missing meta-
data information (cf. Table 1 for total number of fields)
after contacting the authors.
Automated meta-annotation retrieval challenges
During automated retrieval of metadata fields, we
observed several alternate representations of information
for certain annotation types in the archives. For example,
age information can be provided in the Characteristics sec-
tion of GEO or ArrayExpress as ‘age: 57 years’ or ‘Stage
IV, male, 57 years’ and so on. We attempted to
prenormalize these diverse representations and automatic-
ally extract the correct information, however, due to the
heterogeneity in data representation, manual curation was
still required.
Although ArrayExpress and GEO provide program-
matic access to their meta-annotations, much essential in-
formation appears in fields meant for general categories.
For example, information about the sample source and
clinical disease presentation appear in the sample title
‘PBMC mRNA from Alzheimer’s disease patient 2’.
Adhering to the standard submission protocol for data
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Table 1. Detailed description of Neurodegenerative disease metadata fields outlined for human, mouse and rat
Annotation type Metadata fields Description of the annotation Relevancy for NDD Examples References
Organism
attributes
Age Age of the organism Main factor for predisposition to
disease
84 years, 9 months (32–35)
Gender Gender of the organism Possible disproportionate effect
arising from difference in anat-
omy and hormonal
composition
Male, female (36, 37 )
Phenotype Clinical phenotypes of the or-
ganism from which the sam-
ple was extracted
Supports comparative analysis
for underlying pathomechan-
isms based on the observable/
measurable characteristics
Healthy control,
early incipient
(38)
Behavioural
Effect
Description of behavioural
changes occurring in organ-
ism due to treatment or other
effects
Impact of developed drug or
other environmental factors to
treat or reduce the disease/dis-
ease symptoms
Reduced agitation/
aggression
(39, 40 )
Disease type The disease occurrence is due
to hereditary or effect of en-
vironmental factors
To distinguish the genetic vari-
ability and complexity be-
tween the two types during
analysis
Sporadic, familial (41 )
Stage Disease stage of the organism
from which the sample was
extracted
Capability to distinguish severity
of the affected disease
Incipient, severe,
BRAAK II
(42)
Cause of
death
Reason for the organism’s
death
To determine if Alzheimer’s dis-
ease or its associated comor-
bidities are major contributors
to death rate
Respiratory disorder (43)
Comorbidity Existence of another disease
other than Alzheimer’s
To determine the impact of an-
other disease on Alzheimer’s
disease aetiology and
progression
Type 2 diabetes (44, 45)
Sample
annotations
Post mortem
duration
(PMD)
Duration from death till the
sample extraction from the
dead organism
To assess quality and reliability
of the sample obtained by
measuring RNA integrity that
is influenced by natural deg-
radation of the sample after
death
2.5 hours (46, 47 )
pH pH value of the extracted post-
mortem sample
Indicator of agonal status and
RNA integrity
6 (48–50 )
Functional
effect
Description of functional ef-
fects observed
Observed changes such as gene
expression, post-translation,
or pathway due to external
effects
Decreased expres-
sion of BDNF
gene, reduced Ab
toxicity
(51 , 52)
Brain region Brain region of the extracted
sample
Provides information of patho-
genesis and disease progres-
sion, as AD does not affect all
the brain regions
simultaneously
Hippocampus (53, 54)
Cell and cell
parts
Type of cells or cell parts ex-
tracted from the sample for
analysis (if any)
To determine cell type specific
expression influencing patho-
genesis and regional
vulnerability
Synaptoneurosome,
neurons and
astrocyte
(55, 56)
Body Fluid Type of body fluid used for
analysis
Could serve as biomarkers for
early diagnosis and therapy
monitoring
CSF, blood (57 –59)
The table provides a list of metadata fields, confirmed by disease experts, critical for NDD meta-analysis. The selected fields are classified as organism attributes
and sample annotations based on their relevancy to organism or sample source.
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entry, this information should appear in the
‘Characteristics column’ of ArrayExpress and GEO. Again
inconsistent adherence to annotation standards means that
manual inspection is needed to capture correct and com-
plete information from these archives.
Accessing linked publications
For annotation information that is not directly available
from the source repositories, we refer to the associated full
text publications. However, not all deposited studies link
to an associated publication in PubMed, contributing to a
Table 2. Detailed description of additional metadata fields, defined specifically for mouse and rat models
Annotation type Metadata fields Description of the
annotation
Relevancy for NDD Examples References
Organism
attributes
Physical injury Method used to cause brain
injury in animal models
Consideration for analysing
plaque formation in animal
models to mimic disease
symptoms in human
Traumatic brain injury,
ischemia reperfusion
injury
(60, 61)
Type of
treatment
Description of chemical,
drug, genetic or diet
treatment
Consideration for determining
the effect of treatment on
animal models either to
mimic or treat the disease/
symptoms
Long-term pioglitazone,
BDNF treated
(62, 63 )
Dosage Detailed description of the
dosage associated with
“type of treatment”
description
Consideration of the right
quantity of the substance for
determining the effect on
animal models either to
mimic or treat the disease/
symptoms
Total polyphenol 6mg/
kg/day, received
drinking water with-
out ACE inhibitor
(64 , 65)
Mouse/rat
strain name
Mouse model official or
author given name
To determine the effect of dif-
ferent manipulated animal
models in recapitulating key
AD features capable of
extrapolating to human
studies
C57BL/6-129 hybrid,
Sprague–Dawley rat
(66, 67)
Mouse/rat
weight
Weight of the animal model
during analysis
Establishing a causative link to
metabolic disruption
100–150 g (68 )
These additional metadata fields are defined by disease experts as critical for translating mouse/rat model outcomes to human, in the field of neurodegenerative
diseases.
Go to GEO, AE or 
GEO2R page
Captured 
all 
relevant 
data?
Read associated 
publica!on
Update the curators 
excel sheet
Yes
Automa!cally extract the 
relevant  meta-data fields  and 
pre-fill the cura!on excel sheets
No
Data also 
available in 
prefilled 
columns?
No
Yes
Improve pre-filler method
if possible
NeuroTransDB
Figure 4. Semi-automated workflow for metadata curation. Automatically extracted metadata fields are rechecked by the curators. To capture the
missing fields, curators browse through GEO, ArrayExpress (AE) or GEO2R experiment’s description pages. For cases where the information is still
incomplete, associated fulltext publications and their associated supplementary material are read. All the extracted metadata annotations are stored
in NeuroTransDB. Intermediately, if feasible, automated extraction leverages on curator’s experience for improvement. This process is carried out
half yearly.
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significant loss of information while curating. We at-
tempted to overcome this by searching for an associated
article using the study title with search engines such as
SCAIView and/or Google (http://www.scaiview.com and
https://www.google.com). Supplementary Figure S3 shows
the percentage of articles that were retrieved with different
search strategies. We are aware that not all the experi-
ments in these databases are associated with published art-
icle (14%), but for 9% of the experiments (prioritized as 1)
we were able to link them to publications through a title
search. We strongly encourage study depositors to provide
PubMed annotation whenever available to allow enhanced
meta-annotation. Additionally, database owners should
find a more robust way to update their resources.
Duplication and inconsistent sample counts
We observed differences in sample counts for some experi-
ments between ArrayExpress and GEO, when downloaded
automatically. For example, GSE49160 contained 36 sam-
ples in GEO and 72 samples in ArrayExpress. Following
closer inspection at several similar experiments, we found
that ArrayExpress duplicates sample IDs to provide separ-
ate links to different raw file formats or large raw files split
into smaller ones (57%), processed raw files (17%), separ-
ate entry for each channel in double channel arrays (14%)
and replicates (12%) (cf. Supplementary Figure S4); more-
over, the duplicated samples mostly represented the same
annotation information. Since, we used sample IDs as a
unique entry in our database, the duplicated IDs were
replaced with the last entry from the archive, in
NeuroTransDB, as read by our algorithm; thus a risk of
loosing the raw file or other non-duplicated annotation
information.
Apart from duplication, occasionally some samples
were missing in one archive relative to the other. For ex-
ample, GSE47038 had some additional samples in
ArrayExpress, which were not present in GEO. When we
contacted the ArrayExpress team, they suggested that the
experiment entry could be out of sync, since each entry
from GEO is uploaded into ArrayExpress only once and is
not updated if GEO deletes some samples later. However,
they have now corrected the entry. This demonstrates a
need for periodic review of study records in each database.
Missing RAW filenames
Public transcriptomic archives provide a gateway for the
search and retrieval of studies for subsequent analysis out-
side of the platform. Therefore, one has to obtain the link
between a sample’s raw file name and corresponding
phenotype. However, this is not the case when applying
automated downloads. The majority of the raw file names
present in public archives contain syntactical errors such as
surrounded by brackets or separated by comma; moreover,
such entries could be normalized through a simple script.
In cases where no information about sample’s raw file
name is provided, manual intervention is required to link
sample’s raw file to its respective sample. This clearly indi-
cates the need for standardization of the database entries
for automation and to prevent loss of information.
Incorrect and incomplete metadata information
We also observed inconsistent meta-annotations between a
study deposited in an archive and the information in the linked
publication. In GEO for experiment GSE2880, the sample de-
scription page states that male Wistar rats have been used for
the study. However, when we looked into the associated full
text article, in the Methods section, the authors clearly men-
tion using female Wistar rats (69). We are still waiting for the
author’s reply to correct the gender information for this entry.
Another example is GSE18838, we observe that the ratio of
male to female patients provided in GEO (male/female: 19/9)
is different from that reported in the Supplementary file (male/
female: 18/10); additionally, Supplementary Table S2 provides
detailed challenges faced during mapping of age and gender
information to samples. When searched in ArrayExpress, this
experiment has been removed from the database, for un-
known reasons. In yet another example, GSE36980, the age
information for sample GSM907823 and GSM907823 vary
between GEO (84 and 81 years, respectively) and
ArrayExpress (74 and 86 years, respectively). From these
anecdotal experiences, it is evident that one has to spend
immense effort to obtain correct metadata information.
Database owners and the submitters have to take utmost care
to provide the correct data for reproducibility.
Information extraction from chained references
One further time consuming task included looking follow-
ing chains of references to previous publications for human
and animal model information such as mouse name, cross
breeding steps applied and human subject information. In
some cases, we had to tediously trace back 5–6 cross-
referred publications to obtain the original source of
information.
Normalization of metadata annotations
Meta-annotation involved the curation team extracting the
original text as provided in GEO/ArrayExpress or in the
published literature. We observed many different ways to
express information for each annotation field, with obvi-
ously ramifications for accurate and efficient querying of
NeuroTransDB. In an effort to standardize entries for dif-
ferent annotation fields specific controlled vocabularies
were adopted during curation.
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Age and gender normalization
We observed several different ways of representing age
such as ‘24 yrs’, ‘25 yo’ and ‘236 2 years old’. All age val-
ues were standardised by converting to simple decimal
numbers, e.g. 24.00 for 24 years. Similarly for gender, we
used a consistent representation of ‘M’ and ‘F’. As an ex-
ample, gender information for GSE33528 samples were re-
ported in the associated article (40) as ‘70% of the
participants were women’. Here, we annotated the infor-
mation as ‘70% female’. Although the annotations such as
ranges (e.g. ‘236 2 years old’), ratios (male/female: 19/9),
or percentages (70% female) (40) are study-level annota-
tions, they were provided as sample level annotations; as
they do not contribute to reasonable cohort selection we
did not normalize them.
Phenotype, brain region and stage normalization
Disease phenotype and stage information contributes to
specific details of clinical manifestations whereas the tissue
source (hereafter brain region) caters to the sample origin.
For all the curated phenotype mentions (human), we gener-
ated a binning scheme: diseased, control or treated. These
binned terms were further mapped to controlled vocabula-
ries provided by Alzheimer’s Disease Ontology (ADO)
(32). Other annotated terms that are not specific to AD
were mapped to the Human Disease Ontology (33),
Medical Subject Headings (MESH), Medicinal Dictionary
for Regulatory Activities (MEDDRA) and Systematized
Nomenclature of Medicine - Clinical Terms (SNOMED-
CT) (34) ontologies (http://bioportal.bioontology.org/
ontologies/MESH and http://bioportal.bioontology.org/
ontologies/MEDDRA). This caters the need to query sam-
ples at a more abstract level, for downstream analysis. In
total, for AD, we obtained 481 phenotype mentions as-
signed to at least one entry in the bins generated. Similarly,
all the stage mentions (117 terms) were mapped to ADO,
and ONTOAD (35). Mentions of brain region (41 unique
terms) were tagged to Brain Region and Cell Type
Terminology (BRCT) (http://bioportal.bioontology.org/
ontologies/BRCT?p¼summary). Please refer to
Supplementary File S2 for detailed mapping of human an-
notation terms to controlled vocabularies.
Normalization of animal models
Similar to human phenotype normalization, we have nor-
malized mouse and rat phenotype terms to EFO and
SNOMED-CT. Different treatment procedures have been
used to generate animal models that capture specific as-
pects of human diseases. At times, the incomplete nature of
the models could lead to inadequate or misinterpretation
of results. Thus, it is necessary to know the experimental
procedures used on these animal models. To enhance this
interpretation, we have binned all the captured animal
model information, during the metadata curation, to a
higher level of abstraction, further mapped to EFO, the
National Cancer Institute Thesaurus (36), and the
BioAssay Ontology (37). In addition, we mapped mouse
and rat names to EFO, Jackson Laboratory database iden-
tifiers, and Sage Bionetworks Synapse Ontology (http://jax-
mice.jax.org/query/f?p¼205:1:0 and http://bioportal.
bioontology.org/ontologies/SYN). This provides more
flexibility during querying of samples from specifically
treated animal models. Please refer to Supplementary Files
S3 and S4 for mapping of mouse and rat-related terms to
controlled vocabularies.
For some of the metadata terms, there were no con-
trolled vocabularies available, e.g. ‘Vehicle #1:non-
transgenic’ or ‘BDNF-treated’, describes that the mouse is
non-transgenic and a vehicle in the former case, while in
the second case it is specific gene treatment. Such terms
were mapped to either of the phenotype’s controlled vo-
cabulary. In case of human stage mentions, specific stages
such as Braak II or cognitive scores, such as CERAD,
MMSE, etc. could not be mapped to any staging controlled
vocabulary as most of the ontologies used higher level of
staging, namely Braak. Moreover, in most of the ontolo-
gies cognitive tests are not classified under staging, but ra-
ther as cognitive tests. This has prompted us to generate a
more detailed hierarchical representation of the above-
mentioned binning schemes, which will be published
separately as ontology, specifically for neurodegenerative
gene expression studies. However, for current version, we
stick to the already available controlled vocabularies, in
addition to our internal classification.
Curation results and discussion
Compliance to standards
Authors tend to provide minimum information as required
by the guidelines in archives; publishing major part of the
experimental metadata annotations in associated publica-
tion. To test, whether the authors adhere to the minimum
compliant standards, we performed an assessment of the
complaint scores provided by ArrayExpress, the highest
score being 5, for Alzheimer’s studies. Figure 5 shows the
trend in distribution of retrieved AD experiments (see Data
Retrieval section) in ArrayExpress, based on the published
MIAME and MINSEQE scores (for human, mouse and rat
experiments). We observe the trend of submission is con-
centrated around the score of 4, showing that the submit-
ted data are not fully MIAME or MINSEQE compliant;
leading to variable levels of information stored in these
archives.
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To conclude that not all the submitters’ abide 100% by
the compliant standards, we investigated if this trend is
same for all other disease domains; we chose one among the
most studied cancer disease, Lung Cancer, and generated
similar results to AD. Supplementary Figure S5 shows the
distribution of compliant standards across Lung Cancer
studies. From this observation, we show that the loss of in-
formation follow the same pattern across all submissions
(varying mostly around score of 4). As a result, automated
retrieval and meta-analysis is impeded, due to lack of infor-
mation availability. Details of the experiment IDs investi-
gated for AD and Lung Cancer, along with compliant scores
is provided in Supplementary File S1.
Retrieval and prioritization of indication specific
studies from GEO and ArrayExpress
Retrieval of experiment IDs using a keyword search (cf.
Data Retrieval section) also acquires false positive experi-
ments. Any non-disease specific experiment performed by
an author named ‘Alzheimer’ is also retrieved when search-
ing for AD specific experiments. For example, E-MTAB-
2584 aims to investigate neuronal gp130 regulation in
mechanonociception but was retrieved for AD since one of
its author’s name is Alzheimer. Moreover, we also ob-
tained experiments for related diseases such as Epilepsy, or
Breast Cancer, when querying for AD. For example,
GSE6771, and GSE6773 are Epilepsy studies; GSE33500
belongs to Nasu Hakola Disease; all these studies were
retrieved when queried for Alzheimer. Incorrect organism
specificity was also noticed during prioritization. For ex-
ample, GSE5281 was retrieved as rat study although it
belonged to human. Similarly, GSE2866 was retrieved as
mouse study but it belonged to zebra fish. Although incor-
rectly identified studies are not too high, this still indicates
the need to include organism and disease specificity filter
during prioritization. Additionally, we manually identified
a few experiments that were not retrieved using these key-
words, which were also included in the database.
Further on, just by applying these two filter criteria does
not assure that all retained experiments were specific to
AD. For example, there could be some experiments that
aim at a certain pathway that are also relevant in the area
of neurodegeneration, but the experiment submitted to the
repository does not deal with AD pathology. As a conse-
quence, additional disease relevancy conditions were
included before prioritization (cf. Experiment Prioritization
section). An overview of all the retrieved AD experiments,
categorized to one of the priority classes is shown in
Figure 6. In addition, a list of priority 1 experiments (for
human, mouse and rat) is provided in Supplementary file
S5. This figure indicates that nearly 20% of the retrieved
studies are in any case not related to AD. On the other
hand, to identify the remaining 80% of the experiments
(prioritized as 1 and 2) we need massive manual filtering by
trained personnel. Only if the archives take an initiative to
apply such a structured classification for all uploaded ex-
periments, individual time-cost can be reduced to a greater
extent.
Some experiments contain cell lines or other disease sam-
ples in addition to Alzheimer’s patient samples. Experiment
GSE26927 additionally contain samples from patients suffer-
ing from Parkinson’s disease, multiple sclerosis, etc. To be
able to query only AD related samples for integrative
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Figure 5. Distribution of MIAME and MINSEQE scores for all automatically retrieved Alzheimer’s Disease gene expression experiments in
ArrayExpress Database (for human, mouse and rat), as of December 2014. Percentage is calculated as (total number of AD experiments with a cer-
tain score)/(total number of AD experiments). ‘NA’ are the experiments which were not present in ArrayExpress. These scores reflect adherence to
compliance standards by the data submitters, needed for re-investigation and reproducibility. It is observed that large percentage of experiments fall
under score 4, shows that the required minimum information is still incomplete. The list of experiment IDs along with their associated scores, used
for generating this statistics are provided in Supplementary File S1.
Page 12 of 17 Database, Vol. 2015, Article ID bav099
 by guest on October 2, 2016
http://database.oxfordjournals.org/
Downloaded from 
  Publication 
83 
 
analysis, we additionally included priority information at
sample level. For example, we tagged Alzheimer’s disease
samples to AD1 whereas multiple sclerosis samples to MS1.
Please refer to the README.txt file for various priority no-
tations used.
Metadata curation
The underlying metadata information for any gene expres-
sion study has been underrepresented and thus is largely
under-utilized. To perform large-scale analysis, associated
annotations are of utmost importance. With the availabil-
ity of detailed annotation information, one is capable of se-
lecting studies that focus on a particular attribute, such as
stage or gender. Each priority class has a specific set of
fields for curation; some fields are organism dependent.
After prioritization of experiments (cf. Experiment
Prioritization section), we expect to have !100% coverage
of essential clinical and relational parameters during man-
ual metadata curation for priority 1 studies. For example,
age, gender, phenotype and stage are basic experimental
variables for human studies. Additionally, in case of ani-
mal models, mouse and rat strain names are important for
translational pipelines, as some strains are highly specific
models for human NDD while others not (38). Irrespective
of the organisms, samples mapped to their corresponding
raw file identifiers are vital for running large-scale analysis.
However, as shown in Figure 7, this does not hold true for
human studies. From Figure 7, it is evident that even after
performing thorough curation, we cannot achieve 100% in
capturing information for these five basic metadata fields,
a fact that is largely due to patient data privacy regula-
tions. Similar is the case with mouse and rat information,
see Supplementary Figure S6. Moreover, information
related to animal models are much more scare, obstructing
automated retrieval. Hence, manual curation accuracy is
highly dependent on information availability, as curators
cannot harvest information for annotation fields that are
not available. On the contrary, the level of detail also de-
pends on the type or aim of the experiment carried out.
The authors and database owners obviously need to focus
on the qualitative aspect of the experimental information,
especially the phenotype of the sample, to allow normal-
ized access for beginners, with standard prose, in order to
support a robust computational analysis across all studies
in ArrayExpress and GEO.
We selected five of the most common metadata fields
(common to any disease domain such as age, gender, pheno-
type, stage and raw filename) and carried out a trend analysis
of information availability versus time. Figure 8 (A) shows
the trend over time for the metadata information provided in
the archives versus the number of annotation fields that can
be harvested after manual curation for human AD priority 1
experiments. Although a bit obscure, we can observe that the
level of information submitted to the databases remains al-
most stable in the last decade (between 2 and 4 metadata
fields). Moreover, with manual curation support, we were
able to capture the majority of the remaining metadata from
associated publications, Figure 8 (B) shows the shift in the
mean value of the metadata availability. However, the trend
is recently declining since the authors submit relatively lesser
level of detailed information than in former times in the asso-
ciated publications.
The incompleteness of metadata annotations contrib-
uted to a substantial increase in curation workload through
an increased need for publication reading. This leads to a
steep increase of the cost of the trained personal for cur-
ation. Overall, for the prioritization and metadata curation
of AD gene expression studies, we spent about 1 year of
four biocurators effort (working 10 h/week). This does not
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include the expert’s effort, who constantly provided guid-
ance and monitored the curation work during the same
duration.
Accessing NeuroTransDB
Metadata annotations for priority 1 AD gene expression
studies for human, mouse and rat organisms, from GEO
and ArrayExpress, are stored as MySQL tables separately;
downloadable as dump files at Fraunhofer SCAI File
Transfer Protocol (FTP) website: http://www.scai.
fraunhofer.de/NeuroTransDB.html. Please refer to the
README.txt for details of how to install and use MySQL
dumps. Additionally, these tables are provided as Excel
files to allow users to use the curated information in their
preferred tools/interface. Currently, the data is in its non-
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normalized form. Normalized data, tagged with standard
ontologies (cf. Normalization of Metadata Annotations
section), will be made available through the
AETIONOMY Knowledge Base. Currently, we have pro-
vided human priority 1 studies normalized using our in-
ternal binning scheme. Half yearly updates are planned.
Our ultimate goal is to makeNeuroTransDB a comprehen-
sive resource for researchers working on large-scale meta-
analysis in the field of neurodegenerative diseases.
Conclusion and future directions
NeuroTransDB fills the gap for large-scale meta-analysis
on publicly available gene-expression studies in the field of
neurodegeneration. It joins bits of missing metadata infor-
mation, scattered in public archives and associated publi-
cations, into a consistent, easily accessible and regularly
updated data resource. Additionally, in this paper, we have
systematically specified key issues encountered during se-
lection of relevant gene expression studies from public
archives, along with their associated metadata informa-
tion. We observed a huge lack of structured metadata in
these archives, hampering automated large-scale reusabil-
ity on a usable level of abstraction. We present here recom-
mendations, as guidelines, for prioritizing relevant studies
and a step-by-step protocol for metadata curation. The
challenges faced in the course of the development of these
guidelines have been pointed out, and the huge manual ef-
fort has been made explicit.
The work presented here has listed metadata fields, which
have been generated based on disease expert consultation.
They are highly important for choosing the right subsets of
expression studies to answer complex biological questions
underlying a diseased pathology. Some additional fields are
included for animal models studies to allow maximal use for
translational research. For all the manually curated fields, we
describe normalization strategies in an attempt to provide
standards for more robust automated querying and interoper-
ability. Our results show the amount of information that is
scattered in various resources, requiring extensive manual ef-
fort to capture the same. Additionally, we report that even
with comprehensive manual harvesting, we were not able to
capture 100% of information to fill for the basic annotation
fields. We demonstrate convincingly that data availability de-
pends largely on the meticulousness of the submitters.
Additionally, it also depends on the aim of the experiment
carried out. On an average, considering all the retrieved AD
experiments, the submitters provide about 60% of the most
basic metadata information. The outlined guidelines could be
of significant value to other researchers working on gene-ex-
pression studies. The described key issues we faced during
such a curation work could influence the data submission
and data storage architecture of public repositories.
Subsequently, we plan to extend the curation pipeline
to other NDD diseases namely, Huntington’s disease. A
more gene-expression specific ontology will be built based
on the curated annotations for selecting a subset of studies
for meta-analyses. Although, microarray studies are the
major contributors to the public repositories, RNA-Seq
data are rapidly growing. We comprehend that it will be
necessary for us to identify all the relevant RNA-Seq stud-
ies, since their large storage space has contributed to dis-
perse nature of the available raw data.
Supplementary Data
Supplementary data are available atDatabaseOnline.
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5.2.1 Supplementary	Figures	
 
 
 
 
Figure S1: Landscape of transcriptomic data availability for neurodegenerative diseases and cancer in GEO and
ArrayExpress. Here, we compare the data availability obtained by a simple keyword search for the two clinically
problematic disease domains, neurodegenerative diseases (NDD) and cancer [2,14]; also includes the statistics for
two most common diseases in each domain. The numbers on the bars represent quantification of the available
experiments, for the selected disease in respective databases (as of 26th July, 2015). The above statistics clearly
indicates that NDD field suffers from limited data availability.
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Figure S2: Screenshot of the sample information provided by authors in GEO and associated publication for
GSE36980. (A) Is an example of the excel sheet used by our curators for meta7data curation
(B) Shows the sample information (GSM907797) provided by the authors in GEO database. (C) Is a screenshot of the
Supplementary Table 2 where additional information about the patients is provided. From (B) we know that the AD
patient is a female and 95 years old, but in (C) there are two rows (marked in red boxes) that match this information.
Thus, we could not map additional information such as stage, diagnosis, etc. to the respective samples.
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Figure S3: Search strategies applied to retrieve published
articles linked to priority 1 Alzheimer’s Disease gene
expression studies (human, mouse and rat) for metaCdata
curation.
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Figure S4: Probable reasons behind duplicated sample
information in ArrayExpress for priority 1 Alzheimer’s
Disease gene expression studies (human, mouse, and rat).
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Figure S5: Distribution of MIAME and MINSEQE scores for randomly queried Lung Cancer gene expression
experiments in ArrayExpress Database (for human, mouse, and rat), as of May 8, 2015. Percentage is calculated
as (total number of Lung Cancer experiments with a certain score)/(Total selected Lung Cancer experiments). To
align with the quantity of AD experiments, we investigated (randomly) 100 microarray and 10 sequencing
experiments in ArrayExpress. The Lung Cancer domain resembles the trend pattern of Alzheimer experiments in
adhering to compliant standards, concentrated mostly around score of 4. For rat, there was just one sequencing
experiment. The list of experiment IDs along with their associated scores, used to generate this statistics, are
provided in supplementary file S1.
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Figure S6: Coverage of basic metaBdata annotation fields for mouse and rat AD priority 1 samples with automated
retrieval and manual curation. It is clear from the above statistics that manual curation accuracy for basic
annotations, such as age, gender, and raw file information, is highly dependent on data availability. The cell type
information for mouse, which was automatically downloaded, contained both brain regions, and cell type
information. Thus, after manual curation we observe reduced information in mouse cell type.
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5.2.2 Supplementary	Tables	
 
!
Experiment*ID** Contact*Reason* Response*of*the*authors*
GSE47036* Mismatch!in!sample!labelling!between!GEO! database! and! the! associated!publication! Provided! us! the! correct!mapping! file,! in! addition!authors! corrected! the! error! in!GEO!database!
GSE47038* Difference! in! number! of! samples!between! GEO! (58! samples)! and!ArrayExpress!(64!samples)! ArrayExpress! synced! the!sample!count!to!GEO!database!
GSE29652* Difficulty! in! mapping! the! sample!information!from!GEO!to!the!detailed!information! provided! in! publication!(Table!1)!
The! authors! provided! us!additional! file! mapped! to!Source! name! (cf.$ GEO! sample!page)! along! with! detailed!information! of! how! to! map!these! different! IDs! to! the! case!information!in!Table!1!
GSE36980* Could! not! map! the! patient!information!(Subject!No.)!provided!in!Supplementary! Table! 2! to! the! GEO!sample!IDs!
Authors! provided! additional!supplementary! file! which!contained! GEO! sample! IDs!mapped! to! subject! numbers! in!Supplementary!Table!S2!
GSE26927* Unable! to! map! the! Cohort!characteristics!provide!in!Table!1!!(or!Supplementary!Online!Resource!1)!of!the!paper!with!sample!information!in!GEO.! In! addition,! the! number! of!samples!used!in!the!analysis!(113),!as!described! in! the! paper,! differs! from!the!number!of!samples!in!GEO!(118).!
Author! provided! the! mapping!information!of!sample!title!with!cohort! characteristics.!Additionally,! the! authors!reported!that!only!113!samples!out!of!118!were!of!good!quality,!thus! the! difference! in! sample!numbers.!!
 
Table* S1:! Detailed* listing* of* GEO* experiment* IDs* where* we* contacted* the* authors* for* missing* or*
mismatched*information.*Along!with!the!experiment!IDs!we!provide!the!reason!for!contacting!the!authors!and!their!response.!!!
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Sample'ID'
from'GEO'
Sample'title'from'GEO'
(resemble'patient'ID)'
Associated'sample'age'
provided'in'GEO'
website'
Patient'ID'in'
supplementary'
file'
Associated'gender'
information'in'
supplementary'file'
GSM466881' PD#rep1# Male# PD8# M#
GSM466882' PD#rep2# Female# PD9# M#
GSM466883' PD#rep3# Male# PD11# M#
GSM466884' PD#rep4# Male# PD13# M#
GSM466885' PD#rep5# Male# PD14# M#
GSM466886' PD#rep6# Male# PD15# M#
GSM466887' PD#rep7# Male# PD15x# M#
GSM466888' PD#rep8# Female# PD17# F#
GSM466889' PD#rep9# Male# PD18# M#
GSM466890' PD#rep11# Female# PD20# F#
GSM466891' PD#rep12# Male# PD21# M#
GSM466892' PD#rep13# Male# PD22# M#
GSM466893' PD#rep14# Male# PD22x# M#
GSM466894' PD#rep15# Male# PD23# M#
GSM466895' PD#rep16# Male# PD23x# M#
GSM466896' PD#rep17# Female# PD27# M#
GSM466897' PD#rep18# Male# PD30# M#
GSM466898' Ctrl#rep_2# Female# CNT4# F#
GSM466899' Ctrl#rep_3# Female# CNT5# F#
GSM466900' Ctrl#rep_4# Male# CNT6# F#
GSM466901' Ctrl#rep_5# Male# CNT15# F#
GSM466902' Ctrl#rep_6# Male# CNT16# F#
GSM466903' Ctrl#rep_7# Female# CNT18# F#
GSM466904' Ctrl#rep_8# Female# CNT19# M#
GSM466905' Ctrl#rep_9# Male# CNT20# M#
GSM466906' Ctrl#rep_10# Male# CNT21# F#
GSM466907' Ctrl#rep_11# Female# CNT24# M#
GSM466908' Ctrl#rep_12# Male# CNT#25# F#
'
Table'S2:#Detailed'mapping'of'GEO’s'Sample'ID'and'Patient'ID'(from'supplementary'Table'S6'of'the'
associated'publication)'along'with'their'associated'gender'information'of'experiment'GSE18838.#Here#we#mapped# the#Sample#and#Patient# IDs#with#an#assumption# that# they#are# in#natural# sorted#order.##Samples#for#which#we#could#not#map#the#metaLdata#information#between#GEO#archive#and#supplementary#file#(Table#S6)#of#the#associated#published#article#are#highlighted#in#green.#The#difference#in#male/female#ratio# between# GEO# samples# (male/female:# 19/9)# and# Supplementary# Table# S6# (male/female:# 18/8)#provides#enough#evidence#that#the#information#is#misleading.#
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5.3 Summary	
The database introduced here, NeuroTransDB, aims to assist researchers to re-use public 
omics data efficiently in NDD research. The presented work here is a good example to 
demonstrate that FAIRification of public omics data requires more than just reformatting 
and mapping to standard ontologies. Firstly, it reports on the key issues faced during 
retrieval of the subset of studies from public repositories. The keyword-based search 
possibilities provided by these repositories guarantees higher recall but misses out on the 
clinical relevancy to the queried indication and organism. Next, it draws attention to the 
need for comprehensive and precise harvesting of metadata annotations. Most of the data 
submitters do not comply to standards such as MIAME or MINSEQE during submission. 
This has resulted in missing or erroneous metadata annotations. Even when provided, the 
inconsistent and incomplete annotations are scattered as unstructured prose in the 
originating publications or associated supplementary files. Moreover, due to the varied 
nature of these files, automated extraction of annotations from these sources is not 
straightforward. Hence, large effort from dedicated individuals is required to harvest this 
valuable information. Finally, adding to the obstacles is the lack of uniform representation 
and mapping to standard vocabularies or ontologies.  
In this work, we carry out FAIR transformation of the public omics studies to increase the 
added value for translational research in NDD; by navigating around the above-mentioned 
obstacles. To increase Findability and Accessibility of the data, relevant studies were 
prioritised based on a simple binning approach: in vivo and in vitro systems. A set of 
classification rules that account for sample source, organism and disease specificity were 
stated for prioritisation. Consulting the disease experts, a list of metadata fields that are 
needed for translational research (both human and animal models) was laid out. These 
metadata fields are very specific to NDD research and are scalable to a usable level of 
abstraction based on the research question at hand. Using a semi-automated curation 
workflow, missing and incorrect metadata fields were manually curated by gathering 
information from several sources: (i) directly from databases; (ii) subsections, tables, 
figures or supplementary files of originating publications; (iii) chained references for 
original source of information; (iv) contacting the data submitters or corresponding authors. 
Moreover, the trend analysis showed a drop in furnishing basic metadata information such 
age, and gender over the last decade. Harvested metadata fields were normalised using 
Discovery-based Data Harvesting 
94 
public vocabularies and ontologies. To enable richer integration and Interoperability, these 
metadata fields were annotated with the URIs provided by the ontologies. Thus, qualifying 
for globally accepted standard for data exchange and knowledge representation on web, 
RDF. Finally, Reusability is greatly enhanced by providing data in a machine-readable 
format with provenance on original data source, context, and information on curated 
metadata. In addition, since NeuroTransDB is based on publicly-funded GEO and 
ArrayExpress databases, its data is free for public use without any restrictions.  
To the best of our knowledge, this is the first database that systematically harvests metadata 
annotations specific to NDD research along the FAIR principles. The work presented here 
can act as a general guideline for prioritising and harvesting metadata information for any 
biomedical data. The transformed FAIR data increases the value of the public data in 
integrative data analysis, reported in Chapter 3; enabling researchers to ask questions that 
was previously not easily viable. The prioritised studies, with correct metadata annotations, 
enable researchers to precisely select samples for integrative meta-analysis; thereby 
increasing the accuracy of derived statistics. Chapter 6 proposes a new approach using gene 
regulatory networks to perform meta-analysis and identify robust expression patterns 
across heterogeneous datasets. 
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Chapter	6 	Knowledge	Instructed	Gene	
Regulatory	Networks	
 
6.1 Introduction	
Gene regulatory networks (GRNs) have attracted a lot of attention to model dependencies 
between the molecular entities from gene expression data. They serve as a blueprint of 
regulatory relations governing biological events, which can be used to derive biological 
hypothesis; to guide new experimental designs; as network based biomarkers; differential 
analysis. A variety of algorithms have been proposed to model GRNs that enhance our 
understanding of diseases: similarity measures (mutual information), regression-based, 
Bayesian models, or ensemble approaches. When considering biological consistency, the 
differences between these methods are not large. However, due to improved stability and 
accuracy, ensemble-based methods have gained popularity. Moreover, global gene 
expression analysis outperforms results derived from single experiment to classify 
subgroups or identify common patterns.  
Meta-analysis approaches result in more robust and reliable gene signatures across 
heterogeneous datasets by enhancing the statistical power; overcoming the variability of 
individual experiments. Modelling GRNs using meta-analysis approach identifies 
molecular mechanisms and key drivers in an unbiased way. A more conventional approach 
is to merge results that are gene-centric (DE genes) or through functional enrichment of 
dysregulated genes. Despite the promising potential, these approaches tend to converge 
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towards ‘what is already known’. To improve the reliability without increasing the 
computational costs, one can exploit existing sources of knowledge to discard or enforce 
edges that are already known. But not all prior knowledge sources are reliable and 
guarantee a high level of confidence, which may lead to noisy results. Thus, there is a need 
for a more robust approach utilising prior knowledge such that the networks scale well, 
reduce computational effort, and do not converge to known players.  
In this publication, we have developed an approach that iteratively self-instructs the 
generation of GRNs to unravel general principles of AD patho-mechanisms, firstly using 
literature knowledge and subsequently enriching with data-driven functional analysis. By 
integrating heterogeneous AD datasets, this approach has the capability to identify non-
obvious subtle changes in expression level playing a central role in dysregulated events.  
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Abstract	
Background: Alzheimer’s disease (AD) progressively destroys cognitive abilities in the 
aging population with tremendous effects on memory. Despite recent progress in 
understanding the underlying mechanisms, high drug attrition rates have put a question 
mark behind our knowledge about its etiology. Re-evaluation of past studies could help us 
to elucidate molecular-level details of this disease. Several methods to infer such networks 
exist, but most of them do not elaborate on context specificity and completeness of the 
generated networks, missing out on lesser-known candidates.  
Method: In this study, we present a novel strategy that corroborates common mechanistic 
patterns across large scale AD gene expression studies and further prioritizes potential 
biomarker candidates. To infer gene regulatory networks (GRNs), we applied an optimized 
version of the BC3Net algorithm, named BC3Net10, capable of deriving robust and 
coherent patterns. In principle, this approach initially leverages the power of literature 
knowledge to extract AD specific genes for generating viable networks.  
Results: Our findings suggest that AD GRNs show significant enrichment for key signaling 
mechanisms involved in neurotransmission. Among the prioritized genes, well-known AD 
genes were prominent in synaptic transmission, implicated in cognitive deficits. Moreover, 
less intensive studied AD candidates (STX2, HLA-F, HLA-C, RAB11FIP4, ARAP3, 
AP2A2, ATP2B4, ITPR2, and ATP2A3) are also involved in neurotransmission, providing 
new insights into the underlying mechanism.  
Conclusion: To our knowledge, this is the first study to generate knowledge-instructed 
GRNs that demonstrates an effective way of combining literature-based knowledge and 
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data-driven analysis to identify lesser known candidates embedded in stable and robust 
functional patterns across disparate datasets.  
Keywords: Alzheimer Disease; Gene Regulatory Networks; Microarray Analysis; 
Synaptic Transmission 
 
Background  
Alzheimer’s disease (AD) is a very complex idiopathic disease contributing to immense 
personal and societal burden, with ∼13.8 million people being affected by 2050 [1] in the 
US alone. High failure rate of AD drugs (98%) in Phase 3 trials have resulted in no new 
FDA approved drugs since 2003 [2]. Moreover, the five previously approved AD drugs 
just provide symptomatic relief [3]. Not all, but a substantial proportion of these studies 
focused on amyloid-beta (Aβ) and tau accumulations as being synonymous to the AD 
pathology [4], leading to an unprecedented wealth of molecular and clinical data. Despite 
the disappointing outcome of the clinical trials, neurology researchers still believe in the 
definiteness of these two hypotheses [5]. This reaffirms that pathological mechanisms 
underlying AD are much more complex than the current consideration, thus, opening up 
possibilities for new therapeutic targets. Working towards unraveling dysregulated events 
heralding known and unknown patterns could fill the gaps between AD hallmarks [6].  
Existing experimental data, not being fully exploited, contain compelling evidence that 
have the potential to contribute next groundbreaking discoveries. The great challenge, 
however, lies in harmoniously integrating these data and interpreting them differently to 
derive new-novel insights while maintaining the biological connections. The term, 
“Horizontal Meta-analysis” implies the integration of results from several independent 
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studies [7], thereby increasing the statistical power of the derived conclusion. A more 
conventional gene-centric approach is to intercross differentially expressed (DE) genes 
across studies based on majority voting [8], merging gene ranks [9], and combining p-
values [8]. However, differing factors can lead to a low overlap and discrepancies between 
studies such as the applied statistical methods, different platforms of the quantitative 
measurements, and heterogeneity of the patient cohorts [10]. Moreover, these approaches 
do not shed light on the co-ordinated genes that collectively orchestrates the underlying 
(patho-)mechanism. A more consistent and robust approach is through functional 
enrichment of the dysregulated genes using KEGG [11], MSigDB [12], and other sources 
of pathway knowledge. However, these approaches have a tendency to converge towards 
genes that express in large magnitudes and generated hypotheses are restricted by current 
understanding of pathways.  
Network-based approaches that rely on the coherence of expression changes between 
functionally dependent genes, could provide an effective means to overcome the above-
mentioned challenges. Such inferred networks have the capability to determine subtle 
expression shifts between correlated gene pairs that are linked to the dysregulation events. 
Particularly, these signatures are largely consistent across different studies; thus, 
emphasizing on its benefits for large scale meta-analysis. In the last few years, we have 
seen a swarm of methods that infer such networks based on co-expression, regulation, and 
causal information namely WGCNA [13], BC3Net [14], MRNET [15], ARACNE [16], 
GENIE3 [17], and CLR [18]. Among these, WGCNA and the bagging version of C3Net 
(BC3Net) are popular and computationally efficient methods. BC3Net is an ensemble 
method that statistically infers GRNs based on the strongest mutual dependencies between 
genes. Whereas, WGCNA clusters genes on the basis of calculated pairwise correlation 
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coefficients. In the meanwhile, BC3Net has been reported in providing meaningful 
biological insights for large-scale studies [19,20].  
Traditional GRNs identify patterns through differential co-expression analysis [21–23], 
displaying grouping of patterns based on dysregulated and co-ordinated biomolecular 
changes. Integration of such priors drastically improves the context specificity of the 
inferred networks relative to using data as the sole source [24–26]. However, these spurious 
discriminative structures, in a given disease context, may vary since DE genes are highly 
inconsistent across studies [27]. Biologically speaking, one may argue that the differences 
in functionally enriched components, derived from DE genes are more consistent than 
gene-centric activities [28]. But this approach misses out on less informative and less 
studied non-DE genes, which act in groups, contributing to the observed phenotype or a 
part of cascade effect. Furthermore, overlaying the inferred networks with known 
interactions, cataloged in databases or harvested from published literature expand the 
knowledge space [29,30]. However, an intriguing question on completeness, veracity and 
context specificity of these interactions has proven to be a major setback [31].  
Here we propose a new approach to identify common signature patterns across public AD 
studies and prioritize lesser known AD candidates that unravel the general principles of the 
intrinsic patho-mechanisms. To identify AD mechanistic footprints, we established an 
optimized workflow around BC3Net to extract more robust and coherent co-expressed gene 
patterns (named BC3Net10). The approach allows us to converge lesser known candidates 
into the final generated GRNs. Moreover, to generate context-specific GRNs, the main 
rationale applied was to leverage the power of prior knowledge and functionally enriched 
candidates in the data. Firstly, we identified most frequently discussed genes in the 
scientific literature using our literature mining environment SCAIView; this is called the 
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“seed”. We are aware that the generated GRNs may be biased due to the incomplete nature 
of the prior knowledge. To overcome this limitation, we extended the seed by adding all 
the genes from the enriched pathways, determined for the high scoring inferred interactions 
from BC3Net10. Several iterations are performed until there are no more genes to be added 
to the seed. Finally, an aggregated GRN from all the iterations, for each dataset, is generated 
to prioritize functional context and determine lesser known candidates from the genetic 
variant analysis. Figure 1 presents an overview of the strategy in this study, and descriptions 
of the methodology are available in the Material and Methods section. This work suggests 
a context-specific strategy for future interpretation of the GRNs. Taken together, our work 
demonstrates that optimizing the GRN generation can provide a powerful resource to 
prioritize novel candidate genes (could serve as biomarkers) and common functional 
components that axles the disease progression.  
Material and Methods  
Selection of datasets  
We collated eight Alzheimer’s disease datasets (cf. Table 1) that are composed of 50 or 
more samples (for diseased and control phenotype) from the previously developed value-
added database, NeuroTransDB [32]. Briefly, this database contains manually curated 
metadata annotations for eligible neurodegenerative studies. The datasets have been 
harvested from publicly available resources namely, Gene Expression Omnibus (GEO) 
[33] and ArrayExpress [34], using a keyword-based search approach.  
Furthermore, datasets that fulfilled the following criteria were retained for generating gene 
regulatory networks: (i) oligonucleotide arrays for analysis consistency, (ii) availability of 
raw data to facilitate uniform pre-processing and (iii) expression profiling carried out on 
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brain tissue. A list of four potential datasets that comply with the above conditions is 
eligible for further analysis: GSE5281, GSE44771, GSE44770, and, GSE44768. An 
overview of the platform, stage, and brain region information for the same is given in Table 
1. Among these, GSE44771, GSE44770, GSE44768 were from a single study reported by 
Zhang et al. [35] for late-onset AD.  
Pre-processing and gene annotation  
The four selected datasets were processed identically to reduce variance and to maintain 
consistent quality. All analysis was carried out with R (Version 3.1.3) [36], an open-source 
statistical language, using the packages from Bioconductor (Version 3.0) [37]. The overall 
step-by-step workflow is shown in Figure 1.  To eliminate the variance effect of non-
specific hybridization, all the downloaded raw data were uniformly normalized by 
performing background correction, quantile normalization, and averaging the expression 
values of duplicate probes on log2-transformed intensity values. For Affymetrix platform, 
robust multi-array average method (rma) [38] available in Bioconductor package affy was 
applied. Similar methods available in Bioconductor package limma [39] were applied on 
Rosetta/Merck Human 44k 1.1 microarray chip.  
Affymetrix probes to gene symbols annotation mapping were obtained from the 
“hgu133plus2.db” Bioconductor package. In the case of Rosetta/Merck chip, the gene 
symbol annotations were provided directly along with the intensity values. For multiple 
probes mapping to the same gene within an array, average expression values were used. 
Unmapped probes were excluded from further analyses. As a result of this preprocessing 
step, we retained 20155 in GSE5281, 11254 in GSE44771, 10437 in GSE44770, and 12000 
in GSE44768 genes for further analysis.  
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Quality control and outlier detection  
Using the Bioconductor package arrayQualityMetrics [40], we assessed the array quality 
and removed the outlier samples. Describing shortly, arrayQualityMetrics determine 
outliers using three different metrics: (i) distance between samples using principal 
component analysis (ii) array intensity distributions of all samples on the array (iii) 
individual array quality through MA-plots. If a sample is detected as an outlier in either of 
the three metrics, we discard it from further analysis. In the four selected datasets, 9 in 
GSE5281, 19 in GSE44771, 27 in GSE44770, and 12 in GSE44768 arrays were outliers. 
The list of identified outlier arrays is provided in Supplementary File S3. The remaining 
arrays that passed the quality control were processed as described earlier.  
Leveraging stable gene regulatory networks  
In order to derive AD relevant GRNs, we divided the AD gene expression profile based on 
their phenotypes, disease and normal. Subsequently, BC3Net10 algorithm was applied only 
on diseased samples for AD seed genes, cf. Figure 1. GRNs were generated independently 
for each dataset, visualized as igraph objects in Cytoscape tool [41]. Network topological 
properties such as node degree, hub genes, etc. were determined using the Bioconductor 
package igraph.  
Filter pre-processed data for seed gene list  
Prior to GRN generation, each pre-processed dataset was restricted to the genes in the seed. 
Initially, it consists of a set of literature-derived genes that have high probability of direct 
or indirect involvement in AD pathogenesis (see Section Gathering initial seed genes). The 
rationale behind applying this filtration is to maintain the disease specificity and reduce 
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high run time due to bootstrapping in BC3NET. Furtheron, after every functional 
enrichment iteration we again restrict the expression data to the new seed.   
Gathering initial seed genes  
The backbone of the seed comprises of the results harnessed from our text-mining 
knowledge framework, SCAIView [42]. SCAIView is a knowledge discovery framework 
that supports named entity recognition, information retrieval, and information extraction 
on large textual sources. Its capability to rank documents and biomedical entities based on 
the relevancy score allows retrieval of significant players in a disease context [43,44]. 
Querying SCAIView for AD related genes resulted in 4808 genes, as of 2nd January 2016. 
Only the top 500 retrieved genes were used as the initial seed, depicted as i=1 in Figure 1.  
Optimized GRN construction  
For the construction of GRNs, R package bc3net was applied to the processed data with 
100 bootstraps (B=100). Briefly explained, one aggregated network was generated by 
applying the C3Net algorithm on 100 bootstrapped data, which were inferred from given 
processed dataset. Statistically, non-significant edges inferred by C3Net and BC3Net were 
discarded using Bonferroni’s multiple testing correction, α = 0.05. In the resulting 
aggregated network, edge weights represent the frequency of a correlated gene pair in 100 
random sampling, ranging from 0 to 1.  
During random sampling, true and most prominent correlations are stochastically more 
likely to be selected than the non-correlated ones. This is reflected in BC3Net networks, 
where three independently generated GRNs, inferred from the same gene expression 
dataset (GSE5281), have an edge overlap of ∼74% (for no edge weight cutoff) and ∼89% 
(for edge weight>=0.5); the node overlap always remained 100%. The BC3Net parameters 
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used for performing this analysis are: boot=100, estimator= “pearson”, disc= “equalwidth”, 
mtc1=TRUE, alpha1=0.05, adj1= “bonferroni”, mtc2=TRUE, alpha2=0.05, adj2= 
“bonferroni”, weighted=TRUE, igraph=TRUE, verbose=FALSE and number of seed 
genes=4808 (see Section Gathering initial seed genes). However, less frequently appearing, 
yet plausible, edge interactions could offer the potential for promising candidates that are 
buried in expression data.  
We observed that the intersection between independently generated GRNs saturated after 
5-10 repetitions of the BC3Net algorithm on the same dataset. Thus, in order to expand the 
knowledge space around AD candidates and for completeness, we propose an optimization 
of the randomness to devise a more recall optimized GRNs. More specifically, we applied 
the BC3Net algorithm to the same dataset 10 times, named BC3Net10. Finally, we 
aggregated the 10 independently generated GRNs into one. The final edge weight is now 
the mean of the computed edge score from 10 GRNs. This increases the prospect of 
deducing more reasonable functional speculations in complex diseases with the high 
probability of novelty for further investigations.  
Subnetwork selection and functional enrichment analysis  
The choice of a threshold can significantly affect the integrity of the network and the co-
expression modules derived from it. In this regard, computed edge weight (mean 
weight>0.5) from BC3Net10 was used as the filter criteria for selecting significant gene 
pairs in the generated GRNs. This increases the significance level by 50% for the inferred 
interactions in each dataset.  
The overlap between the inferred interactions/edges was very low (zero genes common to 
all 4 subnetworks, see Figure 2) when BC3Net was applied on the initial seed. Several 
  Publication 
 107 
reasons can be presumed for lack of common and stable genes such as different platforms, 
distinct brain tissues, diverse patient cohort, and treatment heterogeneity. However, 
numerous studies have already shown that the functional signatures are more stable relative 
to individual gene level information [45–48]. In this context, to extract the most 
representative biological pathways for genes in the subnetworks (separately for each 
dataset), we performed functional enrichment analysis (based on one-sided Fisher’s exact 
test) for KEGG pathway information using ConsensusPathDB (CPDB) [49] (Release 30). 
Using the Bioconductor package, org.Hs.eg.db [50] we mapped the gene symbols to Entrez 
gene identifiers obtained from CPDB.  
Identification of enriched candidates and seed gene list enrichment  
We devised a strategy to expand the seed through functional enrichment analysis of the 
individual network modules inferred by the GRNs, enabling us to quantify the saturation 
of the inferred network. We extracted significant pathways (for the p-value<0.05) common 
between the determined subnetworks of the four datasets, generated using the initial seed. 
We added a new gene (called enriched candidate) to the seed when the gene belongs to the 
respective CPDB and KEGG pathway gene set that is significantly enriched across all 4 
inferred GRNs and is not present in our initial seed. Further, we repeated the functional 
enrichment analysis to determine overlapping pathways for the enriched seed. We 
leveraged the identified enriched candidates in these pathways by subsequent inclusion in 
the seed iteratively until saturation. Once the seed has reached its saturation, we merge the 
networks of all iterations, separately for each dataset, to generate an aggregated network. 
This approach goes beyond just candidate enrichment, corresponding to a maximal AD 
specificity with minimal noise and harvesting lesser known genes in GRNs.  
 
Knowledge Instructed Gene Regulatory Networks 
 108 
Gene list prioritization by genetic variant analysis 
For the consensus network, we identified genes (involved in significant pathways and hub 
genes) to prioritize them using genetic variant analysis. Multiple genetic variants are 
attributed in the etiology of complex diseases. To investigate the impact of genetic 
variation, we extracted AD evidences for single-nucleotide polymorphisms (SNPs) from 
GWAS catalog [51], GWAS Central [52] and gwasDB [53], resulting in 11,314 SNPs. 
Further, linkage disequilibrium (LD) analysis was carried out to enrich the list of AD 
associated genetic variants, which were sorted based on their chromosome location. 
Linkage disequilibrium is SNP’s property on a contiguous stretch of a chromosome that 
describes the degree to which an allele of one genetic variant is inherited or correlated with 
an allele of another genetic variant within a population. The LD analysis was performed 
using HaploReg v2 (developed by Broad Institute of MIT) [54] based on dbSNP-137 [55], 
motif instances (based on PWMs provided by the ENCODE project database) [56], 
enhancer annotations (adding 90 cell types from the Roadmap Epigenome Mapping 
Consortium) [57], and eQTLs (from the GTex eQTL browser) [58]. With LD threshold 
cutoff of r2 = 0.8, we obtained 115,782 SNPs. Furtheron, these SNPs were filtered based 
on the ENSEMBL SNP Effect predictor that estimates the influence of SNP variants on the 
respective transcripts of a gene and their gene products [59], shortlisting 4,831 SNPs. Genes 
obtained from the aggregated networks were boiled down to those associated with 
shortlisted SNPs. Finally, these refined genes were ranked using a cumulative score of their 
SNPs from RegulomeDB [60], dbSNP’s functional annotation [55], ENSEMBL’s Variant 
Effect Predictor [61] and regulatory feature annotation by ENSEMBL variant database 
[62]. RegulomeDB’s ranking is based on the functional annotations from ENCODE 
database [63], chromatin states from the Roadmap Epigenome Consortium [64], DNase-
  Publication 
 109 
footprinting [65], position weighted matrix for transcription factor binding [66], and DNA 
methylation [67].  
Results and Discussion  
Algorithm convergence and network properties  
Under the premise that lesser known genes are not prominently represented in literature, 
we extended the set of seed genes through functional enrichment (see Section Subnetwork 
selection and functional enrichment analysis). As depicted in Figure 1, BC3Net10 was 
applied on the identified four datasets for different seed lists to generate AD GRNs. 
Iteration 1, where we generated GRNs for SCAIView genes resulted in 10 overlapping and 
significant pathways between the four datasets. From these pathways, we obtained 820 
genes that were earlier not present in the seed. Hence, there is a clear need for further 
enrichment of the seed, which is done by including these newly identified candidates to the 
seed and repeating the functional enrichment step. In the second iteration, we identified 38 
overlapping significant pathways between the datasets. This iteration continues seven times 
until there are no newer candidates to be added. Table 2 provides the statistics of the number 
of pathways identified in each iteration, along with the number of enriched candidate genes 
that were added to the seed. A detailed list of the enriched candidates (as HGNC symbols) 
identified in each iteration is provided in Supplementary File S1. A sharp increase in the 
number of enriched candidates is observed in the first two iterations, which drops to zero 
in the seventh iteration. We assume that this indicates the completeness of the gene set that 
belongs to AD, specific to the selected four datasets.  
Extension of the GRNs using enriched seed is a knowledge guided approach, which relies 
on the functional information derived from the gene expression data. We note that the 
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GRNs grow progressively, both inferred interactions and the participating candidates, but 
in the process, eliminates few of the previously inferred interactions. A potential reason is 
that the extension of the expression matrix with new seed contributes to a shift in the 
significance of the inferred interactions by BC3Net. It implies that although we obtain a 
final GRN for saturated seed (iteration 7), aggregating networks from earlier iterations 
could capture interactions that were previously inferred as potential. The fraction of nodes 
and edges from each iteration that makes up the aggregated network, for each dataset, is 
presented in Figure 3. We observe that the addition of nodes, in each iteration, across 
datasets, remained stable whereas the same cannot be said for the edges. The variance in 
edges could be presumed that the newly added set of genes bring in higher functional 
relevance through newly inferred interactions in one or the other iteration.  
An assessment of the completeness of a GRN for AD specific genes can be precisely 
estimated by plotting the mean and the variance of the number of nodes and edges present 
in each dataset for each iteration. From Figure 4 (a), it is evident that the enrichment of the 
most relevant genes reach saturation. This increases the statistical significance of the GRNs 
suggesting an increment in the biological confidence. It is apparent that not all the genes 
present in the seed agree across platforms due to various differing experimental factors. 
However, we expect functional signatures across the datasets to be more agreeable. 
Analyzing edges, see Figure 4 (b), we observe that they orient three times, at saturation, to 
the number of nodes. The relative higher number of edges demonstrate that the gene sets 
are highly related, showing immense inter-connectivity between several functional 
modules. The high variance observed, in both nodes and edges, is contributed by the large 
network size of GSE5281 relative to the other three datasets. Details of the number of nodes 
and edges present in each dataset at each iteration is provided are Supplementary File S2.  
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Hub genes  
Hub genes have a higher grade of lethality when dysregulated in a pathological condition, 
referred to as centrality lethality rule [68]. For each aggregated GRN, a gene was defined 
as a hub gene when it had a higher degree of distribution (>95% quantile). By this criterion, 
we identified 29 in GSE5281, 8 in GSE44768, 14 in GSE44770, and 1 in GSE44771 as 
hub genes. Table 3 displays the list of identified hub genes along with their node degree 
and pathway annotation (only for significant pathways, see Functional homogeneity across 
datasets section). Interestingly, there were no common hub genes between the four datasets. 
It was evident that six of the hub genes were perturbed in multiple pathways. Many of the 
hub genes were functionally enriched in neurotrophin signaling, endocytosis, and estrogen 
signaling pathways. Additional associated pathways with hub genes include calcium 
signaling, adipocytokine signaling, NOD-like receptor signaling, insulin signaling, 
apoptosis, thyroid signaling, and pancreatic secretion. The majority of these hub genes 
formed a connected subnetwork within each dataset, indicative of a possible cooperative 
effect in AD pathology (see Supplementary Figure S1). In the case of GSE44771, due to 
the presence of a single hub gene, we extracted the largest subnetwork associated with 
HSPA2.  
Functional homogeneity across datasets  
Are the core functional modules (set of interconnected-genes) unique to a human brain 
region or do they depict patterns reflecting the tight linkage between different regions of 
the brain? To address these questions, we compared the final determined significant 
pathways across the four aggregated GRNs (outlined in Methods). The functional 
enrichment analysis revealed 187 in GSE5281, 120 in GSE44768, 170 in GSE44770, and 
43 in GSE44771 inferred modules within significant KEGG pathways. We computed a 
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simple overlap between the four GRNs to assess the conserved pathways, resulting in 34 
pathways. Because this list contained pathways that were not directly relevant to the core 
pathophysiology of AD, we categorized them into subsets based on their pertinence to AD, 
see Table 4. Please refer to Supplementary File S4 for details of summary statistics. From 
these, we chose to focus on pathways that exacerbate the AD phenotype, classified as 
“Potential”. Table 4 also provides the statistics of the number of genes enriched for these 
pathways in each dataset. Interestingly, there are no common genes between the four 
datasets when compared at the pathway level. However, many of the genes are shown to 
be involved in more than one potential pathway, providing the basis for functional 
connectivity in AD.  
Regulatory underpinning across Consensus network  
As described in Section Functional homogeneity across datasets, the genes in different 
GRNs are complementary for the top significant pathways. Thus, to provide a broader 
coverage than a single GRN and to infer stronger relationships through consensus, we 
merged the four aggregated GRNs into one, called consensus network. What we expect is 
to uplift the most promising pathways due to the assembly of more participating genes. To 
assess the concept of functional enrichment, we plot the p-values of all the significant 
pathways, listed in Table 4, for each of the aggregated and consensus GRNs, see Figure 5. 
From the figure, it is evident that these pathways have attained higher significance level 
(better p-values) in consensus GRN due to the gene complementarity from the aggregated 
GRNs.  
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Prioritizing through genetic variant analysis  
We compiled 608 genes from listed significant pathways across datasets (see Table 4) and 
hub genes. We mapped these genes to the 4,831 shortlisted ENSEMBL SNPs (see 
Methods). For the obtained 167 mapped genes, we ranked them based on the calculated 
cumulative score for their potential functional consequences in a disease context. 
Restricting the ranked genes to the RegulomeDB score of 3, we generated a final list of 44 
high ranked genes. In addition, we looked into the AD GWAS meta-analysis study carried 
out by Lambert et. al [69]. Among all their listed genes carrying genetic AD risks, we found 
three (AP2A2, DPYSL2, and EPHA1) of them to be present in our 608 gene list, including 
one (EPHA1) newly reported in their study; these three were added to our final gene list. 
Please refer to Table 5 for detailed ranking and RegulomeDB score. Additional 
investigation revealed 14 out of 47 genes from our final gene list are either validated by 
eQTLs studies or experimentally evident that the SNPs are linked to the active promoter 
region of the gene. These genes include IL1B, NSF, HLA-F, NOTCH4, VCL, PSAP, 
STX2, GGA2, STK11, CSF3R, LMNA, CTNNA2, HLA-C and RAB11FIP4. When we 
performed a comprehensive analysis of the biomedical literature, we found that many of 
these genes had no evidence of being linked to AD, but were rather known to be involved 
in AD co-morbidity diseases (see Supplementary Table S1).  
Well known prioritized AD candidates  
Apart from the new novel candidates, our method also determined well-known candidates 
(nearly 50 articles in AD) such as IL1B, NTRK2, GRIN2A, FYN, and DPYSL2. The IL1B 
gene is a pro-inflammatory cytokine that has been long studied for its modulatory effect in 
AD. It is reported that the expression of IL1B significantly increases with the increase of 
AD-related neurofibrillary pathology [70]. Synaptic plasticity, such as long-term 
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potentiation, is crucial for learning and memory. A neurotransmitter modulator, BDNF, 
mediates neuronal survival and plasticity by regulating neurotrophins through NTRK2. AD 
patients with cognitive deficits have been accounted with reduced levels of BDNF [71–73]. 
Similarly, GRIN2A is a subunit of NMDA receptors, whose reduced expression increases 
the vulnerability of neurons to excitotoxicity in AD, correlated with cognitive impairment 
due to reduced plasticity [74,75]. A strong correlation between lower levels of BDNF and 
cognitive deficits in AD patients was recently reported by Buchman et al. [76]. Recent 
research work has suggested BDNF as an upstream regulator of FYN gene, a Src family 
kinase, leading to enhanced cascade effect of NMDA mediated excitotoxicity and regulates 
the activity of hyperphosphorylated tau [77,78]. In addition, it mediates the synaptic 
deficits that are induced by Aβ [79]. DPYSL2 mediates synaptic signaling to facilitate 
neuronal guidance through regulation of calcium channels. Furthermore, FYN 
phosphorylates DPYSL2 within the brain and its hyperphosphorylation is causally related 
to Aβ neurotoxicity [80]. Taken together, these findings suggest that synaptic transmission 
is critical for regulating Aβ production in AD. Further studies, along these lines, may 
provide insights into the precise molecular mechanism underlying this part of AD etiology.  
Mechanistic interpretation of newly prioritized candidates in neurotransmission  
Neurotransmission is a pivotal brain function that declines with progressing age. However, 
in the case of AD there is a drastic and non-uniform deterioration of synaptic 
neurotransmission [81]. It is known that soluble oligomeric amyloid-β, rather than 
insoluble deposits that form plaques (extracellular), are detrimental to synaptic currents 
through calcium channel modulation, leading to excitotoxic cascades that mediate AD 
progression [82] and are related to the formation of neurofibrillary tangles (intracellular) 
[83]. Emerging research strongly supports the hypothesis of dysregulated calcium 
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homeostasis influencing the presence of neurotoxic Aβ in AD patients [84]. Increased 
endocytosis activity, enlarged endosomes, has been reported by Cataldo et al. [85] as the 
earliest intraneuronal neuropathologic feature of AD, subsequently impairing the 
modulation of NMDA receptor. NMDA excitotoxicity leads to the pathological overload 
of calcium resulting in synaptic impairment and ultimately neuronal death [86].  
We observed that three of the “Potential” pathways are significantly involved in 
neurotransmission: calcium signaling, endocytosis, and synaptic vesicle cycle (see Figure 
6). To assess the modularity of the prioritized candidates in these identified pathways, we 
extracted the functional relevance of their combination. This confirms our previous 
findings associated with well-known candidates (see Section Well known prioritized AD 
candidates). To gain new insights in this context we focused on lesser known prioritized 
candidates in Alzheimer’s that are involved in these three pathways (less than 5 
publications): STX2, HLA-F, HLA-C, RAB11FIP4, ARAP3, AP2A2, ATP2B4, ATP2A3, 
and ITPR2. Below, we briefly discuss the possibility of these candidates to presumably 
bear potential as new targets in AD (detailed description is provided in Supplementary File 
S5).  
The presence of Aβ oligomers impairs the process of STX2 binding to SNARE proteins 
hindering the effective release of neurotransmitter during synaptic vesicle fusion in the 
presence of increased calcium influx [87,88]. From several previous studies, one can 
postulate that HLA-F and HLA-C mediated dysregulated trafficking of amyloid plaques in 
endocytosis could be correlated to the memory deficits in early AD [89–91]. Several recent 
evidence point to the fact that faulty amyloid-β processing can be detected in the membrane 
trafficking events (linked to RAB11 proteins) of early endosomes, promoting an effective 
early diagnosis [92,93]. ARAP3 modulates actin cytoskeleton’s remodeling by regulating 
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ARF and RHO family members [94] and a growing body of evidence suggest that axonal 
transport defects due to its abnormality could be responsible for neurite degeneration and 
tau toxicity [95–98]. Impairment of APP shuttling by AP2A2 (part of AP-2 complex [99]) 
from the endocytotic pathway to autophagy degradation leads to intracellular aggregation 
of Aβ [100]. The next three candidates (ATP2B4, ATP2A3, and ITPR2) participate in 
neuronal calcium shuttling. A substantial body of evidence indicates ATP2B4, a plasma 
membrane Ca(2+) ATPases (PMCAs) is inhibited by Aβ peptides [101], causing cell death 
[102]. Similarly, ATP2A3’s function in handling calcium load and release is perturbed by 
the mutation in PSEN1 (regulates the intramembrane Aβ processing) [103]. Increased 
expression of ITPR2 could lead to calcium toxicity in neurons and finally cell death 
[104,105]. 
Conclusion  
The identification of biological mechanisms underlying normal physiology and – when 
dysregulated – contributing to or even directly causing disease phenotypes is a key 
objective of current integrative biology. Strategies, both data- and knowledge-driven, for 
mechanism-identification have shown to deliver valuable insights into disease 
mechanisms, however, both approaches have their specific drawbacks. Here, we 
demonstrate a new approach that combines literature-based knowledge and data-driven 
analysis through gene regulatory networks in a flexible and adaptive way. Thus, allowing 
us to identify stable and robust patterns of co-expressed genes across several large disparate 
datasets, in parallel, which enhances the interpretability around “interesting patterns” of co-
regulated genes. 
We developed an adapted version of BC3Net, called as BC3Net10, that supports a more 
fine-granular specification of functional context by “injecting” sets of seed genes (derived 
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from literature) into the algorithm. The seed genes were iteratively extended through 
functional enrichment applied on generated GRNs until convergence. Through several 
iterations of “selecting and injecting seed genes” and subsequent co-expression analysis, 
we come up with stable, knowledge-instructed GRNs across several experiments. We show 
the ability of our approach to identify functional context around subtle signals that would 
typically be expected for highly individual “modifier” functions not in the core of a 
dysregulation event, but have the potential to modulate the clinical path of a disease. Hence, 
making this approach ideally suited for biomarker identification. We show that by the 
enhanced functional interpretation of the GRNs shed more light on the role of 
neurotransmission physiology in early dysregulation events presumed to be part of 
Alzheimer ́s Disease etiology. This warrant further investigation of their potential as 
therapeutic targets.  
We would like to point out that there is more potential to the method presented here: in the 
course of IMI-project AETIONOMY we found limited coverage of signals in knowledge 
based models coming from the analysis of either gene expression or genetic variation 
information (GWAS studies). The methodology presented here bears the potential to 
establish biologically meaningful context around “isolated signals” in knowledge-based 
models to “embed” previously “non-interpretable” (at functional level) genes into a wider 
(knowledge based) context. Insights drawn from this approach could provide a novel 
foundation for the formation of new hypotheses. Although microarray data is the obvious 
starting point, the next logical step would be to extend this work to incorporate orthogonal 
datatypes such as NGS and single cell data. This could provide a broader view of disease 
etiology and enable comprehensive in silico investigations. It remains to be shown that the 
method we introduce here scales up to a really large number of experiments of different 
sample size. 
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Figures 
 
Figure 1  The overall strategy applied to obtain robust gene expression patterns 
across public Alzheimer’s disease studies. Firstly, four gene expression datasets were 
shortlisted from NeuroTransDB database. The selected studies underwent preprocessing 
and quality control. In each dataset, the intensity values were limited to the seed gene list. 
To enrich the seed, functional enrichment was applied where genes from the identified 
significant pathways from each dataset’s subnetwork (edge weight>0.5), generated using 
BC3Net10 approach, were included. When no additional genes were identified, 
subnetworks from each iteration, separately for each dataset, were merged into an 
aggregated network for further prioritization of the genes using genetic variant analysis  
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Figure 2 Venn diagram depicting the gene overlap between the subnetworks (edge 
weight>0.5) of the four datasets, generated using the initial seed. The initial seed was 
compiled from top 500 genes retrieved by querying SCAIView for Alzheimer’s disease 
related genes. It is evident that there are no common genes among the four dataset’s 
subnetworks. Differing factors between platforms, analytical methods, tissue source, etc. 
could contribute to such a behavior.  
 
(a) Fraction of added nodes in different iterations  (b) Fraction of added edges in different 
iterations  
Figure 3 Stratification of the nodes and edges in four aggregated networks. Each stack in 
the bar plot represents the fraction of nodes added in that iteration (IT) relative to the 
aggregated network (considered as 1). The addition of nodes remained stable across the 
datasets in each iteration. However, the inclusion of edges varies, which could be presumed 
due to newly inferred interactions from the newly included nodes in each iteration 
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Figure 4 Mean and variance distribution across four datasets for the added nodes and edges 
in each iteration.  Enrichment of nodes and edges reach saturation after 7th iteration, 
suggesting the completeness of the generated GRNs. Relatively high number of edges (see 
y-axis range) show immense inter-connectivity between the genes in the GRNs. (a) Boxplot 
for mean and variance distribution of nodes (b) Boxplot for mean and variance distribution 
of edges  
 
 
 
Figure 5 The landscape of p-value for the final list of significant pathways. For easy 
visualization, we have used 1-pvalue instead of p-value on Y-axis.  Each line in the graph 
represents aggregated GRN for specified dataset (see chart legend). The listed pathways 
show higher significance level in consensus GRN in comparison to the individual dataset 
aggregated GRNs  
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Figure 6 Subnetworks of the three shortlisted potential pathways (extracted from 
consensus network) involved in neurotransmission. Nodes in Cyan are involved in more 
than one pathways and the size of the nodes depends on the number of pathways involved. 
Triangle nodes represent the presence of a SNP. (a) Calcium signaling pathway (b) 
Endocytosis pathway (c) Synaptic vesicle cycle 
 
Tables 
GEO ID  Number of Samples  Sample Source  
 
Stage Platform 
Diseased Control 
GSE5281  87 74 Entorhinal 
cortex, 
Hippocampus, 
Primary visual 
cortex, 
Prefrontal 
cortex, Medial 
- Affymetrix HG 
U133 Plus 2  
 
BDKRB1
CCKAR
CALML3
ATP2A3
TRHR
TACR2
PLCB2
SLC25A5
PPP3CA
PDE1C
GNAQ
CAMK2A
PHKA1
ERBB3
CYSLTR2
PLCB3ATP2A2ITPKA
CAMK2G
HTR2C
GRIN2C
CACNA1E
TNNC2
P2RX5
P2RX1PTGFR
GRM5
PLCB1
GRIN2A
CHRNA7
ATP2B1
SLC8A1
CAMK4
EDNRB
RYR2
HTR2A
PTGER1
CAMK2D
ATP2B2
ATP2B4
P2RX2
NOS3
CALM3
AVPR1A
HTR4
ADRB1
PRKCB
CALM1
PRKX VDAC3
CHRM3
CACNA1G CHRM1
RYR3
PLN
GNAS
ITPKB SLC25A6
ITPR2PLCD4
ITPKC
CALML5
RAB5C
VPS37A
GIT2
RAB11A
EHD2
VPS4B
RABEP1
CCR5
PARD6A
PARD6G
RAB11FIP4
CHMP7
ARRB1
CHMP4BGRK6
SMAD2
PSD
PARD3
FGFR2
CHMP2A
ADRB1
ADRBK2
HLA-F
HLA-E
HLA-G
TGFBR2
HLA-B
HLA-A
HLA-C
WWP1
EEA1
CHMP5
ACAP2
EPS15FOLR2
RAB11FIP2
ACAP3
TFRC
PIP5K1C
EPN1
GRK7
DNM2
SH3GL1
ARAP3
RAB11FIP3
ADRBK1
PIP5K1A
RAB11FIP1
AP2M1
PML
DNM1
ARFGAP1
CLTC
CLTCL1
ASAP2
VPS4A
AP2A2
PSD3
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ERBB3
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SMAD6
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SH3KBP1
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temporal gyrus, 
Superior frontal 
gyrus 
GSE44768  129 101 Cerebellum  LOAD  Rosetta/Merck 
Human 44k 1.1 
microarray  
GSE44771  129 101 Visual cortex  LOAD  Rosetta/Merck 
Human 44k 1.1 
microarray 
GSE44770  129 101 Dorsolateral 
prefrontal 
cortex  
LOAD  Rosetta/Merck 
Human 44k 1.1 
microarray 
GSE13214 52 40 Hippocampal, 
Cortex frontal 
Braak 4-6 Homo sapiens 
4.8K 02-01 
amplified 
cDNA 
GSE15222 176 187 Cortical tissue LOAD Sentrix 
HumanRef-8 
Expression 
BeadChip 
GSE29676 350 200 Blood - Invitrogen 
ProtoArray 
v5.0 
GSE33528 615 600 Blood LOAD Illumina 
Human- 
Hap650Yv2 
Genotyping 
BeadChip 
Table 1 List of datasets shortlisted from NeuroTransDB for generating gene regulatory 
networks. Final selected studies are highlighted in bold  
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Iteration (i)  Seed No. of overlapping 
pathways between the 
four datasets 
No. of enriched 
candidate genes 
obtained from the 
overlapping pathways  
1     SCAIView (500)   10 820 
2   i1+820   38 1148 
3     i2 + 1148   30 361 
4     i3+361   30 84 
5     i4+84   32 41 
6     i5+41   33 7  
7 i6+7 37 - 
Table 2 Statistics of the iterative functional enrichment approach 
 
GEO ID Gene Symbols Hub Degree Pathway 
Annotation 
(CPDB) 
Similar results in 
other datasets? 
 
 
 
 
 
GSE5281  
HFE 244 - - 
ATP2A3 162 Calcium signaling, 
pancreatic 
secretion  
- 
GLP1R 150 Insulin Secretion - 
ADRBK1 145 Endocytosis GSE44770  
CACNG4, 
CACNG6  
141 - - 
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KCNJ5  
 
132 Estrogen signaling - 
P2RX2  130 Calcium signaling GSE44770 
KPNA2 122 - - 
NOX1 118 - - 
CACNG5 113 - - 
EPN1 113 Endocytosis - 
WAS 112 - - 
CASP10 111 Apoptosis - 
HSPB6, EPHA4 109 - - 
ADNP 108 - - 
DNAH3 106 - - 
GRIN2A 105 Calcium signaling - 
UBQLN1 101 - - 
IL34, ATP5A1, 
UBE2L3 
100 - - 
DPYSL2 99 - - 
FOLR2 98 Endocytosis - 
NPR1 96 - - 
DNM1L, KLC1, 92 - - 
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ATP5G3 
 
 
 
 
GSE44768 
RASGRF1 80 - - 
DNAL4 63 - - 
EPHA1 60 - - 
CHRND 59 - - 
TRPC1 54 Pancreatic 
secretion 
GSE5281, 
GSE44770 
PAK7 50 - - 
NDUFA4 44 - - 
CHMP4B 44 Endocytosis - 
 
 
 
 
 
 
 
GSE44770 
IVNS1ABP 103 - - 
FGF18 92 - - 
ATF2 90 Estrogen signaling, 
Insulin secretion 
- 
 
CTSG 88 - - 
GABRE 86 - - 
FBXL2 81 - - 
GAPDH 75 - - 
DIO1 72 Thyroid hormone 
signaling 
- 
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CACNB3, CDK2 66 - - 
NFKBIB 66 Adipocytokine 
signaling, 
neurotrophin 
signaling, NOD-
like receptor 
signaling  
GSE44768 
PRDM4 64 Neurotrophin 
signaling 
- 
MAPK9 63 Adipocytokine 
signaling, 
neurotrophin 
signaling, NOD-
like receptor 
signaling 
- 
PIK3CB 63 Apoptosis, 
estrogen signaling, 
neurotrophin 
signaling, thyroid 
hormone 
signaling  
GSE5281 
GSE44771 HSPA2 18 Endocytosis, 
estrogen signaling 
- 
Table 3 Hub genes identified in the aggregated network for the four datasets. The genes 
are sorted by their hub degree within each dataset. Only significant pathways are listed here 
(see Table 4 for the list)  
 
Common 
Pathways 
Pathway 
Category 
Total 
no. of 
genes in 
the 
pathwa
y 
Number of genes enriched for the pathway 
GSE528
1 
GSE4476
8 
GSE4477
0 
GSE4477
1 
Consensu
s 
Cancer Basal cell 
carcinoma 
55 5 2 7 1 15 
Cancer Colorectal 
cancer 
62 6 2 8 1 14 
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Cancer Pathways in 
cancer 
398 64 27 40 3 119 
Cancer Small cell lung 
cancer 
86 15 4 9 2 27 
Comorbidit
y 
Amyotrophic 
lateral 
sclerosis 
(ALS) 
51 14 2 5 1 18 
Comorbidit
y 
Arrhythmogen
ic right 
ventricular 
cardiomyopath
y (ARVC) 
74 13 5 8 2 21 
Comorbidit
y 
Dilated 
cardiomyopath
y  
90 17 6 7 2 26 
Comorbidit
y 
Hypertrophic 
cardiomyopath
y (HCM) 
83 14 7 7 2 23 
Comorbidit
y 
Rheumatoid 
arthritis 
91 10 4 7 1 20 
Infection Epithelial cell 
signaling in 
Helicobacter 
pylori 
infection 
68 9 2 6 1 16 
Infection Influenza A 177 25 4 22 2 46 
Infection Shigellosis 61 12 3 7 1 19 
Infection Toxoplasmosis 120 14 3 12 2 26 
Infection Tuberculosis 179 21 4 23 3 46 
Infection Vibrio cholera 
infection 
54 9 2 2 1 13 
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Infection Viral 
myocarditis 
60 12 2 5 2 19 
Others Melanogenesis 101 18 3 10 1 30 
Others Neuroactive 
ligand-receptor 
interaction 
275 57 24 30 3 98 
Potential Apoptosis 86 14 2 6 1 20 
Potential Calcium 
signaling 
pathway 
180 43 12 16 2 62 
Potential Endocytosis 213 47 10 21 4 70 
Potential Neurotrophin 
signaling 
pathway 
120 24 6 17 1 44 
Potential NOD-like 
receptor 
signaling 
pathway 
57 9 3 6 1 16 
Potential PPAR 
signaling 
pathway 
69 11 4 9 2 22 
Potential Synaptic 
vesicle cycle 
63 15 4 8 1 26 
Potential Adipocytokine 
signaling 
pathway 
70 17 6 8 1 27 
Potential Insulin 
secretion 
86 18 3 10 1 28 
Potential Pancreatic 
secretion 
96 21 5 9 1 30 
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Potential 
(hormones) 
Estrogen 
signaling 
pathway 
100 23 4 7 1 32 
Potential 
(hormones) 
Thyroid 
hormone 
signaling 
pathway 
119 26 3 10 1 37 
Potential 
(others) 
Lysosome 122 13 7 11 4 33 
Potential 
(others) 
Phagosome 155 31 4 16 2 48 
Table 4 Landscape of significant pathways (p-value<0.05) determined across datasets  
 
Rank Gene Symbol RegulomeDB score No. evidences 
for Alzheimer’s 
disease 
Pathways involved  
1 IL1B  1b 1073 Apoptosis, NOD-like 
receptor signaling 
2 NSF 1d 8 Synaptic vesicle cycle 
3 HLA-F 1f 0 Endocytosis 
4 NOTCH4 1f 3 Thyroid hormone 
signaling 
5 VCL 1f 10 Shigellosis 
6 PSAP 1f 3 Lysosome 
7 STX2 1f 2 Synaptic vesicle cycle 
8 GGA2 1f 4 Lysosome 
9 STK11 1f 7 Adipocytokine signaling 
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10 CSF3R 1f 5 Pathways in cancer 
11 LMNA 1f 11 Arrhythmogenic right 
ventricular 
cardiomyopathy(ARVC), 
Dilated cardiomyopathy, 
Hypertrophic 
cardiomyopathy(HCM) 
12 CTNNA2 1f 3 Arrhythmogenic right 
ventricular 
cardiomyopathy(ARVC) 
13 HLA-C 1f 1 Endocytosis 
14 RAB11FIP4 1f 0 Endocytosis 
15 GRIN2A 2a 52 Calcium signaling 
16 RBX1 2a 0 Viral Myocarditis 
17 KCNJ5 2a 0 Estrogen signaling 
18 EPHA4 2b 18 Hub Genes 
19 CACNG4 2b 0 Arrhythmogenic right 
ventricular 
cardiomyopathy(ARVC), 
Dilated cardiomyopathy, 
Hypertrophic 
cardiomyopathy(HCM) 
20 PLA2G5 2b 7 Pancreatic secretion 
21 ATP2B4 2b 1 Calcium signaling, 
pancreatic secretion 
22 P2RY14 2b 0 Neuroactive ligand 
receptor interaction 
23 P2RY13 2b 0 Neuroactive ligand 
receptor interaction 
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24 PTGER4 2b 11 Neuroactive ligand 
receptor interaction 
25 ARAP3 2b 0 Endocytosis 
26 FGF1 2b 22 Pathways in cancer 
27 RPS6KA2 2b 0 Neurotrophin signaling 
28 RAPGEF1 2b 0 Neurotrophin signaling 
29 GABBR2 2b 1 Estrogen signaling 
30 PRF1 2b 1 Viral myocarditis 
31 ITGA8 2b 0 Arrhythmogenic right 
ventricular 
cardiomyopathy(ARVC), 
Dilated cardiomyopathy, 
Hypertrophic 
cardiomyopathy(HCM)  
32 AP2A2 2b 0 Endocytosis, Synaptic 
vesicle cycle 
33 ITPR2 2b 2 Calcium signaling, 
Estrogen signaling, 
pancreatic secretion 
34 MED13L 2b 0 Thyroid hormone 
signaling 
35 COL4A1 2b 0 Pathways in cancer 
36 KCNJ6 2b 3 Estrogen signaling 
37 ATP2A3 2b 0 Calcium signaling, 
Pancreatic secretion 
38 ASAP2 3a 1 Endocytosis 
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39 FYN 3a 70 Viral myocarditis 
40 NTRK2 3a 124 Neurotrophin signaling 
41 PAK1 3a 7 Epithelial cell signaling 
in Helicobacter pylori 
infection 
42 COL4A2 3a 0 Small cell lung cancer, 
Pathways in cancer 
43 BMP4 3a 5 Thyroid hormone 
signaling 
44 GABRB3 3a 0 Neuroactive ligand 
receptor interaction 
45 CEBPB 3a 12 Tuberculosis 
46 EPHA1 5 31 Hub Genes 
47 DPYSL2 5 47 Hub Genes 
 Table 5 List of genes prioritized using genetic variant analysis 
 
List of Abbreviations  
AD Alzheimer’s Disease  
GRNs Gene Regulatory Networks  
Aβ Amyloid Beta  
DE Differentially Expressed 
LD Linkage Disequilibrium  
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Supplementary material 
GeneSeedList S1.xls—Enriched candidate genes in each iteration  
This is a .xls file. It contains the list of enriched candidate genes that were added in each 
iteration to the seed gene list. The genes are represented as HGNC symbols.  
 
NumberOfNodesAndEdges S2.xls — Network statistics for each dataset in each iteration  
This is a .xls file. It provides detailed number of nodes and edges present in each dataset 
for each iteration.  
 
Outlier S3.xlsx — Outlier arrays list  
This is a .xlsx file. Each tab in the file provides the details of outlier arrays in each dataset 
that were discarded from our work due to low quality. In addition, the phenotype of the 
array is also provided.  
 
Pathway Statistics S4.xls — Summary statistics of the enriched pathways 
This is a .xls file. Each tab provides the detailed summary statistics for the individual 
dataset (including consensus) such as p-value, adjusted p-value, FDR, etc. of the enriched 
pathways that are obtained from ConsensusPathDB. 
 
Mechanistic Details S5.doc — Detailed mechanistic information of the prioritized 
candidates 
This is a .doc file. It provides detailed mechanistic information for each of the newly 
prioritized candidates. 
 
Supplementary Figure S1.jpg—Connected subnetwork formed by the hub genes in each 
dataset  
 
Supplementary Table S1.xls—comprehensive literature analysis of prioritized 
candidates This is a .xls file. It contains the list of diseases that the prioritized candidate 
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genes are involved in. The information was retrieved by querying the SCAIView 
knowledge discovery tool. 
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6.2.1 	Supplementary	Figure	
 
6.3 Summary	
The presented study emphasises on the potential of literature knowledge and GRNs as a 
powerful framework for large-scale integrative meta-analysis to corroborate common AD 
mechanistic patterns. GRNs were inferred by leveraging the power of an ensemble-based 
method, BC3Net. To expand the knowledge space around previously unattended players, 
an optimised version of BC3Net was developed, BC3Net10. For generating AD specific 
GRNs, 500 most frequently discussed AD genes from the literature were injected into 
BC3Net10. Using this as the ‘seed’, first set of GRNs were generated independently for 
each dataset. Further, to overcome the incomplete nature of prior knowledge and identify 
new candidates from the grey-zone of knowledge, the seed was expanded with the genes 
from significant pathways that were common to these datasets. To obtain a stable and 
complete GRN, the enrichment and injection of seed was iteratively carried out until 
saturation. Although there were significant pathways common across datasets, the genes 
involved were not the same. Thus, to derive a stronger consensus and uplift the most 
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promising pathway the GRNs from different datasets were merged as one consensus GRN. 
The identified genes in these uplifted pathways, genetic variant analysis was applied. This 
resulted in 47 potential gene candidates, among which five well-known AD candidates 
were present. The value of this work comes from the identification of nine lesser known 
candidates that are mainly involved in pathways contributing to neurotransmission.  
Although many sophisticated approaches and methods to generate GRNs using prior 
knowledge have been published in recent years, none have applied prior knowledge to self-
instruct GRNs for identification of subtle signals that bear the potential to modulate the 
clinical path of the disease. To our knowledge, this is the first study to apply such an 
approach to retain inferred interactions that were lost due to shift in the significance 
considering the change in seed. Thus, our method is well-suited to provide a novel 
foundation for the generation of new hypotheses. 
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Chapter	7 Conclusion	and	Outlook	
Integrative approaches are evolving into a promising way for translating big data into 
evidence-based decision support. Influencing healthcare and drug discovery research, they 
widen the knowledge space by contributing a specialised set of insights unique to individual 
resources. These approaches play a vital role in determining the constellation of interrelated 
yet diverse AD factors from disparate public data. However, each data resource and its 
associated computational approaches bring with it a set of unique challenges. 
In this dissertation, I highlighted some of the challenges faced during the integration of 
biomedical data and approaches to address them. Mainly, I focused on solving the issues 
that revolve around two V’s of big data that have an implication on data integration in NDD 
research: Variety and Veracity. The core of this work lies in collating highly curated, and 
context-specific heterogeneous public data in an integrative semantic framework for 
modelling diseases. To collate the disjoint data and to extract unbiased knowledge, new 
methods were developed and improvements to existing methods were achieved. 
Particularly, significant contribution to knowledge discovery, data mining, and network 
inference have been made. Using such a semantic framework, this dissertation reports 
deciphering previously unknown findings and set forth novel hypotheses that can accelerate 
innovation in AD research, deviating from the common Aβ- and tau-centric approaches.   
7.1 Knowledge	discovery	and	data	mining	contribution	
In this dissertation, we developed novel approaches and methods to address the 
fundamental issues in integrative disease modelling for repurposing public data through 
several representative studies. In the first study, called NeuroRDF, we developed a 
semantic-based integrative approach using RDF framework to integrate well-curated and 
indication-specific data from databases, literature, and gene expression studies. This 
approach illustrated the potential of high-quality integrated data to exploit implicit 
associations and prioritise previously unattended AD candidates around well-known 
mechanisms. The remainder of the dissertation was dedicated to developing strategies and 
approaches to harvest, curate, extract, and analyse public data that were integrated into the 
NeuroRDF framework.  
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Although no consensus has yet been reached about the role of miRNAs in AD, several 
recent studies have suggested their value in early diagnosis. Hence, advancements in this 
direction are essential. In the second study, we developed text mining methods to 
automatically extract regulatory relationships of miRNAs with diseases and genes from the 
biomedical literature. Among the evaluated relation extraction approaches, tri-occurrence 
achieved state-of-the-art performance and outperformed existing approaches with 
comparable precision. This work provides the basis for building regulatory networks for 
identification of dysregulated miRNAs. 
High-throughput data have a huge impact on drug discovery and their metadata annotations 
serve as the backbone for standardised retrieval, querying and consistent analysis. 
However, high variability of metadata information stored in public repositories hinders 
integrative meta-analysis. In the third study, we developed a database, named 
NeuroTransDB, primarily aimed to fill the gaps in the meta-analysis by joining bits of 
missing and scattered metadata information for public transcriptomic studies. This is the 
first highly curated metadata database that caters to the needs of NDD research by 
differentiating metadata fields for human and animal models. Additionally, we have 
systematically described the curation guidelines for building such a domain-specific 
database. To unlock the hidden potential of these harvested disparate data, a novel strategy 
that corroborates common mechanistic patterns across biologically related transcriptomic 
data is presented in the fourth study. This is the first study to generate knowledge-instructed 
gene regulatory networks for identifying lesser known candidates embedded in stable and 
robust functional patterns across heterogeneous AD datasets.  
7.2 NDD	research	domain	contribution	
Comprehensive characterisation of the pathological events requires a systems level 
understanding by incorporating existing and new data. Semantic web technologies have 
proven to be particularly useful in providing a formalised framework for heterogeneous 
data integration and analysis. AlzPharm is a good example of a community effort for 
sharing AD data to advance hypothesis-driven therapeutic innovation. In general, a series 
of BioHackathons have aimed to increase interoperability between biological data (both 
structured and unstructured) and bioinformatics tools through semantic web. However, to 
pursue this ambitious aim in dementia and derive novel hypothesis, one needs to first 
address barriers associated with the data itself.  
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Public data in the field of dementia research are very heterogeneous with varying quality 
due to inconsistent diagnosis criteria and lack of adoption to standards; contributing to 
inconsistent reproducibility and reusability. Many commercial tools like MetaCore™, 
Ingenuity Pathway Studio, and NextBio have tried to address these issue by enriching with 
manual curation efforts, but rather fail to add domain context, extract missing values and 
verify incorrect information. In addition, they are not freely available for public use. In this 
dissertation, Chapter 3, NeuroRDF tries to address these issues and demonstrate that well-
curated, precise, and formalised data have a huge impact on the deriving novel hypothesis 
from integrated public data. Even with limited yet well-curated data resources, we were 
able to prioritise MIF as a potential candidate to elucidate AD aetiology. Recently, a study 
conducted by Kassaar et al. [256] on human AD brain samples, has confirmed MIF 
hypothesis. These authors provide new evidence that implicates glucose modified and 
oxidised MIF as a potential link between dementia and diabetes. In addition, their results 
confirm an increase in the concentration of modified and oxidised MIF from early to late 
AD stages. 
To start any research, the scientific literature is the primary source of knowledge; where 
scientists look for relevant and previous findings. It provides a comprehensive view across 
different disciplines and domains. Text mining technologies are a crucial part to extract 
knowledge from the vast growing literature, which otherwise is not achievable through 
manual reading. A recent monograph by Kostoff et al. [257], reported the usage of 
advanced text mining/information retrieval methodology to identify 600 actionable 
foundational causes of AD. Mining information from text is not an isolated problem, rather 
be considered as the evidence to be integrated with the experimental data; increasing the 
confidence of informed-decision making. Conventional preconceptions of cellular and 
molecular regulation, especially in neurology, — depended on genes and proteins — have 
changed with substantial progress in understanding of complex transcriptional landscape 
and non-coding RNA biology [258], especially miRNAs. This dissertation reports one of 
the early efforts for mining miRNA relations from text. The work presented in Chapter 4 
is one of the first ones that contributed to text mining methods and manually curated corpus 
to the miRNA research community [259]. Using this work as a benchmark, several other 
text mining approaches have been built such as miRTex [251], MiNCor [259], and IBRel 
[260]. Among the miRNAs that were reported in NeuroRDF, recently, miR-132 has been 
confirmed to be associated with NFTs accumulation in subjects from two longitudinal 
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cohorts of ageing [261]. A most recent study, by Díez-Planelles et al. [262], linking the 
Huntington’s disease diagnosis with dysregulated expression of circulating miRNAs in 15 
patients, serve as a promising approach for early non-invasive diagnosis and prognosis in 
neurodegenerative diseases; paving way to precision medicine. 
Although open science and global data sharing have gained momentum with recent 
initiatives like ADNI, JPND, and GAAIN. These future research projects/collaborations 
could leverage on existing experimental data to identify critical knowledge gaps in 
dementia. However, existing data resources are far from reusable as they are highly 
dependent on the quality and completeness of metadata.  A recent call by IMI 
“FAIRification of IMI and EFPIA data – IMI2 –  2017-12-02”41 recognizes this hurdle. In 
our third study, we have tried to highlight the need for FAIRification of the largest and 
most widely used public genomics databases, GEO and ArrayExpress, to cater to NDD 
research needs. This work clearly highlights that increasing interoperability of the metadata 
between resources is not sufficient to drive innovation. Moreover, complete and in-depth 
annotations that represent the heterogeneity and diversity in a specific domain like NDD 
are to be addressed first. Most of the existing research articles have tried to address this on 
a case-by-case basis [83,263]. Moreover, animal models have not shown high predictive 
validity in translating to AD clinical trials [264]. Onos et al. [265] have discussed the 
importance of detailed information on mouse models can avoid over interpretation of the 
derived results and help design more predictive mouse models the recapitulate clinical 
pathology for future experiments. Our work, reported in Chapter 5, is the only study which 
is dedicated to addressing these needs in the required breadth and depth for NDD, including 
detailed metadata for animal models, in a more structured way.  
Representing biology as networks allow scientists to understand the cross-functioning of 
the constituent elements. Gene regulatory networks (GRNs) aim to identify organisational 
similarities between molecular and cellular players using expression data. GRNs offer 
insights into causal relationships, biomarkers, perturbation, predict expression changes, etc. 
to advance mechanistic understanding and prioritisation of potential candidates. Zhang et 
al. [201] used GRNs to identify influential modules to further prioritise TYROBP as a key 
                                                
41 https://www.up2europe.eu/calls/fairification-of-imi-and-efpia-data-imi2-2017-12-02_1941.html  
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regulator in LOAD patients, which was confirmed by in vitro experiments. However, most 
of the retrospective approaches undermine the lesser-known evidence that approximate the 
biological truth and clearly tend to converge to our current knowledge of NDD. In addition, 
none of these studies have addressed the context-specificity and completeness of the 
generated GRNs. Chapter 6 reports a novel approach that emphasises on using literature 
knowledge as the seed to iteratively determine the completeness of generated GRN, 
identification of robust mechanistic patterns across studies, and prioritisation of lesser-
known candidates. This work has prioritised 5 well-known and 9 lesser-known AD 
candidates using public gene expression studies. The lesser-known candidates are observed 
to involved in three key pathways of neurotransmission in the generated GRNs: calcium 
signalling, endocytosis and synaptic vesicle cycle. A recent review by the Alzheimer’s 
Association Calcium Hypothesis Workgroup [266] has placed Ca2+ in the centre of NDD; 
increasing the value and confidence the hypothesis derived from GRNs. 
7.3 NDD	projects	contribution	
In principle, the methods and approaches presented in this dissertation can be applied to 
any disease domain with little or no further adaptations. Moreover, the work presented here 
has made novel contributions to two projects:  
1. D10 “In Silico Discovery for putative Biomarkers” – German Federal Ministry 
for Education and Research (BMBF) within BioPharma initiative ‘Neuroallianz’ (grant 
number: 1616060B) 
2. AETIONOMY “Development of Mechanism-based Taxonomy for 
Neurodegenerative Diseases”– EU/EFPIA Innovative Medicines Initiative Joint 
Undertaking grant agreement n◦115568 
In the D10 project, we applied the NeuroRDF framework to Parkinson’s and Epilepsy 
diseases. We formulated complex queries on the integrated data that relates to molecule’s 
biological role in the disease at the systems level. These queries were combined in a 
rationally informed weighting scheme as a set of features to rank putative biomarker 
candidates. The resulting prioritised novel candidates that provide novel mechanistic 
insights are currently being validated by our pharma partner, UCB Pharma. Depicted below 
is the overall workflow of the D10 project, which was previously published in a review: 
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Figure 7.1: The D10 project workflow.  
Here we present a top-down approach where highly-curated and context-specific data are integrated into the 
RDF framework. The candidates are scored based on the feature values determined for complex biological 
queries (features). Finally, the scored candidates are embedded in a mechanistic context for interpretation. 
Reproduced from Hofmann-Apitius et al. [267] under the Creative Commons Attribution License 
The data harvested in the NeuroTransDB database is being utilised for mechanism-based 
patient subgroup identification for Alzheimer’s and Parkinson’s diseases in the 
AETIONOMY project. The data is currently migrated to the tranSMART framework to 
enable selection of relevant datasets for analysis. In addition, the prioritised candidates 
from the fourth study have been integrated into the web server for mechanism enrichment, 
NeuroMMSig42. 
 
                                                
42 http://neurommsig.scai.fraunhofer.de/  
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7.4 Outlook	
The work presented here shows that semantically integrating precise and context-specific 
data, derived from data mining and knowledge-discovery methods, support in identification 
of new molecular players. Certainly, the approach can be extended to other data types such 
as next generation sequencing, imaging, proteomics, so on. However, ‘how to eliminate the 
influence of bias’ in these data sources is still an open question worth exploring. To keep 
up with fast-evolving data, there is a need for more (semi-)automated approaches to make 
the submitted data more interoperable and identifiable, so as to reduce human efforts and 
cost. Recent crowdsourcing work such as CREEDS [268], and OMiCC [269] have proven 
to be efficient ways for annotating metadata and extracting gene signatures from GEO 
studies. Classifier can be trained on this high confidence and curated data to serve as an 
useful tool to automatically label and extract associations. However, the developed corpora 
are context specific. To extend to another domain similar human efforts are required. 
Active learning algorithms have shown to perform better, starting with only a few labelled 
examples, and dynamically improving its performance with user feedback. They have been 
applied to label experiments, text classification, entity recognition, interactions, and so on 
[270–272]. Similar active learning approaches can be developed for network 
reconstruction, which dynamically chooses the algorithm that optimizes to identify 
previously unknown candidates. One way forward to promote reusability and integration 
of public data at a global scale is to ensure that the data and resources developed by 
individual groups or in projects obtain long-term funding to maintain it. 
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